Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 95
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Alzheimer Dementia Among Individuals With Down Syndrome

  • Rubenstein, Eric
  • Tewolde, Salina
  • Michals, Amy
  • Weuve, Jennifer
  • Fortea, Juan|||0000-0002-1340-638X
  • Fox, Matthew P.
  • Pescador Jimenez, Marcia
  • Scott, Ashley
  • Tripodis, Yorghos
  • Skotko, Brian G.
What is the incidence and prevalence of Alzheimer dementia in patients with Down syndrome using data from the US Medicare and Medicaid? In this cohort study of 132 720 adults with Down syndrome enrolled in Medicaid or Medicare between 2011 to 2019, 23.3% of adults had Alzheimer dementia diagnoses, and the mean age of death was 59.2 years. These findings suggest that Alzheimer dementia is almost universal among people with Down syndrome, and administrative claims data may offer valuable insights into improving care for this diverse population. This cohort study examines the prevalence and incidence of Alzheimer disease among individuals with Down syndrome using US Medicare and Medicaid claims data. With the advancement in administrative data as a research tool and the reliance on public health insurance for individuals with Down syndrome, population-level trends in Alzheimer dementia in this population are beginning to be understood. To comprehensively describe the epidemiology of Alzheimer dementia in adults with Down syndrome in a full US Medicare and Medicaid sample. This cohort study included 132 720 adults aged 18 years or older with Medicaid and/or Medicare claims data with an International Statistical Classification of Diseases and Related Health Problems code for Down syndrome. Data were collected from January 1, 2011, to December 31, 2019, and analyzed from August 2023 to May 2024. The main outcome was prevalence of Alzheimer dementia in each calendar year and during the 9-year period. Alzheimer dementia incidence rates by calendar year and age and stratified for race or ethnicity as well as time to death after Alzheimer dementia diagnosis were also assessed. There were 132 720 unique adults with Down syndrome from 2011 to 2019: 79 578 (53.2%) were male, 17 090 (11.7%) were non-Hispanic Black, 20 777 (15.7%) were Hispanic, 101 120 (68.8%) were non-Hispanic White, and 47 692 (23.3%) had ever had an Alzheimer dementia diagnosis. Incidence was 22.4 cases per 1000 person-years. The probability of an incident Alzheimer dementia diagnosis over 8 years was 0.63 (95% CI, 0.62-0.64) for those entering the study between ages 55 to 64 years. Mean (SD) age at incident diagnosis was 54.5 (7.4) years and median (IQR) age was 54.6 (9.3) years. Mean (SD) age at death among those with Alzheimer dementia was 59.2 (6.9) years (median [IQR], 59.0 [8.0] years). The mean (SD) age at onset for the Hispanic group was 54.2 (9.2) years, 52.4 (7.8) years for the American Indian or Alaska Native group, and 52.8 (8.2) years for the mixed race groups compared with 55.0 (7.8) years for the White non-Hispanic group. For age at death, there were no differences by sex. The mean (SD) age at death was later for the White non-Hispanic group (59.3 [6.8] years) compared with the Hispanic group (58.5 [7.8] years), Native American group (57.8 [7.1] years), and mixed race group (58.2 [7.0] years). In this cohort study of adults with Down syndrome who were enrolled in Medicaid and Medicare, Alzheimer dementia occurred at high rates. Consistency with clinical studies of dementia in Down syndrome supports the use of administrative data in Down syndrome-Alzheimer dementia research.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Associations between objective sleep metrics and brain structure in cognitively unimpaired adults: interactions with sex and Alzheimer's biomarkers

  • Stankeviciute, Laura
  • Tort-Colet, Núria
  • Fernández-Arcos, Ana
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Fauria, Karine
  • Holst, Sebastian Camillo
  • Garcés, Pilar
  • Mueggler, Thomas
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Iranzo, Álex
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • Molinuevo, José Luis
  • Grau, Oriol (Grau Rivera)
  • ALFA Study
INTRODUCTION: Sleep disturbances are prevalent in Alzheimer's disease (AD), probably emerging during its preclinical stage. Poor subjective sleep quality is linked to reduced brain volume and cortical thickness (CTh), but associations with objective sleep measures, particularly regarding sex and AD pathology, remain unclear. METHODS: We characterized 171 cognitively unimpaired adults from the ALzheimer and FAmilies (ALFA) Sleep study using actigraphy, MRI, amyloid beta 42/40, and phosphorylated tau at threonine 181 in cerebrospinal fluid. RESULTS: Lower sleep efficiency, higher wake after sleep onset (WASO), and sleep fragmentation were associated with lower CTh in the medial temporal lobe and other regions linked with AD and sleep disruption, even after adjusting for AD biomarkers. Sex and AD biomarkers modified these associations, with longer WASO showing a stronger correlation with lower CTh in females. DISCUSSION: Disrupted sleep may reduce cortical integrity independently of AD biomarkers, suggesting alternative pathways. Females appear more vulnerable to impaired sleep, and AD pathology may exacerbate AD-related changes in CTh. Highlights: Poor sleep efficiency, increased WASO, and sleep fragmentation are associated with reduced CTh in regions vulnerable to early AD, independently of amyloid and tau pathology. In the presence of AD pathology, this relationship is altered, with A+T+ individuals exhibiting increased CTh associated with sleep disruption. Sex-specific effects suggest females are more vulnerable to sleep-related cortical thinning. These findings highlight the potential of targeting sleep as a secondary prevention strategy to preserve brain integrity and mitigate neurodegenerative processes in AD-vulnerable regions., The ALFA+ study receives funding from ‘la Caixa’ Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer's Association, and an anonymous international charity foundation through the TriBEKa Imaging Platform project (TriBEKa‑17‑519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under Grant 2017-SGR-892. H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (2022-01018 and 2019-02397), the European Union's Horizon Europe Research and Innovation Programme under Grant Agreement 101053962, Swedish State Support for Clinical Research (ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (201809-2016862), the AD Strategic Fund and the Alzheimer's Association (ADSF-21-831376-C, ADSF-21-831381-C, and ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (FO2022-0270), the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie Grant Agreement 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003). K.B. is supported by the Swedish Research Council (2017‑00915); the Alzheimer Drug Discovery Foundation (ADDF), USA (RDAPB‑201809‑2016615); the Swedish Alzheimer Foundation (AF‑742881); Hjärnfonden, Sweden (FO2017‑0243); the Swedish state under the agreement between the Swedish government and the County Councils, the ALF‑agreement (ALFGBG‑715986); the European Union Joint Program for Neurodegenerative Disorders (JPND2019‑466‑236); the National Institutes of Health (NIH), USA (Grant 1R01AG068398‑01); and the Alzheimer's Association 2021 Zenith Award (ZEN‑21‑848495). M.S.C. receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 Research and Innovation Programme (Grant Agreement 948677), the Instituto de Salud Carlos III (PI19/00155, PI22/00456), and from the ERC under the EU's ‘la Caixa’ Foundation (ID 100010434) and from the EU's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant (847648, LCF/BQ/PR21/11840004). J.D.G. is supported by the Spanish Ministry of Science and Innovation (RYC‑2013‑13054). J.D.G. has also received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (Grant Agreement 115952), EIT Digital (Grant 2021), and from Ministerio de Ciencia y Universidades (Grant Agreement RTI2018‑102261). G.S-B. receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency, PID2020-119556RA-I00. O.G.R. receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117), and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva Programme IJC2020-043417-I).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A plasma biomarker panel for detecting early amyloid-β accumulation and its changes in middle-aged cognitively unimpaired individuals at risk for Alzheimer's disease

  • González Escalante, Armand
  • Milà Alomà, Marta
  • Brum, Wagner S.
  • Ashton, Nicholas J.
  • Ortiz Romero, Paula, 1994-
  • Shekari, Mahnaz
  • Campo, Marta del
  • Anastasi, Federica
  • Quijano-Rubio, Clara
  • Kollmorgen, Gwendlyn
  • Minguillón, Carolina
  • Sánchez Benavides, Gonzalo
  • Grau, Oriol (Grau Rivera)
  • Gispert, Juan Domingo
  • Zetterberg, Henrik
  • Vilor Tejedor, Natàlia, 1988-
  • Blennow, Kaj
  • Suárez-Calvet, Marc
Background: Plasma biomarkers of Alzheimer's disease (AD) change during preclinical stages, indicating potential for detecting amyloid-β (Aβ) pathology in cognitively unimpaired (CU) individuals. Given the need for accurate, scalable biomarkers, we evaluated a fully automated plasma panel to detect and monitor longitudinal Aβ accumulation in CU individuals. Methods: In this longitudinal study, we examined a plasma panel (Aβ42/40, p-tau181, GFAP, NfL, p-tau217 and ApoE4) in CU participants at risk for AD. We assessed the biomarkers' performance to detect Aβ pathology and the cross-sectional and longitudinal relationships between the biomarkers and Aβ accumulation, neurodegeneration and cognition. Findings: We included 400 middle-aged CU participants, of whom 135 (33.8%) were CSF Aβ-positive. All plasma biomarkers differed between Aβ-positive and -negative individuals, with plasma Aβ42/40, p-tau217, p-tau181/Aβ42, and p-tau217/Aβ42 showing the best performance in detecting A+ CU individuals. However, plasma Aβ42/40 was sensitive to random variability. Plasma p-tau217/Aβ42 had the highest performance in detecting PET A+ individuals (AUC = 0.94). All baseline plasma biomarkers were associated with longitudinal increases in Aβ deposition (mean follow-up [SD]: 3.27 ± 0.5). Longitudinal changes in plasma p-tau217 and p-tau217/Aβ42 were associated with concurrent changes in Aβ (both CSF and PET) and soluble tau pathology. Interpretation: In CU individuals, several plasma biomarkers at baseline detect Aβ accumulation and are associated with its short-term change. Plasma p-tau217, and p-tau217/Aβ42 longitudinal changes reflect concurrent Aβ accumulation during this period. These findings help enrich studies in CU individuals at risk of progressing to AD. Funding: ERC-2020-STG (Grant agreement No. 948677); ERA PerMed-ERA NET and the Generalitat de Catalunya (SLD077/21/000001); PI19/00155; PI22/00456, LCF/BQ/PR21/11840004., This publication is part of the ALFA study (ALzheimers and Families). The authors would like to express their most sincere gratitude to the ALFA project participants and relatives without whom this research would not have been possible. The authors thank Roche Diagnostics International Ltd for providing the kits to measure Plasma and CSF biomarkers and GE Healthcare for providing the doses of [18F]flutemetamol PET. The NeuroToolKit is a panel of exploratory prototype assays designed to robustly evaluate biomarkers associated with key pathologic events characteristic of AD and other neurological disorders, used for research purposes only and not approved for clinical use (Roche Diagnostics International Ltd, Rotkreuz, Switzerland). Elecsys Phospho-Tau (181P) CSF and Elecsys Total-Tau CSF assays are approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. We thank the collaborators of the ALFA Study: Alba Cañas, Albina Polo, Ana Fernández-Arcos, Annabella Beteta, Anna Brugulat-Serrat, Anna Soteras, Blanca Rodríguez-Fernández, Carme Deulofeu, Ferran Lugo, Irene Cumplido-Mayoral, Jordi Huguet, Laura Hernández, Maria Emilio, Patricia Genius, Paula Marne, Sandra Pradas, Sherezade Fuentes, and Wiesje Pelkmans. MMA receives funding from the Alzheimer’s Association Research Fellowship Program (AARF-23-1141384). FA receives funding from the JDC2022-049347-I grant, funded by the MCIU/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR. GSB is supported by the Agencia Estatal de Investigación AEI/10.13039/501100011033 through the project PID2020-119556RA-I00 and by Instituto de Salud Carlos III (ISCIII) through the project CP23/00039 (Miguel Servet contract), co-funded by the European Union (FSE+). OGR’s institution is supported by Roche Pharmaceuticals and Spanish Ministry of Science, Innovation and Universities (IJC2020-043417-I). HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer’s Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). NVT is supported by the Spanish Ministry of Science and Innovation - State Research Agency (grant RYC2022-038136-I, cofunded by the European Union FSE+ and grant PID2022-143106OA-I00 cofunded by the European Union FEDER). Additionally, NVT is supported by the William H. Gates Sr. Fellowship from the Alzheimer’s Disease Data Initiative. KB is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270, and #AF-994551), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022–2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, and Familjen Rönströms Stiftelse, Stockholm, Sweden. MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through the project SLD077/21/000001; Project “PI19/00155” and “PI22/00456”, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The mediating role of neuroimaging-derived biological brain age in the association between risk factors for dementia and cognitive decline in middle-aged and older individuals without cognitive impairment: a cohort study

  • Cumplido-Mayoral, Irene
  • Brugulat Serrat, Anna, 1986-
  • Sánchez Benavides, Gonzalo
  • González Escalante, Armand
  • Anastasi, Federica
  • Milà Alomà, Marta
  • López-Martos, David
  • Akinci, Muge
  • Falcón, Carles
  • Shekari, Mahnaz
  • Cacciaglia, Raffaele
  • Arenaza Urquijo, Eider M.
  • Minguillón, Carolina
  • Fauria, Karine
  • Molinuevo, José Luis
  • Suárez-Calvet, Marc
  • Grau, Oriol (Grau Rivera)
  • Vilaplana, Verónica
  • Gispert, Juan Domingo
  • ALFA Study
Background: Neuroimaging-based brain-age delta has been shown to be a mediator linking cardiovascular risk factors to cognitive function. We aimed to assess the mediating role of brain-age delta in the association between modifiable risk factors of dementia and longitudinal cognitive decline in middle-aged and older individuals who are asymptomatic, stratified by Alzheimer's disease pathology. We also explored whether the mediation effect is specific to cognitive domain. Methods: In this cohort study, we included participants from the ALFA+ cohort aged between 45 years and 65 years who were cognitively unimpaired and who had available structural MRI, cerebrospinal fluid β-amyloid (Aβ)42 and Aβ40 measurements obtained within 1 year of each other, modifiable risk factors assessment, and cognitive evaluation over 3 years. Participants were recruited from the Barcelonaβeta Brain Research Center (Barcelona, Spain). Included individuals underwent a first assessment between Oct 25, 2016, and Jan 28, 2020, and a follow-up cognitive assessment 3·28 (SD 0·27) years later. We computed brain-age delta and composites of different cognitive function domains (preclinical Alzheimer's cognitive composite [PACC], attention, executive function, episodic memory, visual processing, and language). We used partial least squares path modelling to explore mediation effects in the associations between modifiable risk factors (including cardiovascular, mental health, mood, metabolic or endocrine history, and alcohol use) and changes in cognitive composites. To assess the role of Alzheimer's disease pathology, we computed separate models for Aβ-negative and Aβ-positive individuals. Findings: Of the 419 participants enrolled in ALFA+, 302 met our inclusion criteria, of which 108 participants were classified as Aβ-positive and 194 as Aβ-negative. In Aβ-positive individuals, brain-age delta partially mediated (percent mediation proportion 15·73% [95% CI 14·22-16·66]) the association between modifiable risk factors and decline in overall cognition (across cognitive domains). Brain-age delta fully mediated (mediation proportion 28·03% [26·25-29·21]) the effect of modifiable risk factors on the PACC, wherein increased values for risk factors correlated with an older brain-age delta, and, consequently, an older brain-age delta was linked to greater PACC decline. This effect appears to be primarily driven by memory decline. Mediation was not significant in Aβ-negative individuals (3·52% [0·072-4·17]) on PACC, although path coefficients were not significantly different from those in the Aβ-positive group. Interpretation: Our findings suggest that brain-age delta captures the association between modifiable risk factors and longitudinal cognitive decline in middle-aged and older people. In asymptomatic middle-aged and older individuals who are Aβ-positive, the pathology might be the strongest driver of cognitive decline, whereas the effect of risk factors is smaller. Our results highlight the potential of brain-age delta as an objective outcome measure for preventive lifestyle interventions targeting cognitive decline. Funding: La Caixa Foundation, the TriBEKa Imaging Platform, and the Universities and Research Secretariat of the Catalan Government. Translation: For the Spanish translation of the abstract see Supplementary Materials section., This publication is part of the ALFA study. We thank the ALFA project participants and relatives, without whom this research would not have been possible. We thank Kaj Blennow and Henrik Zetterberg for performing the measurements of cerebrospinal fluid Aβ42:Aβ40 ratio. We thank Roche Diagnostics International for providing the kits to measure cerebrospinal fluid biomarkers. The Roche NeuroToolKit is a panel of exploratory prototype assays designed to evaluate biomarkers associated with key pathological events characteristic of Alzheimer's disease and other neurological disorders, used for research purposes only and not approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. The ALFA+ study receives funding from La Caixa Foundation (100010434; LCF/PR/GN17/50300004) and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa 17 519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government (2021 SGR 009132017-SGR-892). MS-C receives funding from the European Research Council under the EU Horizon 2020 research and innovation programme (948677; project PI19/00155), funded by Instituto de Salud Carlos III and co-funded by the EU, and from a fellowship from La Caixa Foundation (100010434) and from the EU Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant (847648; LCF/BQ/PR21/11840004). DL-M is supported by Instituto de Salud Carlos III (PI19/00117; co-funded by European Regional Development Fund, European Social Fund A Way to Make Europe, and Investing in your Future). EMA-U is supported by the Spanish Ministry of Science and Innovation State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund and the Spanish Ministry of Science and Innovation (PID2019-111514RA-I00). VV has been supported by the Spanish Research Agency (PID2020-116907RB-I00 of the call MCIN/AEI/10.13039/501100011033). JDG is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054). JDG has also received research support from the EU and European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative Joint Undertaking AMYPAD (115952), European Institute of Innovation and Technology Digital (2021), and from Ministerio de Ciencia y Universidades (RTI2018-102261). GS-B receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency (PID2020-119556RA-I00). OG-R receives funding from the Alzheimer's Association Research Fellowship (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117), and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva programme IJC2020-043417-I).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Effect of parity and ß-amyloid on cognition and hippocampal volume in postmenopausal women

  • Gallay, Clara
  • Soldevila-Domenech, Natalia
  • López-Martos, David
  • Sánchez Benavides, Gonzalo
  • Huguet, Jordi
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • Salvadó, Gemma
  • Sundermann, Erin E.
  • Grau, Oriol (Grau Rivera)
  • Brugulat Serrat, Anna, 1986-
  • ALFA Study
Background and objectives: Epidemiologic studies exploring the effect of parity on Alzheimer disease (AD) yield mixed results, and little is known about how parity may modify the impact of AD pathology on brain and cognitive aging. We examined the effect of parity and AD pathology on hippocampal volume (HV) and cognitive changes in cognitively unimpaired (CU) postmenopausal women. Methods: Analysis was performed on CU postmenopausal women from the ALFA+ observational cohort based in the BarcelonaBeta Brain research center, who completed 1 or 2 visits spaced by ∼3 years (mean = 3.38, SD = 0.55) with reproductive data, cognitive testing (modified Preclinical Alzheimer's Cognitive Composite), CSF biomarkers (Aβ42 and Aβ40), and structural MRI. We used linear mixed-effects models to investigate the interactive effects of parity, time, and Aβ status (based on CSF Aβ42/Aβ40) on cognition and HV. APOE-ε4 status, age, and total intracranial volume were included as covariates. Results: A total of 254 women were included in our analyses ranging from 49.2 to 73.4 years (mean age = 61.2) at visit 1. A significant interaction between parity and Aβ status was observed for cognitive decline and HV. In women with positive amyloid status, higher parity was associated with steeper cognitive decline (β = -0.035, 95% CI -0.068 to -0.003, p = 0.033) and lower HV across time points (β = -0.134, 95% CI -0.263 to -0.005, p = 0.036). Discussion: In CU postmenopausal women, higher parity interacts with AD pathology to influence cognitive decline and HV reductions. These findings suggest that parity may affect resilience to AD pathology in preclinical AD stages., The research leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer's Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant 2021 SGR 00913. C. Gallay is supported by the Alzheimer Association Clinician Scientist Fellowship grant (AACSF-23-1145154). G. Sanchez-Benavides receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency, PID2020-119556RA-I00. M. Suárez-Calvet receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 Research and Innovation Programme (grant agreement 948677), Project “PI19/00155,” funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, from a fellowship from “la Caixa” Foundation (ID 100010434), and from the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant agreement 847648. J. Domingo-Jispert has received research support from the EU/EFPIA Innovative Medicines Initiative JointUndertaking AMYPAD (grant agreement 115952), EIT Digital (Grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018-102261). G. Salvado received funding from the European Union's Horizon 2020 Research and Innovation Program under 503 Marie Sklodowska-Curie action grant agreement number 101061836, an Alzheimer's Association Research 504 Fellowship (AARF-22-972612), the Brightfocus Foundation (A2024007F), the Alzheimerfonden (AF-980942, 505 AF-994514, AF-1012218), Greta och Johan Kocks research grants and travel grants from the Strategic Research 506 Area MultiPark (Multidisciplinary Research in Parkinson's Disease) at Lund University. E. Sundermann receives funding from the NIH (5R01AG074221). O. Grau-Rivera receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117) and from the Spanish Ministry of Science Innovation and Universities (Juan de la Cierva programme IJC2020-043417-I). A. Brugulat-Serrat receives funding from the Alzheimer Association Clinician Scientist Fellowship (AACSF-23-1145154).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Sex/gender effects of glial reactivity on preclinical Alzheimer's disease pathology

  • Vila-Castelar, Clara
  • Akinci, Muge
  • Palpatzis, Eleni
  • Aguilar Dominguez, Pablo
  • Operto, Grégory
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Blennow, Kaj
  • Zetterberg, Henrik
  • Falcón, Carles
  • Fauria, Karine
  • Gispert, Juan Domingo
  • Grau, Oriol (Grau Rivera)
  • Suárez-Calvet, Marc
  • Arenaza Urquijo, Eider M.
  • ALFA Study
Glial reactivity may contribute to sex/gender differences in Alzheimer's disease (AD) pathophysiology. Here, we investigated the differential effect of cerebrospinal fluid (CSF) glial markers on AD pathology and neurodegeneration by sex/gender among cognitively unimpaired older adults at increased risk of developing AD. We included 397 participants from the ALFA+ cohort with CSF Aβ42/40, p-tau181, sTREM2, YKL40, and GFAP, magnetic resonance imaging-based hippocampal volume (n = 299), and amyloid burden (centiloids) measured with [18F] flutemetamol positron emission tomography (n = 341). We ran multiple linear regression models to assess the association between glial markers, AD pathology and hippocampal volumes and their interaction with sex/gender, using False Discovery Rate to correct for multiple comparisons. Glial markers significantly contributed to explain amyloid burden, tau pathology, and hippocampal volumes, beyond age and/or primary AD pathology in a sex/gender-specific manner. Compared to men, women showed increased amyloid burden (centiloids) and CSF p-tau181 with increasing levels of sTREM2 and YKL40, and YKL40 and GFAP, respectively. Compared to women, men with greater tau burden showed lower hippocampal volumes as CSF YKL40 levels increased. Overall, our findings suggest that glial reactivity may contribute to sex/gender differences in AD progression, mostly, downstream amyloid. Further research identifying sex/gender-specific temporal dynamics in AD development is warranted to inform clinical trials., This publication is part of the ALFA study (ALzheimer and FAmilies). The authors would like to express their sincerest gratitude to the ALFA project participants, without whom this research would have not been possible. Collaborators of the ALFA study are: Federica Anastasi, Annabella Beteta, Anna Brugulat-Serrat, Raffaele Cacciaglia, Irene Cumplido-Mayoral, Alba Cañas, Marta del Campo, Carme Deulofeu, Ruth Dominguez, Maria Emilio, Ana Fernández-Arcos, Sherezade Fuentes, Patricia Genius, Armand González-Escalante, Laura Hernández, Felipe Hernández-Villamizar, Jordi Huguet, David López-Martos, Ferran Lugo, Paula Marne, Tania Menchón, Carolina Minguillon, Paula Ortiz, Wiesje Pelkmans, Albina Polo, Sandra Pradas, Blanca Rodríguez-Fernandez, Gonzalo Sánchez-Benavides, Mahnaz Shekari, Anna Soteras, Laura Stankeviciute, Marc Vilanova and Natalia Vilor-Tejedor. The authors would like to thank Jordi Huguet (Barcelonaβeta Brain Research Center, Barcelona) and Robin de Flores (INSERM, Caen, France) for their contributions to hippocampal subfield segmentation with Automated Segmentation of Hippocampal Subfields (ASHS). The Roche NeuroToolKit is a panel of exploratory prototype assays designed to robustly evaluate biomarkers associated with key pathologic events characteristic of AD and other neurological disorders, used for research purposes only and not approved for clinical use. Elecsys β-amyloid (1–42) CSF, Elecsys Phospho-Tau (181P) CSF and Elecsys Total-Tau CSF assays are approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. The research leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. The research leading to these results has received funding by the Ministry of Science and Innovation (PID2019-111514RA-I00) and the Alzheimer’s Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID) to EMA-U. EMA-U is supported by the Spanish Ministry of Science and Innovation - State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF). EMA-U receives support from EU Joint Programme-Neurodegenerative Disease Research J(PND2022-138). EP is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). OG-R is supported by the Spanish Ministry of Science and Innovation –State Research Agency (IJC2020-043417-I/MCIN/AEI/10.13039/501100011033) and the European Union laquoNextGenerationEUraquo/PRTR. MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (Grant agreement No. 948677), the Instituto de Salud Carlos III through the projects PI19/00155 and PI22/00456 (Co-funded by European Regional Development Fund (FEDER) “A way to make Europe”), and receives the support of a fellowship from ”la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (fellowship code LCF/BQ/PR21/11840004). CV-C is supported by a grant from the National Institute on Aging (K99AG073452).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

sTREM2 is associated with amyloid-related p-tau increases and glucose hypermetabolism in Alzheimer's disease

  • Biel, Davina
  • Suárez-Calvet, Marc
  • Hager, Paul
  • Rubinski, Anna
  • Dewenter, Anna
  • Steward, Anna
  • Roemer, Sebastian
  • Ewers, Michael
  • Haass, Christian
  • Brendel, Matthias
  • Franzmeier, Nicolai
  • Alzheimer’s Disease Neuroimaging Initiative
Microglial activation occurs early in Alzheimer's disease (AD) and previous studies reported both detrimental and protective effects of microglia on AD progression. Here, we used CSF sTREM2 to investigate disease stage‐dependent drivers of microglial activation and to determine downstream consequences on AD progression. We included 402 patients with measures of earliest beta‐amyloid (CSF Aβ1‐42) and late‐stage fibrillary Aβ pathology (amyloid‐PET centiloid), as well as sTREM2, p‐tau181, and FDG‐PET. To determine disease stage, we stratified participants into early Aβ‐accumulators (Aβ CSF+/PET−; n = 70) or late Aβ‐accumulators (Aβ CSF+/PET+; n = 201) plus 131 controls. In early Aβ‐accumulators, higher centiloid was associated with cross‐sectional/longitudinal sTREM2 and p‐tau181 increases. Further, higher sTREM2 mediated the association between centiloid and cross‐sectional/longitudinal p‐tau181 increases and higher sTREM2 was associated with FDG‐PET hypermetabolism. In late Aβ‐accumulators, we found no association between centiloid and sTREM2 but a cross‐sectional association between higher sTREM2, higher p‐tau181 and glucose hypometabolism. Our findings suggest that a TREM2‐related microglial response follows earliest Aβ fibrillization, manifests in inflammatory glucose hypermetabolism and may facilitate subsequent p‐tau181 increases in earliest AD., The study was funded by grants from the LMU (FöFoLe,1032, awarded to NF;FöFoLe,1119, awarded to DB), the Hertie foundation for clinical neurosciences(awarded to NF), and the SyNergy excellence cluster (EXC2145/ID390857198).MSC receives funding from the European Research Council (ERC) under theEuropean Union’s Horizon2020research and innovation programme (Grantagreement No.948677), the Instituto de Salud Carlos III (PI19/00155), and froma fellowship from“la Caixa”Foundation (ID100010434) and from theEuropean Union’s Horizon2020research and innovation programme underthe Marie Skłodowska-Curie grant agreement No.847648(LCF/BQ/PR21/11840004). We thank the ADNI participants and their families who made thisstudy possible. Open Access funding enabled and organized by Projekt DEAL.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: an international overview

  • Delaby, Constance
  • Grau, Oriol (Grau Rivera)
  • Puig-Pijoan, Albert
  • Suárez-Calvet, Marc
  • Lehmann, Sylvain
Introduction: the current practice of quantifying cerebrospinal fluid (CSF) biomarkers as an aid in the diagnosis of Alzheimer's disease (AD) varies from center to center. For a same biochemical profile, interpretation and reporting of results may differ, which can lead to misunderstandings and raises questions about the commutability of tests. Methods: We obtained a description of (pre-)analytical protocols and sample reports from 40 centers worldwide. A consensus approach allowed us to propose harmonized comments corresponding to the different CSF biomarker profiles observed in patients. Results: the (pre-)analytical procedures were similar between centers. There was considerable heterogeneity in cutoff definitions and report comments. We therefore identified and selected by consensus the most accurate and informative comments regarding the interpretation of CSF biomarkers in the context of AD diagnosis. Discussion: this is the first time that harmonized reports are proposed across worldwide specialized laboratories involved in the biochemical diagnosis of AD., This manuscript was facilitated by the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART), through the Biofluid Based Biomarkers Professional Interest Area (BBB-PIA). The views and opinions expressed in this publication represent those of the authors and do not necessarily reflect those of the BBB-PIA membership, ISTAART, or the Alzheimer's Association. The authors thank the French Society of Clinical Biology, the ISTAART BBB-PIA, and the Society for Neurochemistry and Clinical CSF analysis for their help in initiating this work. Constance Delaby received no support for the present manuscript. Charlotte Teunissen received the following grants during the last 36 months: Research of CET is supported by the European Commission (Marie Curie International Training Network, grant agreement No 860197 [MIRIADE], and JPND), Health Holland, the Dutch Research Council (ZonMw), Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands, Alzheimer Association. CT and WF are recipients of ABOARD, which is a public-private partnership receiving funding from ZonMw (#73305095007) and Health∼Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). More than 30 partners participate in ABOARD. ABOARD also receives funding from Edwin Bouw Fonds and Gieskes-Strijbisfonds. IV is appointed on a research grant by Alzheimer Nederland (NL-17004). She received no support for the present manuscript. Kaj Blennow is supported by the Swedish Alzheimer Foundation (#AF-742881) and Hjärnfonden, Sweden (#FO2017-0243). He received no support for the present manuscript. Daniel Alcolea received funding from Institute of Health Carlos III (ISCIII), Spain PI18/00435 and INT19/00016, and by the Department of Health Generalitat de Catalunya PERIS program SLT006/17/125. He received no support for the present manuscript. Ivan Arisi was partly supported by: Fondo Ordinario Enti (FOE D.M 865/2019) funds in the framework of a collaboration agreement between the Italian National Research Council and EBRI (2019-2021); POR (Operative Program Lazio Region, Italy) FESR (European Program Regional Development) 2014-2020, Public Notice “LIFE 2020” MODIAG Project. Elodie Bouaziz-Amar received no support for the present manuscript. Anne Beaume received no support for the present manuscript. Aurélie Bedel received no support for the present manuscript. Giovanni Bellomo is supported by University of Perugia, CIRMMP, IRST Istituto Romagnolo per lo Studio e la Cura dei Tumori, Innuvatech srl. He received no support for the present manuscript. Edith Bigot-Corbel received no support for the present manuscript. Maria Bjerke received no support for the present manuscript. Marie-Céline Blanc-Quintin received no support for the present manuscript. Mercè Boada received support from LA CAIXA, IMI, ISCIII H2020 the European Union/EFPIA Innovative Medicines Initiative Joint Undertaking MOPEAD project (Grants No. 115985) and is also supported by national grant, PI17/01474 from Acción Estratégica en Salud, integrated into the Spanish National Plan of R+D+I and founded by ISCIII (Instituto de Salud Carlos III)-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER- “Una manera de Hacer Europa”). She received no support for the present manuscript. Olivier Bousigues is supported by A2MCL Alsace Alzheimer. He received no support for the present manuscript. Miles D. Chapman received no support for the present manuscript. Mari L. DeMarco is supported by the Michael Smith Foundation for Health Research, Brain Canada (Canada Brain Research Fund), Health Canada, Women's Brain Health Initiative, Alzheimer Society of Canada, St. Paul's Foundation, Djavad Mowafaghian Centre for Brain Health at the University of British Columbia and the Canadian Consortium for Neurodegeneration and Aging; with all funds provided to the University of British Columbia. Mara D'Onofrio was partly supported by Fondo Ordinario Enti (FOE D.M 865/2019) funds in the framework of a collaboration agreement between the Italian National Research Council POR (Operative Program Lazio Region, Italy) FESR (European Program Regional Development) 2014-2020, Public Notice “LIFE 2020″, MODIAG Project. She received no support for the present manuscript. Julien Dumurgier received no support for the present manuscript. Diane Dufour received no support for the present manuscript. Sebastiaan Engelborghs is supported for various projects: Research Project GSKE/FMRE, Research Project FWO Vlaanderen, PhD fellowship FWO Vlaanderen (n = 3), VLAIO PhD fellowship. He received no support for the present manuscript. Hermann Esselmann received no support for the present manuscript. Anne Fogli received no support for the present manuscript. Audrey Gabelle received no support for the present manuscript. Elisabetta Galloni received no support for the present manuscript. Clémentine Gondolf received no support for the present manuscript. Frédérique Grandhomme received no support for the present manuscript. Oriol Grau-Rivera receives grants from the Spanish Ministry of Science, Innovation and Universities (FJCI-2017-33437), and from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568). He received no support for the present manuscript. Melanie Hart receives UCLH Biomedical Research Centre support from NIHR (Neurosciences). She received no support for the present manuscript. Takeshi Ikeuchi received the following grants to his institution AMED: 21dk0207049, 21dk0207045, 21ek0109545, 20ek0109350, 20ek0109392. He received no support for the present manuscript. Andreas Jeromin received no support for the present manuscript. Kensaku Kasuga received no support for the present manuscript. Ashvini Keshavan is supported by the Weston Brain Institute/Selfridges Foundation grant UB170045. She received no support for the present manuscript. Michael Khalil received unrestricted research grants from Biogen and Novartis. He received no support for the present manuscript. Peter Körtvelyessy received no support for the present manuscript. Agnieszka Kulczynska-Przybik received no support for the present manuscript. Jean-Louis Laplanche received no support for the present manuscript. Qiao-Xin Li received no support for the present manuscript. Alberto Lleó is supported by grants from Generalitat de Catalunya (PERIS SLT002/16/00408), Instituto de Salud Carlos III (PI17/01896), Instituto de Salud Carlos III CIBERNED. He received no support for the present manuscript. Catherine Malaplate received no support for the present manuscript. Marta Marquié is supported by the Instituto de Salud Carlos III (ISCIII) Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER-Una manera de hacer Europa) grant PI19/00335. She received no support for the present manuscript. Colin M. Masters received no support for the present manuscript. Barbara Mroczko received a grant from The Binding Site Group and Biokom Diagnostyka. She received no support for the present manuscript. Léonor Nogueira received no support for the present manuscript. Adelina Orellana received no support for the present manuscript. Markus Otto is supported by BMBF, Thierry Latran foundation, EU, DFG. He received no support for the present manuscript. Jean-Baptiste Oudart is supported by Astrazeneca grant for a research program on EGFR targeted therapy resistance in NSCLC. He received no support for the present manuscript. Claire Paquet received no support for the present manuscript. Federico Paolini received no support for the present manuscript. Lucilla Parnetti received no support for the present manuscript. Armand Perret-Liaudet received no support for the present manuscript. Katell Peoc'h is supported by contract with Siemens Healthineers. She received no support for the present manuscript. Koen Poesen received no support for the present manuscript. Albert Puig-Pijoan received no support for the present manuscript. Isabelle Quadrio received no support for the present manuscript. Murielle Quillard-Muraine received no support for the present manuscript. Benoît Rucheton received no support for the present manuscript. Susanne Schraen received no support for the present manuscript. Jonathan M. Schott is supported by the Medical Research Council, Alzheimer's Research UK, Weston Brain Institute, British Heart Foundation, Alzheimer's Association. He received no support for the present manuscript. Leslie M. Shaw is supported by NIA for ADNI Biomarker Core, UPENN ADRC Biomarker Corr, MJ Fox PPMI for CSF Biomarker measurements, Roche for IIS study of AD biomarkers. He received no support for the present manuscript. Marc Suárez-Calvet receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (Grant agreement No. 948677). He also receives funding from the Instituto de Salud Carlos III (PI19/00155) and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva Programme grant IJC2018-037478-I). He received no support for the present manuscript. Magda Tsolaki received no support for the present manuscript. Hayrettin Tumani is supported by Alexion, Bayer, Biogen, Celgene, Genzyme-Sanofi, Merck, Novartis, Roche, Teva. He received no support for the present manuscript. Chinedu T Udeh-Momoh is supported by Alzheimer research UK (Project Grant). He received no support for the present manuscript. Lucie Vaudran received no support for the present manuscript. Marcel M. Verbeek is supported by the BIONIC project (no. 733050822, which has been made possible by ZonMw within the framework of “Memorabel,” the research and innovation program for dementia, as part of the Dutch national “Deltaplan for Dementia”: zonmw.nl/dementiaresearch), and the CAFÉ project (the National Institutes of Health, USA, grant number 5R01NS104147-02). The BIONIC project is a consortium of Radboudumc, LUMC, ADX Neurosciences, and University of Rhode Island University. MM Verbeek is also supported by a grant from the Selfridges Group Foundation. He received no support for the present manuscript. Federico Verde received no support for the present manuscript. Lisa Vermunt is supported by Alzheimer Nederland. She received no support for the present manuscript. Jonathan Volgesgang is supported by Clinician Scientist Research Fellowship, German Research Foundation (Deutsche Forschungsgesellschaft, project number: 413501650; 09/01/2019-02/28/2021); Eric Dorris Memorial Fellowship (McLean Hospital; 07/01/2020-06/30/2021). He received no support for the present manuscript. Jens Wiltfang is supported by Federal Ministry of Education and Research (BMBF) State of Lower Saxony; He received no support for the present manuscript. Henrik Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019-0228), the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), and the UK Dementia Research Institute at UCL. He received no support for the present manuscript. Sylvain Lehmann received no support for the present manuscript.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Memory performance mediates subjective sleep quality associations with cerebrospinal fluid Alzheimer's disease biomarker levels and hippocampal volume among individuals with mild cognitive symptoms

  • Stankeviciute, Laura
  • Blackman, Jonathan
  • Tort-Colet, Núria
  • Fernández-Arcos, Ana
  • Sánchez Benavides, Gonzalo
  • Suárez-Calvet, Marc
  • Iranzo, Álex
  • Molinuevo, José Luis
  • Gispert, Juan Domingo
  • Coulthard, Elizabeth
  • Grau, Oriol (Grau Rivera)
Sleep disturbances are prevalent in Alzheimer's disease (AD), affecting individuals during its early stages. We investigated associations between subjective sleep measures and cerebrospinal fluid (CSF) biomarkers of AD in adults with mild cognitive symptoms from the European Prevention of Alzheimer's Dementia Longitudinal Cohort Study, considering the influence of memory performance. A total of 442 participants aged >50 years with a Clinical Dementia Rating (CDR) score of 0.5 completed the Pittsburgh Sleep Quality Index questionnaire and underwent neuropsychological assessment, magnetic resonance imaging acquisition, and CSF sampling. We analysed the relationship of sleep quality with CSF AD biomarkers and cognitive performance in separated multivariate linear regression models, adjusting for covariates. Poorer cross-sectional sleep quality was associated with lower CSF levels of phosphorylated tau and total tau alongside better immediate and delayed memory performance. After adjustment for delayed memory scores, associations between CSF biomarkers and sleep quality became non-significant, and further analysis revealed that memory performance mediated this relationship. In post hoc analyses, poorer subjective sleep quality was associated with lesser hippocampal atrophy, with memory performance also mediating this association. In conclusion, worse subjective sleep quality is associated with less altered AD biomarkers in adults with mild cognitive symptoms (CDR score 0.5). These results could be explained by a systematic recall bias affecting subjective sleep assessment in individuals with incipient memory impairment. Caution should therefore be exercised when interpreting subjective sleep quality measures in memory-impaired populations, emphasising the importance of complementing subjective measures with objective assessments., Data used in the preparation of this article were obtained from the Longitudinal Cohort Study (LCS), delivered by the European Prevention of Alzheimer's Disease (EPAD) Consortium. As such investigators within the EPAD-LCS and EPAD Consortium contributed to the design and implementation of EPAD and/or provided data but did not participate in the analysis or writing of this report. A complete list of EPAD Investigators can be found at: https://ep-ad.org/wp-content/uploads/2020/12/202010_List-of-epadistas.pdf. The EPAD-LCS was launched in 2015 as a public–private partnership, led by Chief Investigator Professor Craig Ritchie MB BS. This work used data and/or samples from the EPAD project which received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement number 115736 and an Alzheimer's Association Grant (SG21-818099-EPAD).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A head-to-head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic

  • Anastasi, Federica
  • Fernández-Lebrero, Aida
  • Ortiz Romero, Paula, 1994-
  • Torres-Torronteras, Javier
  • González Escalante, Armand
  • Contador, José
  • García Escobar, Greta
  • Manero, Rosa María
  • Navalpotro-Gómez, Irene
  • Jiménez-Moyano, Esther
  • Grau, Oriol (Grau Rivera)
  • Campo, Marta del
  • Puig-Pijoan, Albert
  • Suárez-Calvet, Marc
Introduction: Blood-based biomarkers for Alzheimer's disease (AD) have been widely studied, but direct comparisons of several biomarkers in clinical settings remain limited. Methods: In this cross-sectional study, plasma biomarkers from 197 participants in the BIODEGMAR cohort (Hospital del Mar, Barcelona) were analyzed. Participants were classified based on AD cerebrospinal fluid (CSF) core biomarkers. We assessed the ability of plasma p-tau181, p-tau217, p-tau231, t-tau, and Aβ42/40 to classify Aβ pathology status. Results: Plasma p-tau biomarkers had a greater diagnostic performance and larger effect sizes compared to t-tau and Aβ42/40 assays in detecting Aβ pathology. Among them, plasma p-tau217 consistently outperformed the others, demonstrating superior area under the curves. Furthermore, p-tau217 showed the strongest correlation between plasma and CSF levels, underscoring its potential as a reliable surrogate for CSF biomarkers. Discussion: Several plasma biomarkers, targeting different epitopes and using different platforms, demonstrated high performance in detecting AD in a memory clinic setting. Highlights: Plasma p-tau biomarkers demonstrated higher diagnostic performance and larger effect sizes than t-tau and Aβ42/40 assays in detecting Alzheimer's disease. Among the p-tau biomarkers, p-tau217 assays consistently outperformed the others, providing superior classification of Aβ pathology status across different phosphorylation sites. p-tau217 assays showed the strongest correlation between plasma and CSF levels, indicating its potential as a reliable surrogate for CSF biomarkers. Several plasma p-tau biomarkers can be used in a specialized memory clinic to accurately detect Alzheimer's disease., Federica Anastasi receives funding from the JDC2022-049347-I grant, funded by the MCIU/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR. Henrik Zetterberg is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union's Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer's Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). Marc Suárez-Calvet receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through the project SLD077/21/000001; Project “PI19/00155″ and “PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from ”la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts

  • Lantero Rodríguez, Juan
  • Vrillon, Agathe
  • Fernández-Lebrero, Aida
  • Ortiz Romero, Paula, 1994-
  • Snellman, Anniina
  • Montoliu-Gaya, Laia
  • Brum, Wagner S.
  • Cognat, Emmanuel
  • Dumurgier, Julien
  • Puig-Pijoan, Albert
  • Navalpotro-Gómez, Irene
  • García-Escobar, Greta
  • Karikari, Thomas K.
  • Vanmechelen, Eugeen
  • Ashton, Nicholas J.
  • Zetterberg, Henrik
  • Suárez-Calvet, Marc
  • Paquet, Claire
  • Blennow, Kaj
Background Cerebrospinal fluid (CSF) p-tau235 is a novel biomarker highly specific of Alzheimer’s disease (AD). However, CSF p-tau235 has only been studied in well-characterized research cohorts, which do not fully reflect the patient landscape found in clinical settings. Therefore, in this multicentre study, we investigated the performance of CSF p-tau235 to detect symptomatic AD in clinical settings and compared it with CSF p-tau181, p-tau217 and p-tau231. Methods CSF p-tau235 was measured using an in-house single molecule array (Simoa) assay in two independent memory clinic cohorts: Paris cohort (Lariboisière Fernand-Widal University Hospital Paris, France; n=212) and BIODEGMAR cohort (Hospital del Mar, Barcelona, Spain; n=175). Patients were classified by the syndromic diagnosis (cognitively unimpaired [CU], mild cognitive impairment [MCI] or dementia) and their biological diagnosis (amyloid-beta [Aβ]+ or Aβ ). Both cohorts included detailed cognitive assessments and CSF biomarker measurements (clinically validated core AD biomarkers [Lumipulse CSF Aβ1–42/40 ratio, p-tau181 and t-tau] and in-house developed Simoa CSF p-tau181, p-tau217 and p-tau231). Results High CSF p-tau235 levels were strongly associated with CSF amyloidosis regardless of the clinical diagnosis, being significantly increased in MCI Aβ+ and dementia Aβ+ when compared with all other Aβ− groups (Paris cohort: P ˂0.0001 for all; BIODEGMAR cohort: P ˂0.05 for all). CSF p-tau235 was pronouncedly increased in the A+T+ profile group compared with A−T− and A+T− groups (P ˂0.0001 for all). Moreover, CSF p-tau235 demonstrated high diagnostic accuracies identifying CSF amyloidosis in symptomatic cases (AUCs=0.86 to 0.96) and discriminating AT groups (AUCs=0.79 to 0.98). Overall, CSF p-tau235 showed similar performances to CSF p-tau181 and CSF p-tau231 when discriminating CSF amyloidosis in various scenarios, but lower than CSF p-tau217. Finally, CSF p-tau235 associated with global cognition and memory domain in both cohorts. Conclusions CSF p-tau235 was increased with the presence of CSF amyloidosis in two independent memory clinic cohorts. CSF p-tau235 accurately identified AD in both MCI and dementia patients. Overall, the diagnostic performance of CSF p-tau235 was comparable to that of other CSF p-tau measurements, indicating its suitability to support a biomarker-based AD diagnosis in clinical settings., Open access funding provided by University of Gothenburg. This study was funded by the Swedish Research Council (#2017-00915 and #2022-00732), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-742881), Hjärnfonden, Sweden (#FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236) and the National Institute of Health (NIH), USA, (grant #1R01AG068398-01). AV is supported by Fondation Ophtalmologique Adolphe de Rothschild and Fondation Vaincre Alzheimer. AES was supported by the Paulo Foundation, the Orion Research Foundation sr, and currently holds a postdoctoral fellowship from the Academy of Finland (#341059). TKK was funded by the Swedish Research Council (Vetenskapsrådet #2021-03244), the Alzheimer’s Association Research Fellowship (#AARF-21-850325), the Aina (Ann) Wallströms and Mary-Ann Sjöbloms stiftelsen and the Emil och Wera Cornells stiftelsen. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694) and the UK Dementia Research Institute at UCL (UKDRI-1003). MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677), Project “PI19/00155”, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

P-tau235: a novel biomarker for staging preclinical Alzheimer's disease

  • Lantero Rodriguez, Juan
  • Snellman, Anniina
  • Benedet, Andrea L.
  • Milà Alomà, Marta
  • Camporesi, Elena
  • Montoliu-Gaya, Laia
  • Ashton, Nicholas J.
  • Vrillon, Agathe
  • Karikari, Thomas K.
  • Gispert, Juan Domingo
  • Salvadó, Gemma
  • Shekari, Mahnaz
  • Toomey, Christina E.
  • Lashley, Tammaryn L.
  • Zetterberg, Henrik
  • Suárez-Calvet, Marc
  • Brinkmalm, Gunnar
  • Rosa-Neto, Pedro
  • Blennow, Kaj
Alzheimer's disease (AD) is characterised by a long preclinical phase. Although phosphorylated tau (p-tau) species such as p-tau217 and p-tau231 provide accurate detection of early pathological changes, other biomarkers capable of staging disease progression during preclinical AD are still needed. Combining exploratory and targeted mass spectrometry methods in neuropathologically confirmed brain tissue, we observed that p-tau235 is a prominent feature of AD pathology. In addition, p-tau235 seemed to be preceded by p-tau231, in what appeared to be a sequential phosphorylation event. To exploit its biomarker potential in cerebrospinal fluid (CSF), we developed and validated a new p-tau235 Simoa assay. Using three clinical cohorts, we demonstrated that (i) CSF p-235 increases early in AD continuum, and (ii) changes in CSF p-tau235 and p-tau231 levels during preclinical AD are consistent with the sequential phosphorylation evidence in AD brain. In conclusion, CSF p-tau235 appears to be not only a highly specific biomarker of AD but also a promising staging biomarker for the preclinical phase. Thus, it could prove useful tracking disease progression and help enriching clinical trial recruitment.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: the NeuroToolKit

  • Johnson, Sterling C.
  • Suárez-Calvet, Marc
  • Suridjan, Ivonne
  • Minguillón, Carolina
  • Gispert, Juan Domingo
  • Jonaitis, Erin
  • Michna, Agatha
  • Carboni, Margherita
  • Bittner, Tobias
  • Rabe, Christina
  • Kollmorgen, Gwendlyn
  • Zetterberg, Henrik
  • Blennow, Kaj
Background: Alzheimer's disease (AD) is a complex and heterogeneous disease, which requires reliable biomarkers for diagnosis and monitoring disease activity. Preanalytical protocol and technical variability associated with biomarker immunoassays makes comparability of biomarker data across multiple cohorts difficult. This study aimed to compare cerebrospinal fluid (CSF) biomarker results across independent cohorts, including participants spanning the AD continuum. Methods: Measured on the NeuroToolKit (NTK) prototype panel of immunoassays, 12 CSF biomarkers were evaluated from three cohorts (ALFA+, Wisconsin, and Abby/Blaze). A correction factor was applied to biomarkers found to be affected by preanalytical procedures (amyloid-β1-42, amyloid-β1-40, and alpha-synuclein), and results between cohorts for each disease stage were compared. The relationship between CSF biomarker concentration and cognitive scores was evaluated. Results: Biomarker distributions were comparable across cohorts following correction. Correlations of biomarker values were consistent across cohorts, regardless of disease stage. Disease stage differentiation was highest for neurofilament light (NfL), phosphorylated tau, and total tau, regardless of the cohort. Correlation between biomarker concentration and cognitive scores was comparable across cohorts, and strongest for NfL, chitinase-3-like protein-1 (YKL40), and glial fibrillary acidic protein. Discussion: The precision of the NTK enables merging of biomarker datasets, after correction for preanalytical confounders. Assessment of multiple cohorts is crucial to increase power in future studies into AD pathogenesis., The ALFA+ study receives funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). For the Wisconsin studies, CSF assay kits were provided by Roche Diagnostics GmbH. Data were collected under the following grants from the NIH National Institute of Aging: R01 AG027161, R01 AG037639, R01AG054059 UF1AG051216, P50 AG033514, and P30 AG062715. Support was also provided by the NIH National Center for Advancing Translational Sciences (NCATS), grant UL1TR000427 (Clinical and Translational Sciences). MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 Research and Innovation Programme (grant agreement No. 948677), the Instituto de Salud Carlos III (PI19/00155), and a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie (grant agreement No. 847648; LCF/BQ/PR21/11840004). JDG is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054). JDG has also received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (Grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018-102261). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532); the European Research Council (#681712); Swedish State Support for Clinical Research (#ALFGBG-720931); the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862); the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C); the Olav Thon Foundation; the Erling-Persson Family Foundation; Stiftelsen för Gamla Tjänarinnor; Hjärnfonden, Sweden (#FO2019-0228); the European Union’s Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE); and the UK Dementia Research Institute at UCL. KB is supported by the Swedish Research Council (#2017-00915); the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615); the Swedish Alzheimer Foundation (#AF-742881); Hjärnfonden, Sweden (#FO2017-0243); the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986); the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236); the National Institute of Health (NIH), USA (grant #1R01AG068398-01); and the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease

  • Milà Alomà, Marta
  • Shekari, Mahnaz
  • Salvadó, Gemma
  • Ortiz Romero, Paula, 1994-
  • González Escalante, Armand
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Gispert, Juan Domingo
  • Suárez-Calvet, Marc
  • Blennow, Kaj
Blood biomarkers indicating elevated amyloid-β (Aβ) pathology in preclinical Alzheimer's disease are needed to facilitate the initial screening process of participants in disease-modifying trials. Previous biofluid data suggest that phosphorylated tau231 (p-tau231) could indicate incipient Aβ pathology, but a comprehensive comparison with other putative blood biomarkers is lacking. In the ALFA+ cohort, all tested plasma biomarkers (p-tau181, p-tau217, p-tau231, GFAP, NfL and Aβ42/40) were significantly changed in preclinical Alzheimer's disease. However, plasma p-tau231 reached abnormal levels with the lowest Aβ burden. Plasma p-tau231 and p-tau217 had the strongest association with Aβ positron emission tomography (PET) retention in early accumulating regions and associated with longitudinal increases in Aβ PET uptake in individuals without overt Aβ pathology at baseline. In summary, plasma p-tau231 and p-tau217 better capture the earliest cerebral Aβ changes, before overt Aβ plaque pathology is present, and are promising blood biomarkers to enrich a preclinical population for Alzheimer's disease clinical trials., The research leading to these results received funding from ‘la Caixa’ Foundation (ID 100010434), under agreement LCF/PR/GN17/10300004 and the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). E.V. was supported by Flanders Innovation and Entrepreneurship (VLAIO grant no. 140105). C.M. received funding within the context of EURO-FINGERS, a EU Joint Programme–Neurodegenerative Disease Research (JPND) project. The EURO-FINGERS project is supported through the following funding organizations under the aegis of JPND—www.jpnd.eu: Finland: Academy of Finland; Germany: Federal Ministry of Education and Research; Spain: National Institute of Health Carlos III; Luxembourg: National Research Fund; Hungary: National Research, Development and Innovation Office; and The Netherlands: Netherlands Organisation for Health Research and Development (ZonMW-Memorabel no. 733051102). H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (grant no. 2018-02532), the European Research Council (ERC, grant no. 681712), Swedish State Support for Clinical Research (grant no. ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (grant no. 201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (grant nos. ADSF-21-831376-C, ADSF-21-831381-C and ADSF-21-831377-C), the Olav Thon Foundation, the Erling–Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (grant no. FO2019-0228), the EU’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement no. 860197 (MIRIADE) and the UK Dementia Research Institute at University College London (UCL). J.D.G. is supported by the Spanish Ministry of Economy and Competitiveness (RYC-2013-13054) and received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant no. 115952) and from Ministerio de Ciencia, Innovación y Universidades (grant no. RTI2018-102261). M.S.C. receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 948677), the Instituto de Salud Carlos III (PI19/00155), and from the ERC under the EU’s ‘la Caixa’ Foundation (ID 100010434) and from the EU’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant (no. 847648, LCF/BQ/PR21/11840004). K.B. is supported by the Swedish Research Council (grant no. 2017-00915), the ADDF, USA (grant no. RDAPB-201809-2016615), the Swedish Alzheimer Foundation (grant no. AF-742881) (grant nos. AF-930351, AF-939721 and AF-968270), Hjärnfonden, Sweden (grant nos. FO2017-0243 and ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF agreement (grant nos. ALFGBG-715986 and ALFGBG-965240), the EU Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the National Institutes of Health (grant no. 1R01AG068398-01) and the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Omega-3 blood biomarkers relate to brain glucose uptake in individuals at risk of Alzheimer's disease dementia

  • Lázaro, Iolanda
  • Grau, Oriol (Grau Rivera)
  • Suárez-Calvet, Marc
  • Fauria, Karine
  • Minguillón, Carolina
  • Shekari, Mahnaz
  • Falcón, Carles
  • Garcia Prat, Marina
  • Huguet, Jordi
  • Molinuevo, José Luis
  • Gispert, Juan Domingo
  • Sala Vila, Aleix
  • ALFA Study
Introduction: Brain glucose hypometabolism is a preclinical feature of Alzheimer's disease (AD). Dietary omega-3 fatty acids promote brain glucose metabolism, but clinical research is incipient. Circulating omega-3s objectively reflect their dietary intake. Methods: This was a cross-sectional study in 320 cognitively unimpaired participants at increased risk of AD dementia. Using lipidomics, we determined blood docosahexaenoic (DHA) and alpha-linolenic (ALA) acid levels (omega-3s from marine and plant origin, respectively). We assessed brain glucose metabolism using [18-F]-fluorodeoxyglucose (FDG) positron emission tomography (PET). Results: Blood ALA directly related to FDG uptake in brain areas known to be affected in AD. Stronger associations were observed in apolipoprotein E ε4 carriers and homozygotes. For DHA, significant direct associations were restricted to amyloid beta-positive tau-positive participants. Discussion: Blood omega-3 directly relate to preserved glucose metabolism in AD-vulnerable brain regions in individuals at increased risk of AD dementia. This adds to the benefits of omega-3 supplementation in the preclinical stage of AD dementia. Highlights: Blood omega-3s were related to brain glucose uptake in participants at risk of Alzheimer's disease (AD) dementia.Complementary associations were observed for omega-3 from marine and plant sources.Foods rich in omega-3 might be useful in early features of AD., The research leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. OG-R is supported by the Spanish Ministry of Science and Innovation –State Research Agency (IJC2020-043417-I/MCIN/AEI/10.13039/501100011033) and the European Union laquoNextGenerationEUraquo/PRTR. MSC receives funding from the European Research Council (ERC) under the European Unionʼs Horizon 2020 research and innovation programme (Grant agreement No. 948677), Project “PI19/00155,” funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Unionʼs Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648(LCF/BQ/PR21/11840004). This work was supported by funding from Instituto de Salud Carlos III (PI22/00071) and by a grant from the California Walnut Commission, Folsom, CA, US (to AS-V). The funding agencies had no input in the study design, data collection, analyses, or writing and submission of the manuscript.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profile

  • Milà Alomà, Marta
  • Shekari, Mahnaz
  • Salvadó, Gemma
  • Gispert, Juan Domingo
  • Arenaza Urquijo, Eider M.
  • Operto, Grégory
  • Falcón, Carles
  • Vilor Tejedor, Natàlia, 1988-
  • Grau, Oriol (Grau Rivera)
  • Sala Vila, Aleix
  • Sánchez Benavides, Gonzalo
  • González de Echávarri, José Maria
  • Minguillón, Carolina
  • Suárez-Calvet, Marc
  • Molinuevo, José Luis
  • ALFA Study
Background: Understanding the changes that occur in the transitional stage between absent and overt amyloid-β (Aβ) pathology within the Alzheimer's continuum is crucial to develop therapeutic and preventive strategies. The objective of this study is to test whether cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF, structural, and functional neuroimaging biomarker profile. Methods: Cross-sectional study of 318 middle-aged, cognitively unimpaired individuals from the ALFA+ cohort. We measured CSF Aβ42/40, phosphorylated tau (p-tau), total tau (t-tau), neurofilament light (NfL), neurogranin, sTREM2, YKL40, GFAP, IL6, S100B, and α-synuclein. Participants also underwent cognitive assessments, APOE genotyping, structural MRI, [18F]-FDG, and [18F]-flutemetamol PET. To ensure the robustness of our results, we used three definitions of low burden of Aβ pathology: (1) positive CSF Aβ42/40 and < 30 Centiloids in Aβ PET, (2) positive CSF Aβ42/40 and negative Aβ PET visual read, and (3) 20-40 Centiloid range in Aβ PET. We tested CSF and neuroimaging biomarker differences between the low burden group and the corresponding Aβ-negative group, adjusted by age and sex. Results: The prevalence and demographic characteristics of the low burden group differed between the three definitions. CSF p-tau and t-tau were increased in the low burden group compared to the Aβ-negative in all definitions. CSF neurogranin was increased in the low burden group definitions 1 and 3, while CSF NfL was only increased in the low burden group definition 1. None of the defined low burden groups showed signs of atrophy or glucose hypometabolism. Instead, we found slight increases in cortical thickness and metabolism in definition 2. Conclusions: There are biologically meaningful Aβ-downstream effects in individuals with a low burden of Aβ pathology, while structural and functional changes are still subtle or absent. These findings support considering individuals with a low burden of Aβ pathology for clinical trials. Trial registration: NCT02485730., The research leading to these results has received funding from “la Caixa” Foundation (LCF/PR/GN17/10300004) and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2017-SGR-892. JDG holds a “Ramón y Cajal” fellowship (RYC-2013-13054). EMA-U is supported by the Spanish Ministry of Science, Innovation and Universities - Spanish State Research Agency (RYC2018-026053-I). NV-T is funded by a post-doctoral grant, Juan de la Cierva Programme (FJC2018-038085-I), Ministry of Science and Innovation–Spanish State Research Agency. OG-R is supported by the Spanish Ministry of Science, Innovation and Universities (FJCI-2017-33437), and receives funding from the Alzheimer’s Association Research Fellowship Program (2019-AARF-644568). ASV is the recipient of an Instituto de Salud Carlos III Miguel Servet II fellowship (CP II 17/00029). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), and the UK Dementia Research Institute at UCL. KB is supported by the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-742881), Hjärnfonden, Sweden (#FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986), and European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236). MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (Grant agreement No. 948677). MSC also receives funding from the Instituto de Salud Carlos III (PI19/00155) and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva Programme grant IJC2018-037478-I).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the alzheimer disease continuum

  • Benedet, Andrea L.
  • Milà Alomà, Marta
  • Salvadó, Gemma
  • Shekari, Mahnaz
  • Operto, Grégory
  • Gispert, Juan Domingo
  • Minguillón, Carolina
  • Molinuevo, José Luis
  • Suárez-Calvet, Marc
  • Translational Biomarkers in Aging and Dementia (TRIAD) study
  • ALFA Study
  • BioCogBank Paris Lariboisière cohort
Importance: Glial fibrillary acidic protein (GFAP) is a marker of reactive astrogliosis that increases in the cerebrospinal fluid (CSF) and blood of individuals with Alzheimer disease (AD). However, it is not known whether there are differences in blood GFAP levels across the entire AD continuum and whether its performance is similar to that of CSF GFAP. Objective: To evaluate plasma GFAP levels throughout the entire AD continuum, from preclinical AD to AD dementia, compared with CSF GFAP. Design, setting, and participants: This observational, cross-sectional study collected data from July 29, 2014, to January 31, 2020, from 3 centers. The Translational Biomarkers in Aging and Dementia (TRIAD) cohort (Montreal, Canada) included individuals in the entire AD continuum. Results were confirmed in the Alzheimer's and Families (ALFA+) study (Barcelona, Spain), which included individuals with preclinical AD, and the BioCogBank Paris Lariboisière cohort (Paris, France), which included individuals with symptomatic AD. Main outcomes and measures: Plasma and CSF GFAP levels measured with a Simoa assay were the main outcome. Other measurements included levels of CSF amyloid-β 42/40 (Aβ42/40), phosphorylated tau181 (p-tau181), neurofilament light (NfL), Chitinase-3-like protein 1 (YKL40), and soluble triggering receptor expressed on myeloid cells 2 (sTREM2) and levels of plasma p-tau181 and NfL. Results of amyloid positron emission tomography (PET) were available in TRIAD and ALFA+, and results of tau PET were available in TRIAD. Results: A total of 300 TRIAD participants (177 women [59.0%]; mean [SD] age, 64.6 [17.6] years), 384 ALFA+ participants (234 women [60.9%]; mean [SD] age, 61.1 [4.7] years), and 187 BioCogBank Paris Lariboisière participants (116 women [62.0%]; mean [SD] age, 69.9 [9.2] years) were included. Plasma GFAP levels were significantly higher in individuals with preclinical AD in comparison with cognitively unimpaired (CU) Aβ-negative individuals (TRIAD: Aβ-negative mean [SD], 185.1 [93.5] pg/mL, Aβ-positive mean [SD], 285.0 [142.6] pg/mL; ALFA+: Aβ-negative mean [SD], 121.9 [42.4] pg/mL, Aβ-positive mean [SD], 169.9 [78.5] pg/mL). Plasma GFAP levels were also higher among individuals in symptomatic stages of the AD continuum (TRIAD: CU Aβ-positive mean [SD], 285.0 [142.6] pg/mL, mild cognitive impairment [MCI] Aβ-positive mean [SD], 332.5 [153.6] pg/mL; AD mean [SD], 388.1 [152.8] pg/mL vs CU Aβ-negative mean [SD], 185.1 [93.5] pg/mL; Paris: MCI Aβ-positive, mean [SD], 368.6 [158.5] pg/mL; AD dementia, mean [SD], 376.4 [179.6] pg/mL vs CU Aβ-negative mean [SD], 161.2 [67.1] pg/mL). Plasma GFAP magnitude changes were consistently higher than those of CSF GFAP. Plasma GFAP more accurately discriminated Aβ-positive from Aβ-negative individuals than CSF GFAP (area under the curve for plasma GFAP, 0.69-0.86; area under the curve for CSF GFAP, 0.59-0.76). Moreover, plasma GFAP levels were positively associated with tau pathology only among individuals with concomitant Aβ pathology. Conclusions and relevance: This study suggests that plasma GFAP is a sensitive biomarker for detecting and tracking reactive astrogliosis and Aβ pathology even among individuals in the early stages of AD., The Translational Biomarkers in Aging and Dementia (TRIAD) is supported by the Canadian Institutes of Health Research (MOP-11-51-31; RFN 152985, 159815, 162303); Canadian Consortium of Neurodegeneration and Aging (MOP-11-51-31 -team 1); Weston Brain Institute, Brain Canada Foundation (Canadian Foundation for Innovation Project 34874; 33397), and the Fonds de Recherche du Québec–Santé (Chercheur Boursier, 2020-VICO-279314). The Alzheimer’s and Families (ALFA) study receives funding from “La Caixa” Foundation (LCF/PR/GN17/10300004) and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Dr Benedet is supported by the Swedish Alzheimer Foundation, Stiftelsen för Gamla Tjänarinnor, and Stohne Stiftelsen. Dr Vrillon is supported by Fondation Adolphe de Rotschild, Fondation Philippe Chatrier, Association des Anciens Internes des Hôpitaux de Paris, Fondation Vaincre Alzheimer, Stiftelsen för Gamla Tjänarinnor, Demensfundet, and Stohne Stiftelsen. Dr Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (grant 2018-02532), the European Research Council (grant 681712), Swedish State Support for Clinical Research (grant ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF) (grant 201809-2016862), the Alzheimer Disease (AD) Strategic Fund and the Alzheimer’s Association (grants ADSF-21-831376-C, ADSF-21-831381-C, and ADSF-21-831377-C), the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (grant FO2019-0228), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), and the UK Dementia Research Institute at University College London. Dr Blennow is supported by the Swedish Research Council (grant 2017-00915), the ADDF (grant RDAPB-201809-2016615), the Swedish Alzheimer Foundation (grant AF-742881), Hjärnfonden, Sweden (grant FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the Avtal om Läkarutbildning och Forskining agreement (grant ALFGBG-715986), the European Union Joint Program for Neurodegenerative Disorders (grant JPND2019-466-236), and the National Institutes of Health (grant 1R01AG068398-01). Dr Suárez-Calvet receives funding from the European Research Council under the European Union’s Horizon 2020 research and innovation programme (grant 948677), the Instituto de Salud Carlos III (grant PI19/00155), and the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva Programme grant IJC2018-037478-I).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Subjective cognitive decline and anxious/depressive symptoms during the COVID-19 pandemic: what is the role of stress perception, stress resilience, and β-amyloid?

  • Akinci, Muge
  • Sánchez Benavides, Gonzalo
  • Brugulat Serrat, Anna, 1986-
  • Peña-Gómez, Cleofé
  • Palpatzis, Eleni
  • Shekari, Mahnaz
  • Deulofeu, Carme
  • Fuentes-Julian, Sherezade
  • Salvadó, Gemma
  • González de Echávarri, José Maria
  • Suárez-Calvet, Marc
  • Minguillón, Carolina
  • Fauria, Karine
  • Molinuevo, José Luis
  • Gispert, Juan Domingo
  • Grau, Oriol (Grau Rivera)
  • Arenaza Urquijo, Eider M.
  • ALFA Study
Background: the COVID-19 pandemic may worsen the mental health of people reporting subjective cognitive decline (SCD) and therefore their clinical prognosis. We aimed to investigate the association between the intensity of SCD and anxious/depressive symptoms during confinement and the underlying mechanisms. Methods: two hundred fifty cognitively unimpaired participants completed the Hospital Anxiety and Depression Scale (HADS) and SCD-Questionnaire (SCD-Q) and underwent amyloid-β positron emission tomography imaging with [18F] flutemetamol (N = 205) on average 2.4 (± 0.8) years before the COVID-19 confinement. During the confinement, participants completed the HADS, Perceived Stress Scale (PSS), Brief Resilience Scale (BRS), and an ad hoc questionnaire on worries (access to primary products, self-protection materials, economic situation) and lifestyle changes (sleep duration, sleep quality, eating habits). We investigated stress-related measurements, worries, and lifestyle changes in relation to SCD. We then conducted an analysis of covariance to investigate the association of SCD-Q with HADS scores during the confinement while controlling for pre-confinement anxiety/depression scores and demographics. Furthermore, we introduced amyloid-β positivity, PSS, and BRS in the models and performed mediation analyses to explore the mechanisms explaining the association between SCD and anxiety/depression. Results: in the whole sample, the average SCD-Q score was 4.1 (± 4.4); 70 (28%) participants were classified as SCD, and 26 (12.7%) were amyloid-β-positive. During the confinement, participants reporting SCD showed higher PSS (p = 0.035) but not BRS scores (p = 0.65) than those that did not report SCD. No differences in worries or lifestyle changes were observed. Higher SCD-Q scores showed an association with greater anxiety/depression scores irrespective of pre-confinement anxiety/depression levels (p = 0.002). This association was not significant after introducing amyloid-β positivity and stress-related variables in the model (p = 0.069). Amyloid-β positivity and PSS were associated with greater HADS irrespective of pre-confinement anxiety/depression scores (p = 0.023; p < 0.001). The association of SCD-Q with HADS was mediated by PSS (p = 0.01). Conclusions: higher intensity of SCD, amyloid-β positivity, and stress perception showed independent associations with anxious/depressive symptoms during the COVID-19 confinement irrespective of pre-confinement anxiety/depression levels. The association of SCD intensity with anxiety/depression was mediated by stress perception, suggesting stress regulation as a potential intervention to reduce affective symptomatology in the SCD population in the face of stressors., This research was supported by Alzheimer’s Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID) to EMAU. EMAU holds a “Ramón y Cajal” fellowship (RYC2018-026053-I). EMAU holds a grant from the Ministry of Science and Innovation (PID2019-111514RA-I00). The research leading to these results has received funding from the “la Caixa” Foundation (LCF/PR/GN17/10300004), the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project. Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant 2017-SGR-892. MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant Agreement No. 948677) and the Instituto de Salud Carlos III (PI19/00155) and a fellowship from “la Caixa” Foundation (ID 100010434) and the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 847648 (LCF/BQ/PR21/11840004).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Proteomic polygenic risk scores of age-related plasma protein levels reveal a role for Metalloproteinase inhibitor 2 (TIMP2) in cognitive performance

  • Anastasi, Federica
  • Genius, Patricia
  • Rodríguez-Fernández, Blanca
  • Yang, Chengran
  • Gorijala, Priyanka
  • Timsina, Jigyasha
  • Hernández-Villamizar, Felipe
  • Lorenzini, Luigi
  • Campo, Marta del
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Cruchaga, Carlos
  • Suárez-Calvet, Marc
  • Vilor Tejedor, Natàlia, 1988-
Several studies in mice have identified blood proteins that influence brain aging, yet translating these findings into humans remains challenging. To address this gap, we conducted a systematic review that identified 12 proteins reported to have an aging or rejuvenating effect in murine brains. Using protein quantitative trait loci data, we computed proteomic polygenic risk scores (protPRSs) capturing the lifelong genetic predisposition to higher or lower plasma protein levels and their regulation. We first validated the prediction accuracy of these protPRSs in two independent cohorts: 10 protPRSs in the Knight-ADRC and 7 protPRSs in the ALFA+ cohort significantly predicted their corresponding protein levels, although effect sizes were modest. We then examined their association with cognitive performance in cognitively unimpaired individuals at risk of Alzheimer's disease of the ALFA+ cohort. Among the protPRSs tested, the metalloproteinase inhibitor 2 (TIMP2) protPRS was significantly associated with better global cognition and episodic memory. These associations were consistent across stratifications by sex, APOE-ε4, and amyloid-β status, although some did not survive multiple testing corrections. TIMP2 protPRS correlated with measured TIMP2 levels, but actual plasma concentrations were not significantly related to cognition. This finding aligns with murine evidence of TIMP2's brain-rejuvenating role. By leveraging genetic predisposition to protein abundance and regulation, protPRSs may provide complementary insight into long-term biological processes not captured by single protein measurements. Our results support TIMP2 as a candidate for further investigation in the context of brain aging and cognitive decline., This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, the Neurogenomics and Informatics Center (NGI: https://neurogenomics.wustl.edu/)and the Departments of Neurology and Psychiatry at Washington University School of Medicine. MS-C receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed (ERAPERMED2021-184); Project "PI19/00155" and "PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from "la Caixa" Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). NV-T was supported by the Spanish Ministry of Science and Innovation - State Research Agency (IJC2020-043216-I/MCIN/AEI/10.13039/501100011033) and the European Union «NextGenerationEU»/PRTR and currently receives funding from the Spanish Research Agency MICIU/AEI/10.13039/501100011033 (grant RYC2022-038136-I cofunded by the European Union FSE+ and grant PID2022-143106OA-I00 cofunded by the European Union FEDER). Additionally, NV-T is supported in part by the William H. Gates Sr. Fellowship from the Alzheimer's Disease Data Initiative. All CRG authors acknowledge the support of the Spanish Ministry of Science, Innovation, and Universities to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

APOE-ε4 modulates the association between regional amyloid deposition and cognitive performance in cognitively unimpaired middle-aged individuals

  • Brugulat Serrat, Anna, 1986-
  • Sánchez Benavides, Gonzalo
  • Cacciaglia, Raffaele
  • Shekari, Mahnaz
  • Milà Alomà, Marta
  • Vilor Tejedor, Natàlia, 1988-
  • Operto, Grégory
  • Falcón, Carles
  • Grau, Oriol (Grau Rivera)
  • Arenaza Urquijo, Eider M.
  • Minguillón, Carolina
  • Fauria, Karine
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • ALFA Study
Purpose: To determine whether the APOE-ε4 allele modulates the relationship between regional β-amyloid (Aβ) accumulation and cognitive change in middle-aged cognitively unimpaired (CU) participants. Methods: The 352 CU participants (mean aged 61.1 [4.7] years) included completed two cognitive assessments (average interval 3.34 years), underwent [18F]flutemetamol Aβ positron emission tomography (PET), T1w magnetic resonance imaging (MRI), as well as APOE genotyping. Global and regional Aβ PET positivity was assessed across five regions-of-interest by visual reading (VR) and regional Centiloids. Linear regression models were developed to examine the interaction between regional and global Aβ PET positivity and APOE-ε4 status on longitudinal cognitive change assessed with the Preclinical Alzheimer's Cognitive Composite (PACC), episodic memory, and executive function, after controlling for age, sex, education, cognitive baseline scores, and hippocampal volume. Results: In total, 57 participants (16.2%) were VR+ of whom 41 (71.9%) were APOE-ε4 carriers. No significant APOE-ε4*global Aβ PET interactions were associated with cognitive change for any cognitive test. However, APOE-ε4 carriers who were VR+ in temporal areas (n = 19 [9.81%], p = 0.04) and in the striatum (n = 8 [4.14%], p = 0.01) exhibited a higher decline in the PACC. The temporal areas findings were replicated when regional PET positivity was determined with Centiloid values. Regionally, VR+ in the striatum was associated with higher memory decline. As for executive function, interactions between APOE-ε4 and regional VR+ were found in temporal and parietal regions, and in the striatum. Conclusion: CU APOE-ε4 carriers with a positive Aβ PET VR in regions known to accumulate amyloid at later stages of the Alzheimer's disease (AD) continuum exhibited a steeper cognitive decline. This work supports the contention that regional VR of Aβ PET might convey prognostic information about future cognitive decline in individuals at higher risk of developing AD. Clinicaltrials: gov Identifier: NCT02485730. Registered 20 June 2015 https://clinicaltrials.gov/ct2/show/NCT02485730 and ClinicalTrials.gov Identifier:NCT02685969. Registered 19 February 2016 https://clinicaltrials.gov/ct2/show/NCT02685969 ., The research leading to these results has received funding from “la Caixa” Foundation (LCF/PR/GN17/10300004) and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant 2021 SGR 00913. NV-T is funded by a postdoctoral grant, Juan de la Cierva Programme (FJC2018-038085-I), Ministry of Science and Innovation-Spanish State Research Agency. Her research has received additional support of “la Caixa” Foundation (LCF/PR/GN17/10300004) and the Health Department of the Catalan Government (Health Research and Innovation Strategic Plan 2016–2020 Grant SLT002/16/00201). OG-R is supported by the Spanish Ministry of Science, Innovation and Universities (IJC2020-043417-I) and receives funding from the Alzheimer’s Association Research Fellowship Program (2019-AARF-644568). EA-U is supported by Alzheimer’s Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID), a “Ramón y Cajal” fellowship (RYC2018-026053-I) and by a grant of the Ministry of Science and Innovation (PID2019-111514RA-I00). MS-C receives funding from the European Research Council under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677), the Instituto de Salud Carlos III (PI19/00155), and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). JD-G holds a “Ramón y Cajal” fellowship (RYC-2013-13054).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Biological brain age prediction using machine learning on structural neuroimaging data: Multi-cohort validation against biomarkers of Alzheimer's disease and neurodegeneration stratified by sex

  • Cumplido-Mayoral, Irene
  • Operto, Grégory
  • Falcón, Carles
  • Shekari, Mahnaz
  • Cacciaglia, Raffaele
  • Milà Alomà, Marta
  • Minguillón, Carolina
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • OASIS study
Brain-age can be inferred from structural neuroimaging and compared to chronological age (brain-age delta) as a marker of biological brain aging. Accelerated aging has been found in neurodegenerative disorders like Alzheimer's disease (AD), but its validation against markers of neurodegeneration and AD is lacking. Here, imaging-derived measures from the UK Biobank dataset (N=22,661) were used to predict brain-age in 2,314 cognitively unimpaired (CU) individuals at higher risk of AD and mild cognitive impaired (MCI) patients from four independent cohorts with available biomarker data: ALFA+, ADNI, EPAD, and OASIS. Brain-age delta was associated with abnormal amyloid-β, more advanced stages (AT) of AD pathology and APOE-ε4 status. Brain-age delta was positively associated with plasma neurofilament light, a marker of neurodegeneration, and sex differences in the brain effects of this marker were found. These results validate brain-age delta as a non-invasive marker of biological brain aging in non-demented individuals with abnormal levels of biomarkers of AD and axonal injury., The project leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17–519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2017-SGR-892 and the Spanish Research Agency (AEI) under project PID2020-116907RB-I00 of the call MCIN/ AEI /10.13039/501100011033. FB is supported by the NIHR biomedical research center at UCLH. MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677), the Instituto de Salud Carlos III (PI19/00155), and from a fellowship from ”la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Longitudinal interplay between subclinical atherosclerosis, cardiovascular risk factors, and cerebral glucose metabolism in midlife: results from the PESA prospective cohort study

  • Tristão Pereira, Catarina
  • Fuster, Valentín
  • Oliva, Belén
  • Moreno Arciniegas, Andrea
  • Garcia-Lunar, Ines
  • Perez-Herreras, Cristina
  • Schöll, Michael
  • Suárez-Calvet, Marc
  • Moro, Maria Angeles
  • Garcia-Alvarez, Ana
  • Fernández Ortiz, Antonio
  • Sánchez González, Javier
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Ibáñez, Borja
  • Gispert, Juan Domingo
  • Cortes-Canteli, Marta
Background: Cardiovascular disease and dementia often coexist at advanced stages. Yet, longitudinal studies examining the interplay between atherosclerosis and its risk factors on brain health in midlife are scarce. We aimed to characterise the longitudinal associations between cerebral glucose metabolism, subclinical atherosclerosis, and cardiovascular risk factors in middle-aged asymptomatic individuals. Methods: The Progression of Early Subclinical Atherosclerosis (PESA) study is a Spanish longitudinal observational cohort study of 4184 asymptomatic individuals aged 40-54 years (NCT01410318). Participants with subclinical atherosclerosis underwent longitudinal cerebral [18F]fluorodeoxyglucose ([18F]FDG)-PET, and annual percentage change in [18F]FDG uptake was assessed (primary outcome). Cardiovascular risk was quantified with SCORE2 and subclinical atherosclerosis with three-dimensional vascular ultrasound (exposures). Multivariate regression and linear mixed effects models were used to assess associations between outcomes and exposures. Additionally, blood-based biomarkers of neuropathology were quantified and mediation analyses were performed. Secondary analyses were corrected for multiple comparisons using the false discovery rate (FDR) approach. Findings: This longitudinal study included a PESA subcohort of 370 participants (median age at baseline 49·8 years [IQR 46·1-52·2]; 309 [84%] men, 61 [16%] women; median follow-up 4·7 years [IQR 4·2-5·2]). Baseline scans took place between March 6, 2013, and Jan 21, 2015, and follow-up scans between Nov 24, 2017, and Aug 7, 2019. Persistent high risk of cardiovascular disease was associated with an accelerated decline of cortical [18F]FDG uptake compared with low risk (β=-0·008 [95% CI -0·013 to -0·002]; pFDR=0·040), with plasma neurofilament light chain, a marker of neurodegeneration, mediating this association by 20% (β=0·198 [0·008 to 0·740]; pFDR=0·050). Moreover, progression of subclinical carotid atherosclerosis was associated with an additional decline in [18F]FDG uptake in Alzheimer's disease brain regions, not explained by cardiovascular risk (β=-0·269 [95% CI -0·509 to -0·027]; p=0·029). Interpretation: Middle-aged asymptomatic individuals with persistent high risk of cardiovascular disease and subclinical carotid atherosclerosis already present brain metabolic decline, suggesting that maintenance of cardiovascular health during midlife could contribute to reductions in neurodegenerative disease burden later in life. Funding: Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III, Santander Bank, Pro-CNIC Foundation, BrightFocus Foundation, BBVA Foundation, "la Caixa" Foundation., We thank the PESA participants and the imaging, administrative, and medical PESA teams. The PESA study is equally co-funded by the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) and Santander Bank (Madrid, Spain) and also receives funding from the Instituto de Salud Carlos III (ISCIII), Madrid, Spain (PI15/02019), the European Regional Development Fund (ERDF—A Way to Build Europe), and the European Social Fund (ESF—Investing in Your Future). CNIC is a Severo Ochoa Center of Excellence (CEX2020-001041-S) and is supported by the ISCIII, the Spanish Ministry for Science and Innovation, and the Pro-CNIC Foundation. CT-P was supported by a “la Caixa” Foundation fellowship (ID 100010434, LCF/BQ/DI19/11730052). MC-C was supported by a Miguel Servet type II research contract (ISCIII, CPII21/00007) and the Fondo de Investigación Sanitaria (ISCIII, PI20/00819). We acknowledge the Sephardic Foundation on Aging and other donors of the Alzheimer's Disease Research (grant number A2022034S), a programme of the BrightFocus Foundation, for support of this research. This work was also partially produced with the support of a 2021 Leonardo Grant for Researchers and Cultural Creators from the BBVA Foundation awarded to MC-C (the Foundation takes no responsibility for the opinions, statements, and contents of this project, which are entirely the responsibility of its authors). BI was supported by the European Research Council (ERC-2018-CoG 819775-MATRIX). MS is supported by the Knut and Alice Wallenberg Foundation (Wallenberg Centre for Molecular and Translational Medicine; KAW2014.0363), the Swedish Research Council (2017-02869, 2021-02678, 2021-06545), the Swedish state under the agreement between the Swedish Government and the County Councils, the ALF-agreement (ALFGBG-813971, ALFGBG-965326), the Swedish Brain Foundation (FO2021-0311), and the Swedish Alzheimer Foundation (AF-740191). MS-C receives funding from the European Research Council (grant agreement number 948677), project “PI19/00155”, funded by ISCIII and co-funded by the EU, and a fellowship from “la Caixa” Foundation (ID 100010434) and from the EU's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement number 847648 (LCF/BQ/PR21/11840004). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018), the EU's Horizon Europe research and innovation programme under grant agreement number 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation, USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the EU's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement number 860197 (MIRIADE), the EU Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (#2017-00915, #2022-00732), the Swedish state under the agreement between the Swedish Government and the County Councils, the ALF-agreement (#ALFGBG-715986, #ALFGBG-965240), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270), Hjärnfonden, Sweden (#FO2017-0243, #ALZ2022-0006), the Alzheimer's Association 2021 Zenith Award (ZEN-21-848495), and the Alzheimer's Association 2022–2025 grant (SG-23-1038904 QC).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platform

  • Palmqvist, Sebastian
  • Anastasi, Federica
  • Puig-Pijoan, Albert
  • Fernández-Lebrero, Aida
  • Contador, José
  • Suárez-Calvet, Marc
  • Hansson, Oskar
Global implementation of blood tests for Alzheimer's disease (AD) would be facilitated by easily scalable, cost-effective and accurate tests. In the present study, we evaluated plasma phospho-tau217 (p-tau217) using predefined biomarker cutoffs. The study included 1,767 participants with cognitive symptoms from 4 independent secondary care cohorts in Malmö (Sweden, n = 337), Gothenburg (Sweden, n = 165), Barcelona (Spain, n = 487) and Brescia (Italy, n = 230), and a primary care cohort in Sweden (n = 548). Plasma p-tau217 was primarily measured using the fully automated, commercially available, Lumipulse immunoassay. The primary outcome was AD pathology defined as abnormal cerebrospinal fluid Aβ42:p-tau181. Plasma p-tau217 detected AD pathology with areas under the receiver operating characteristic curves of 0.93-0.96. In secondary care, the accuracies were 89-91%, the positive predictive values 89-95% and the negative predictive values 77-90%. In primary care, the accuracy was 85%, the positive predictive values 82% and the negative predictive values 88%. Accuracy was lower in participants aged ≥80 years (83%), but was unaffected by chronic kidney disease, diabetes, sex, APOE genotype or cognitive stage. Using a two-cutoff approach, accuracies increased to 92-94% in secondary and primary care, excluding 12-17% with intermediate results. Using the plasma p-tau217:Aβ42 ratio did not improve accuracy but reduced intermediate test results (≤10%). Compared with a high-performing mass-spectrometry-based assay for percentage p-tau217, accuracies were comparable in secondary care. However, percentage p-tau217 had higher accuracy in primary care and was unaffected by age. In conclusion, this fully automated p-tau217 test demonstrates high accuracy for identifying AD pathology. A two-cutoff approach might be necessary to optimize performance across diverse settings and subpopulations., We would like to express our gratitude to the participants, and relatives, in all studies, without whom this research would have not been possible. In addition, we thank B. Arslan for analyzing plasma Aβ in the Gothenburg cohort. The BioFINDER group was supported by the National Institute of Aging (grant no. R01AG083740 to O.H., S.P., R.O. and S.J.), Alzheimer’s Association (grant nos. SG-23-1061717 and ZEN24-1069572 to O.H.), GHR Foundation (O.H. and S.P.), European Research Council (ERC, grant no. ADG-101096455 to O.H.), Swedish Research Council (grant nos. 2023-00356 to O.H., 2021-02219 to N.M.-C. and 2018-02052 to S.P.), ERA PerMed (grant no. ERAPERMED2021-184 to O.H.), the Knut and Alice Wallenberg Foundation (grant no. 2022-0231 to O.H.), the European Union’s (EU’s) Horizon Europe research and innovation program under grant agreement no. 101053962 (to O.H.), the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson’s disease) at Lund University (to O.H.), the Swedish Alzheimer Foundation (grant nos. AF-1011949 and AF-994075 to S.P., AF-994229 to N.M.-C. and AF-981132 to S.P.), the Swedish Brain Foundation (grant nos. FO2023-0163 to N.M.-C., FO2024-0284 and FO2022-0204 to S.P. and FO2021-0293 to O.H.), the family Rönström’s Foundation (grant nos. FRS-0003 to N.M.-C. and FRS-0004 and FRS-0011 to S.P.), the Berg Family Foundation (O.H.), the Parkinson Foundation of Sweden (grant no. 1412/22 to O.H.), the Cure Alzheimer’s fund (O.H.), the Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse (O.H.), the Skåne University Hospital Foundation (grant no. 2020-O000028 to S.P.), EU Joint Programme Neurodegenerative Diseases (grant no. 2019-03401 to N.M.-C.), WASP and DDLS Joint call for research projects (grant no. WASP/DDLS22-066 to N.M.-C.), Regionalt Forskningsstöd (grant no. 2022-1346 to S.P.) and the Swedish Federal Government under the ALF-agreement (grant nos. 2022-Projekt0107 to N.M.-C., 2022-Projekt0080 to O.H. and 2018-Projekt0226 to S.P.). The precursor of [18F]flutemetamol was sponsored by GE Healthcare. For the Gothenburg group, S.K. was financed by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (nos. ALFGBG-1005471, ALFGBG-965923, ALFGBG-81392 and ALFGBG-771071), the Alzheimerfonden (grant nos. AF-842471, AF-737641, AF-929959 and AF-939825), the Swedish Research Council (grant nos. 2019-02075 and 2019-02075_15), Stiftelsen Psykiatriska Forskningsfonden and the Swedish Brain Foundation (grant no. FO2024-0097). A.D. was financed by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (grant no. ALFGBG-984092). H.Z. is a Wallenberg Scholar and a distinguished professor at the Swedish Research Council. K.B. is supported by the Swedish Research Council (grant nos. 2017-00915 and 2022-00732), the Swedish Alzheimer Foundation (grant nos. AF-930351, AF-939721, AF-968270 and AF-994551), Hjärnfonden, Sweden (grant nos. ALZ2022-0006, FO2024-0048-TK-130 and FO2024-0048-HK-24), the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (grant nos. ALFGBG-965240 and ALFGBG-1006418), the Alzheimer’s Association 2022–2025 (grant no. SG-23-1038904 QC), the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, Familjen Rönströms Stiftelse, Stockholm, Sweden and an anonymous philanthropist and donor. The Barcelona group thanks P. Ortiz-Romero, M. de Diego, E. Jiménez, J. Torres and M. del Campo for technical support. F.A. received funding from grant no. JDC2022-049347-I, funded by the MCIU/AEI/10.13039/501100011033 and the EU NextGeneration EU/PRTR. M.S.-C. received funding from the ERC under the EU’s Horizon 2020 research and innovation program (grant no. 948677); ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through project no. SLD077/21/000001; project PI19/00155 and PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the EU; and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and the EU’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie (grant no. 847648 (LCF/BQ/PR21/11840004)). For the Brescia group, A. Pilotto has beensupported by grants of Airalzh Foundation AGYR2021) Life-BIO grant, the LIMPE-DISMOV Foundation Segala Grant 2021, the Italian Ministry of University and Research PRIN COCOON (2017MYJ5TH) and PRIN 2021 RePlast (20202THZAW), the H2020 IMI IDEA-FAST (ID853981) and the Italian Ministry of Health, grant/award nos. RF-2018-12366209 and PNRR-Health PNRR-MAD-2022-12376110. V.Q. was supported by the H2020 IMI IDEA-FAST (grant no. ID853981). C.T. was supported by the PRIN 2021 RePlast (grant no. 20202THZAW). A. Padovani has been supported by grants of the Italian Ministry of University and Research PRIN COCOON (2017MYJ5TH) and PRIN 2021 RePlast (20202THZAW), the H2020 IMI IDEA-FAST (ID853981) and the Italian Ministry of Health, grant/award nos. RF-2018-12366209, RF-2019 RF-2019-12369272 and PNRR-Health PNRR-MAD-2022-12376110. The funders had no role in the design and conduct of the study, collection, management, analysis and interpretation of the data, preparation, review or approval of the paper and decision to submit the paper for publication.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A blood-based multi-pathway biomarker assay for early detection and staging of Alzheimer's disease across ethnic groups

  • Jiang, Yuanbing
  • Ortiz Romero, Paula, 1994-
  • Puig-Pijoan, Albert
  • Fernández-Lebrero, Aida
  • Contador, José
  • Suárez-Calvet, Marc
  • Ip, Nancy Y.
Introduction: Existing blood-based biomarkers for Alzheimer's disease (AD) mainly focus on its pathological features. However, studies on blood-based biomarkers associated with other biological processes for a comprehensive evaluation of AD status are limited. Methods: We developed a blood-based, multiplex biomarker assay for AD that measures the levels of 21 proteins involved in multiple biological pathways. We evaluated the assay's performance for classifying AD and indicating AD-related endophenotypes in three independent cohorts from Chinese or European-descent populations. Results: The 21-protein assay accurately classified AD (area under the receiver operating characteristic curve [AUC] = 0.9407 to 0.9867) and mild cognitive impairment (MCI; AUC = 0.8434 to 0.8945) while also indicating brain amyloid pathology. Moreover, the assay simultaneously evaluated the changes of five biological processes in individuals and revealed the ethnic-specific dysregulations of biological processes upon AD progression. Discussion: This study demonstrated the utility of a blood-based, multi-pathway biomarker assay for early screening and staging of AD, providing insights for patient stratification and precision medicine. Highlights: The authors developed a blood-based biomarker assay for Alzheimer's disease. The 21-protein assay classifies AD/MCI and indicates brain amyloid pathology. The 21-protein assay can simultaneously assess activities of five biological processes. Ethnic-specific dysregulations of biological processes in AD were revealed., This study was supported in part by the National Key R&D Program of China (2021YFE0203000); the Areas of Excellence Scheme of the University Grants Committee (AoE/M-604/16); the Research Grants Council of Hong Kong (the Collaborative Research Fund [C6027-19GF] and the Theme-Based Research Scheme [T13-605/18 W]); the Innovation and Technology Commission (InnoHK; ITCPD/17-9, INNOHK18SC01, ITS/207/18FP, MRP/042/18X, and MRP/097/20X); Chow Tai Fook Charity Foundation (CTFCF18SC01); the Guangdong Provincial Key S&T Program Grant (2018B030336001); the Guangdong Provincial Fund for Basic and Applied Basic Research (2019B1515130004); and the Fundamental Research Program of Shenzhen Virtual University Park (2021Szvup137). Yuanbing Jiang is a recipient of the Hong Kong Postdoctoral Fellowship Award from the Research Grants Council of the Hong Kong Special Administrative Region, China (Project No. HKUST PDFS2324-6S04). Marc Suárez-Calvet received funding from the European Research Council (ERC) under the European Union's Horizon 2020 Research and Innovation Programme (Grant Agreement No. 948677); Project “PI19/00155,” co-funded by Instituto de Salud Carlos III (ISCIII) and the European Union; and a fellowship from “La Caixa” Foundation (ID 100010434); and a fellowship from the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie Grant Agreement (No. 847648; LCF/BQ/PR21/11840004). Henrik Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018 and #2019-02397), the European Union's Horizon Europe Research and Innovation Programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Intracellular fluid accumulation underlies brain volume increases in early Alzheimer's disease

  • Kassinopoulos, Michalis
  • Montesinos, Paula
  • Falcon, Carles
  • Huguet, Jordi
  • Minguillón, Carolina
  • Fauria, Karine
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Molinuevo, José Luis
  • Grau, Oriol (Grau Rivera)
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Suárez-Calvet, Marc
  • Sánchez González, Javier
  • Gispert, Juan Domingo
  • ALFA Study
Abstract In the preclinical stages of Alzheimer's disease, increased brain volume has been associated with amyloid-beta pathology, particularly in regions that undergo volume reductions as the disease progresses. Glial reactivity and water diffusion alterations have been linked to such macroscopic volumetric changes. Brain volume reductions have also been reported following amyloid-beta removal with anti-amyloid therapies with beneficial clinical effects, but it remains unclear whether these changes result from resolving amyloid-triggered neuroinflammation or neurodegeneration. Intravoxel incoherent motion modelling based on multi-shell diffusion-weighted imaging may provide a better understanding of the processes underlying these paradoxical changes. This study used intravoxel incoherent motion diffusion MRI to examine how alterations in cerebral water pools contribute to increased brain volume linked to amyloid-beta deposition and neuroinflammation in cognitively unimpaired individuals. We developed a three-compartment diffusion MRI model with four parameters of cerebral water diffusion: slow diffusion coefficient, fast diffusion coefficient, slow signal portion, and perfusion fraction. We computed these diffusion parameters in 297 cognitively unimpaired late middle-aged adults, 35% of whom showed evidence of amyloid deposition. We examined their correlation with demographic factors (age, sex, apolipoprotein E status), markers of Alzheimer's disease pathology, neurodegeneration, neuroinflammation, and mean diffusivity. Then, we identified regions showing grey matter volume increases related to amyloid burden and examined the association between grey matter volume and diffusion parameters within these regions. We did not find evidence of associations between diffusion parameters and amyloid-related biomarkers, whether assessed by PET or cerebrospinal fluid measures. In contrast, the four diffusion parameters showed strong and widespread associations with biomarkers of neuroinflammation and neurodegeneration, particularly in frontoparietal and cingulate regions. Additionally, in grey matter regions where volume increases were related to amyloid levels, volumes were negatively correlated with the slow diffusion coefficient (P = 0.001), perfusion fraction (P = 0.036) and mean diffusivity (P = 0.047). These findings indicate that diffusion-derived measures are more sensitive to neuroinflammatory and neurodegenerative processes than to amyloid pathology in cognitively unimpaired individuals. Furthermore, the observed negative association between grey matter volume and slow diffusion coefficient in amyloid-related regions may reflect increased cellular complexity rather than intracellular water accumulation. This interpretation suggests that glial remodelling or microstructural changes could underlie brain volume increases in amyloid-positive individuals without overt neurodegeneration. These results underscore the value of intravoxel incoherent motion-derived metrics for gaining deeper insights into the pathophysiological mechanisms of Alzheimer's disease, influencing brain volume changes as well as those resulting from the response to anti-amyloid therapies., The research leading to these results has received funding from 'la Caixa' Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Health Department of the Catalan Government (Health Research and Innovation Strategic Plan (PERIS) 2016–2020 grant# SLT002/16/00201), and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. Henrik Zetterberg is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). Oriol Grau Rivera receives funding from the Alzheimer’s Association Research Fellowship Program (2019-AARF-644568) and is supported by the Spanish Ministry of Science, Innovation and Universities (IJC2020-043417-I). Kaj Blennow is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270, and #AF-994551), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022-2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, and Familjen Rönströms Stiftelse, Stockholm, Sweden. Marc Suárez-Calvet receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (Grant agreement No. 948677) and the Instituto de Salud Carlos III through the projects PI19/00155 and PI22/00456 (Co-funded by European Regional Development Fund, FEDER, ‘A way to make Europe’). Moreover, Marc Suárez-Calvet receives the support of a fellowship from ‘la Caixa’ Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 847648 (fellowship code LCF/BQ/PR21/11840004).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Neuroimaging-derived biological brain age and its associations with glial reactivity and synaptic dysfunction cerebrospinal fluid biomarkers

  • Cumplido-Mayoral, Irene
  • Sánchez Benavides, Gonzalo
  • Vilor Tejedor, Natàlia, 1988-
  • López-Martos, David
  • Brugulat Serrat, Anna, 1986-
  • Milà Alomà, Marta
  • Falcón, Carles
  • Cacciaglia, Raffaele
  • Minguillón, Carolina
  • Fauria, Karine
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Molinuevo, José Luis
  • Grau, Oriol (Grau Rivera)
  • Suárez-Calvet, Marc
  • Vilaplana, Verónica
  • Gispert, Juan Domingo
  • ALFA Study
  • ADNI
Magnetic resonance Imaging (MRI)-derived brain-age prediction is a promising biomarker of biological brain aging. Accelerated brain aging has been found in Alzheimer's disease (AD) and other neurodegenerative diseases. However, no previous studies have investigated the relationship between specific pathophysiological pathways in AD and biological brain aging. Here, we studied whether glial reactivity and synaptic dysfunction are associated with biological brain aging in the earliest stages of the Alzheimer's continuum, and if these mechanisms are differently associated with AD-related cortical atrophy. We further evaluated their effects on cognitive decline. We included 380 cognitively unimpaired individuals from the ALFA+ study, for which we computed their brain-age deltas by subtracting chronological age from their brain age predicted by machine learning algorithms. We studied the cross-sectional linear associations between brain-age delta and cerebrospinal fluid (CSF) biomarkers of synaptic dysfunction (neurogranin, GAP43, synaptotagmin-1, SNAP25, and α-synuclein), glial reactivity (sTREM2, YKL-40, GFAP, and S100b) and inflammation (interleukin-6). We also studied the cross-sectional linear associations between AD signature and these CSF biomarkers, We further evaluated the mechanisms linking baseline brain-age delta and longitudinal cognitive decline by performing mediation analyses. To reproduce our findings on an independent cohort, we included 152 cognitively unimpaired and 310 mild cognitive impaired (MCI) individuals from the ADNI study. We found that higher CSF sTREM2 was associated with a younger brain-age after adjusting for AD pathology, both in ALFA+ cognitively unimpaired and in ADNI MCI individuals. Furthermore, we found that CSF sTREM2 fully mediated the link between older brain-age and cognitive decline in ALFA+. In summary, we showed that the protective microglial state reflected by higher CSF sTREM2 has a beneficial impact on biological brain aging that may partly explains the variability in cognitive decline in early AD stages, independently of AD pathology., The study was approved by the Independent Ethics Committee “Parc de Salut Mar,” Barcelona, and all participants gave written informed consent. The ALFA+ study receives funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa 17 519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 009132017-SGR-892. MS-C receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed (ERAPERMED2021-184); Project “PI19/00155” and “PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (FEDER); and from a fellowship from ”la Caixa” Foundation (ID 100010434) and the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). DLM is supported by the project PI19/00117, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (FEDER). VV has been supported by the project PID2020-116907RB-I00, funded by the Ministry of Science and Innovation - State Research Agency, MCIN/ AEI /10.13039/501100011033. GSB is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project PID2020-119556RA-I00 and by the Instituto de Salud Carlos III (ISCIII) through the project CP23/00039 (Miguel Servet contract), co-funded by the European Union (FSE+). OGR receives funding from the Alzheimer’s Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III co-funded by the European Union (FEDER) (PI19/00117) and from Ministry of Science and Innovation - State Research Agency MCIN/ AEI /10.13039/501100011033 co-funded by the the European Union «NextGenerationEU»/PRTR (IJC2020-043417-I). NV-T is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033, co-funded by the the European Union «NextGenerationEU»/PRTR (IJC2020-043216-I). In addition, NV-T receives funding from the Alzheimer’s Disease Data Initiative (ADDI) through the William H. Gates Sr. Fellowship program, and the PID2022-143106OA-I00 project, funded by MCIN/AEI /10.13039/501100011033 and co-funded by the European Union (FEDER). RC is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project PID2021-125433OA-100 (co-funded by the European Union (FEDER)) and a Ramón y Cajal contract (RYC2021-031128-I, co-funded by the European Union «NextGenerationEU»/PRTR).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer's disease progression

  • Pelkmans, Wiesje
  • Shekari, Mahnaz
  • Brugulat Serrat, Anna, 1986-
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Fauria, Karine
  • Molinuevo, José Luis
  • Grau, Oriol (Grau Rivera)
  • González Escalante, Armand
  • Kollmorgen, Gwendlyn
  • Carboni, Margherita
  • Ashton, Nicholas J.
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • ALFA Study
Introduction: We studied how biomarkers of reactive astrogliosis mediate the pathogenic cascade in the earliest Alzheimer's disease (AD) stages. Methods: We performed path analysis on data from 384 cognitively unimpaired individuals from the ALzheimer and FAmilies (ALFA)+ study using structural equation modeling to quantify the relationships between biomarkers of reactive astrogliosis and the AD pathological cascade. Results: Cerebrospinal fluid (CSF) amyloid beta (Aβ)42/40 was associated with Aβ aggregation on positron emission tomography (PET) and with CSF p-tau181 , which was in turn directly associated with CSF neurofilament light (NfL). Plasma glial fibrillary acidic protein (GFAP) mediated the relationship between CSF Aβ42/40 and Aβ-PET, and CSF YKL-40 partly explained the association between Aβ-PET, p-tau181 , and NfL. Discussion: Our results suggest that reactive astrogliosis, as indicated by different fluid biomarkers, influences the pathogenic cascade during the preclinical stage of AD. While plasma GFAP mediates the early association between soluble and insoluble Aβ, CSF YKL-40 mediates the latter association between Aβ and downstream Aβ-induced tau pathology and tau-induced neuronal injury. Highlights: Lower CSF Aβ42/40 was directly linked to higher plasma GFAP concentrations. Plasma GFAP partially explained the relationship between soluble Aβ and insoluble Aβ. CSF YKL-40 mediated Aβ-induced tau phosphorylation and tau-induced neuronal injury., The ALFA+ study receives funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa‑17‑519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan government under grant no. 2017-SGR-892. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (2022-01018 and 2019-02397), the European Union's Horizon Europe research and innovation program under grant agreement 101053962, Swedish State Support for Clinical Research (ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (201809-2016862), the AD Strategic Fund and the Alzheimer's Association (ADSF-21-831376-C, ADSF-21-831381-C, and ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (FO2022-0270), the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (2017‑00915); the Alzheimer Drug Discovery Foundation (ADDF), USA (RDAPB‑201809‑2016615); the Swedish Alzheimer Foundation (AF‑742881); Hjärnfonden, Sweden (FO2017‑0243); the Swedish state under the agreement between the Swedish government and the county councils, the ALF‑agreement (ALFGBG‑715986); the European Union Joint Programme for Neurodegenerative Disorders (JPND2019‑466‑236); the National Institute of Health (NIH), USA (grant 1R01AG068398‑01); and the Alzheimer's Association 2021 Zenith Award (ZEN‑21‑848495). MSC receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement 948677), the Instituto de Salud Carlos III (PI19/00155, PI22/00456), and the ERC under the EU's ‘la Caixa’ Foundation (ID 100010434) and from the EU's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant (847648, LCF/BQ/PR21/11840004). JDG is supported by the Spanish Ministry of Science and Innovation (RYC‑2013‑13054). JDG has also received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018‑102261). GS-B receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency, PID2020-119556RA-I00. OGR receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117), and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva programme IJC2020-043417-I).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

CSF glial biomarkers are associated with cognition in individuals at risk of Alzheimer's disease

  • Warmenhoven, Noëlle
  • Sánchez Benavides, Gonzalo
  • González Escalante, Armand
  • Milà Alomà, Marta
  • Shekari, Mahnaz
  • López-Martos, David
  • Ortiz Romero, Paula, 1994-
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Minguillón, Carolina
  • Gispert, Juan Domingo
  • Vilor Tejedor, Natàlia, 1988-
  • Arenaza Urquijo, Eider M.
  • Palpatzis, Eleni
  • Ashton, Nicholas J.
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Suárez-Calvet, Marc
  • Grau, Oriol (Grau Rivera)
  • ALFA Study
Introduction: We examined whether baseline glial markers soluble triggering receptor expressed on myeloid cell 2 (sTREM2), chitinase 3-like protein 1 (YKL-40), and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF), and plasma GFAP are associated with cognitive change in cognitively unimpaired (CU) individuals at risk of Alzheimer's disease (AD). Methods: A total of 353 CU (mean age 60.9 years) participants were included (mean follow-up time 3.28 years). Linear regression models with cognition as outcome were used. We also tested whether amyloid beta (Aβ) status modified these associations. Results: Higher baseline CSF sTREM2 was associated with a positive global cognition (Preclinical Alzheimer's Cognitive Composite) rate of change, and better memory and executive outcomes, independently of AD pathology. Higher baseline plasma GFAP was associated with a decline on attention rate of change. Stratified analyses by Aβ status showed that CSF sTREM2 and YKL-40 were positively associated with executive functioning in amyloid negative (Aβ-) individuals. Discussion: Our results suggest that a TREM2-mediated microglial response may be associated with better longitudinal cognitive performance. Highlights: Higher cerebrospinal fluid (CSF) soluble triggering receptor expressed on myeloid cell 2 (sTREM2) relates to better longitudinal cognitive performance. The association between CSF sTREM2 and cognition is independent of Alzheimer's disease (AD) pathology. Targeting microglial reactivity may be a therapeutic strategy for AD prevention., This publication is part of the ALFA study (ALzheimers and Families). The authors would like to thank the collaborators of the ALFA study. Additionally, the authors would like to express their most sincere gratitude to the ALFA project participants and relatives without whom this research would not have been possible. The authors thank Roche Diagnostics International Ltd for providing the kits to measure CSF biomarkers and GE Healthcare for providing the doses of [18F]flutemetamol PET. The Roche NeuroToolKit is a panel of exploratory prototype assays designed to robustly evaluate biomarkers associated with key pathologic events characteristic of AD and other neurological disorders, used for research purposes only and not approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. The ALFA+ study receives funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa17519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. GSB is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project PID2020-119556RA-I00 and by the Instituto de Salud Carlos III (ISCIII) through the project CP23/00039 (Miguel Servet Contract), so-funded by the European Union (FSE+). DLM is supported by the Instituto de Salud Carlos III (ISCIII) through the project PI19/00117 (co-funded by European Regional Development Fund/European Social Fund “A way to make Europe”/“Investing in your future”). CM received funding within the context of EURO-FINGERS, a EU Joint Programme – Neurodegenerative Disease Research (JPND) project. The EURO-FINGERS project is supported through the following funding organizations under the aegis of JPND—www.jpnd.eu: Finland: Academy of Finland; Germany: Federal Ministry of Education and Research; Spain: National Institute of Health Carlos III; Luxembourg: National Research Fund; Hungary: National Research, Development and Innovation Office; and The Netherlands: Netherlands Organisation for Health Research and Development (ZonMW-Memorabel no. 733051102). JDG has received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), Innovative Health Initiative PROMINENT (grant agreement 101112145), EIT Digital (Grant 2021), and from the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project RTI2018102261. EAU has received funding by the Ministry of Science and Innovation (PID2019-111514RA-I00), the Alzheimer's Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID), and the European Union Joint Program for Neurodegenerative Disorders (JPND2022-138, AC22/00060). EAU is also supported by the Spanish Ministry of Science and Innovation—State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF). EP is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (#201700915); the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB2018092016615); the Swedish Alzheimer Foundation (#AF742881); Hjärnfonden, Sweden (#FO20170243); the Swedish state under the agreement between the Swedish government and the County Councils, the ALFagreement (#ALFGBG715986); the European Union Joint Program for Neurodegenerative Disorders (JPND2019466236); the National Institute of Health (NIH), USA (grant #1R01AG06839801); and the Alzheimer's Association 2021 Zenith Award (ZEN21848495). MSC receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (Grant agreement No. 948677), the Instituto de Salud Carlos III (ISCIII) through the projects PI19/00155 and PI22/00456 (Co-funded by European Regional Development Fund (FEDER) “A way to make Europe”), and receives the support of a fellowship funded by “la Caixa” Foundation (ID 100010434), and the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (fellowship code LCF/BQ/PR21/11840004). OGR receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (ISCIII) through the project PI19/00117 co-funded by the European Union (FEDER), and from Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project IJC2020-043417-I, co-funded by the European Union “Next GenerationEU”/PRTR. NVT is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project IJDC2020-043216-I, co-funded by the European Union “Next GenerationEU”/PRTR) and project PID2022-143106OA-I00, co-funded by the European Union (FEDER). In addition, NVT receives funding from the Alzheimer's Disease Data Initiative (ADDI) through the Williams H. Gates Sr. Fellowship Program and the Ajuntament de Barcelona in collaboration with “la Caixa” Foundation though the project 23S06083-001.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Genotypic effects of APOE-ε4 on resting-state connectivity in cognitively intact individuals support functional brain compensation

  • Cacciaglia, Raffaele
  • Operto, Grégory
  • Falcón, Carles
  • González de Echávarri, José Maria
  • Sánchez Benavides, Gonzalo
  • Brugulat Serrat, Anna, 1986-
  • Milà Alomà, Marta
  • Blennow, Kaj
  • Zetterberg, Henrik
  • Molinuevo, José Luis
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • ALFA Study
The investigation of resting-state functional connectivity (rsFC) in asymptomatic individuals at genetic risk for Alzheimer's disease (AD) enables discovering the earliest brain alterations in preclinical stages of the disease. The APOE-ε4 variant is the major genetic risk factor for AD, and previous studies have reported rsFC abnormalities in carriers of the ε4 allele. Yet, no study has assessed APOE-ε4 gene-dose effects on rsFC measures, and only a few studies included measures of cognitive performance to aid a clinical interpretation. We assessed the impact of APOE-ε4 on rsFC in a sample of 429 cognitively unimpaired individuals hosting a high number of ε4 homozygotes (n = 58), which enabled testing different models of genetic penetrance. We used independent component analysis and found a reduced rsFC as a function of the APOE-ε4 allelic load in the temporal default-mode and the medial temporal networks, while recessive effects were found in the extrastriate and limbic networks. Some of these results were replicated in a subsample with negative amyloid markers. Interaction with cognitive data suggests that such a network reorganization may support cognitive performance in the ε4-homozygotes. Our data indicate that APOE-ε4 shapes the functional architecture of the resting brain and favor the idea of a network-based functional compensation., The project leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2017-SGR-892. JDG is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054). MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677) and the Instituto de Salud Carlos III (PI19/00155). KB is supported by the Swedish Research Council (#2017-00915), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-742881), Hjärnfonden, Sweden (#FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the National Institute of Health (NIH), USA, (grant #1R01AG068398-01), and the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 860197 (MIRIADE), and the UK Dementia Research Institute at UCL.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The potential dual role of tau phosphorylation: plasma phosphorylated-tau217 in newborns and Alzheimer’s disease

  • González Ortiz, Fernando
  • Vávra, Jakub
  • Payne, Emma
  • Kirsebom, Bjørn-Eivind
  • Sjöbom, Ulrika
  • Santos, Cristiano
  • Júlvez Calvo, Jordi
  • Kramer, Kaitlin
  • Zalcberg, David
  • Montoliu-Gaya, Laia
  • Turton, Michael
  • Harrison, Peter
  • Hellström, Ann
  • Zetterberg, Henrik
  • Fladby, Tormod
  • Sanders, Robert D.
  • Blennow, Kaj
Tau phosphorylation plays an important role in brain physiology and pathology. During foetal development, it supports microtubule dynamics and neuroplasticity, whereas in Alzheimer’s disease (AD), it drives pathological tau aggregation and tangle formation. In this multicentre study (n = 462), we measured plasma phosphorylated-tau217 in healthy newborns, premature infants, patients with AD and healthy controls across various age groups. Plasma phosphorylated-tau217 levels were significantly higher in newborns compared to healthy individuals of any age group and even exceeded levels observed in patients with AD. In newborns, plasma phosphorylated-tau217 levels inversely correlated with perinatal factors such as gestational age. Longitudinal analysis of preterm infants demonstrated a decline in serum phosphorylated-tau217 levels over the first months of life, approaching levels observed in young adults. In contrast, elevated plasma phosphorylated-tau217 in older individuals was associated with AD pathology. Our findings corroborate the crucial role of tau phosphorylation in early brain development. However, in AD, tau phosphorylation transitions into a pathological mechanism. The high levels of blood-based phosphorylated-tau217 observed at birth and subsequent clearance might indicate distinct regulatory mechanisms that prevent tau aggregation in early life. Further studies are needed to explore the shared mechanisms of tau phosphorylation in newborns and AD., K.B. is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270 and #AF-994551), Hjärnfonden, Sweden (#ALZ2022-0006 and #FO2024-0048-TK-130), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-965240 and #ALFGBG-1006418), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022-2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark and Familjen Rönströms Stiftelse, Stockholm, Sweden. The project was funded by the Norwegian Research Council, JPND/PMI-AD (NRC 311993), the National Institute of Health (R01 AG083874-01). F.G.-O. was funded by the Anna Lisa and Brother Björnsson’s Foundation and Emil och Maria Palms Foundation. M.S.-C. receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement no. 948677), Project ‘PI19/00155’, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 847648 (LCF/BQ/PR21/11840004). B.-E.K. was supported by a grant from Helse-Nord (HNF1540-20). H.Z. is a Wallenberg scholar and a distinguished professor at the Swedish Research Council and receives funding from the Swedish Research Council (#2023-00356, #2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement no. 101053962 and Swedish State Support for Clinical Research (#ALFGBG-71320).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging

  • Imam, Farhad
  • Anastasi, Federica
  • Suárez-Calvet, Marc
  • Vilor Tejedor, Natàlia, 1988-
  • Global Neurodegeneration Proteomics Consortium (GNPC)
More than 57 million people globally suffer from neurodegenerative diseases, a figure expected to double every 20 years. Despite this growing burden, there are currently no cures, and treatment options remain limited due to disease heterogeneity, prolonged preclinical and prodromal phases, poor understanding of disease mechanisms, and diagnostic challenges. Identifying novel biomarkers is crucial for improving early detection, prognosis, staging and subtyping of these conditions. High-dimensional molecular studies in biofluids ('omics') offer promise for scalable biomarker discovery, but challenges in assembling large, diverse datasets hinder progress. To address this, the Global Neurodegeneration Proteomics Consortium (GNPC)-a public-private partnership-established one of the world's largest harmonized proteomic datasets. It includes approximately 250 million unique protein measurements from multiple platforms from more than 35,000 biofluid samples (plasma, serum and cerebrospinal fluid) contributed by 23 partners, alongside associated clinical data spanning Alzheimer's disease (AD), Parkinson's disease (PD), frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). This dataset is accessible to GNPC members via the Alzheimer's Disease Data Initiative's AD Workbench, a secure cloud-based environment, and will be available to the wider research community on 15 July 2025. Here we present summary analyses of the plasma proteome revealing disease-specific differential protein abundance and transdiagnostic proteomic signatures of clinical severity. Furthermore, we describe a robust plasma proteomic signature of APOE ε4 carriership, reproducible across AD, PD, FTD and ALS, as well as distinct patterns of organ aging across these conditions. This work demonstrates the power of international collaboration, data sharing and open science to accelerate discovery in neurodegeneration research., We thank all GNPC V1 consortium members who helped support the creation of the V1 harmonized dataset. We thank the participants, their families as well as the cohorts, institutions and their dedicated staff who helped create this consortium. Funding for the majority of biosample analyses was provided by Gates Ventures and Johnson & Johnson. Funding for cohort creation, participant biosample collection and additional biosample analysis was provided by the following sources. ALLFTD data collection and dissemination was supported by the ALLFTD Consortium (U19: AG063911, funded by the National Institute on Aging (NIA) and the National Institute of Neurological Disorders and Stroke (NINDS)) and the former ARTFL & LEFFTDS Consortia (ARTFL: U54 NS092089, funded by NINDS and the National Center for Advancing Translational Sciences; LEFFTDS: U01 AG045390, funded by the NIA and the NINDS). Additional funding support was provided by the National Institutes of Health (NIH)-NIA for Frontotemporal Dementia: Genes, Images, and Emotions: P01 AG019724 and the UCSF Alzheimer’s Disease Research Center: P30 AG062422. Samples from the National Centralized Repository for Alzheimer’s Disease and Related Dementias (NCRAD), which receives government support under a cooperative agreement grant (U24 AG21886) awarded by the NIA, were used in this study. The ALLFTD proteomic data included in this paper were funded by a grant from Gates Ventures. Alzheimer and Families (ALFA) was supported by funding from the MCIN/AEI/10.13039/501100011033/FEDER, European Union, through the PID2023-153312OB-I00 project; the CaixaResearch Institute under the project titled DETEC-PK; and the RYC2023-043831-I grant, funded by MCIN/AEI/10.13039/501100011033 and the FSE+. Additional researchers receive funding from the JDC2022-049347-I grant, funded by MCIU/AEI/10.13039/501100011033, the European Union NextGenerationEU/PRTR, the Spanish Research Agency MICIU/AEI/10.13039/501100011033 (grant RYC2022-038136-I co-funded by the European Union FSE+, grant PID2022-143106OA-I00 co-funded by the European Union FEDER), the William H. Gates Sr. Fellowship from the Alzheimer’s Disease Data Initiative, the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 948677), ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through project SLD077/21/000001, Project ‘PI19/00155’ and ‘PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation program under Marie Skłodowska-Curie grant agreement no. 847648 (LCF/BQ/PR21/11840004). The ALFA proteomic data included in this paper were funded by a grant from Gates Ventures. Stichting Alzheimer Nederland and Stichting VUmc provided funds for supporting Alzheimer Center Amsterdam infrastructure. Additionally, ZonMw Memorabel program project ‘PRODIA’, as part of the Deltaplan Dementie, and 2bike4alzheimer (Alzheimer Nederland) are acknowledged for funding this study for the generation of proteomics data for Amsterdam UMC. The baseline ABC-PD study (study period 2014–2017) was funded by a pre-competitive grant from Janssen Research and Development, a division of Janssen Pharmaceutica N.V. The follow-up study (study period 2018–2020) was funded by a grant from the Michael J. Fox Foundation for Parkinson’s Research (grant no. 15227). Neither study sponsor was involved in collection, analysis and interpretation of data, writing of the report or decision to submit the manuscript for publication. Janssen Research and Development was only involved in study design of the baseline visit. Answer ALS was supported by NEALS Biofluid Repository, and Answer ALS collected, annotated and granted permission to use ALS biofluid samples. The proteomic data included in this paper were funded by a grant from Gates Ventures. The Baltimore Longitudinal Study of Aging (BLSA) was supported by the Intramural Research Program (IRP) of the NIH-NIA. Banner Health was supported by Arizona ADRC and Arizona APOE grants from the NIA (P30 AG019610 and R01 AG069453), the state of Arizona, the Banner Alzheimer’s Foundation, the Sun Health Foundation, the Michael J. Fox Foundation and Gates Ventures. Work at Lund University was supported by the NIA (R01AG083740), the ERC (ADG-101096455), the Alzheimer’s Association (ZEN24-1069572 and SG-23-1061717), the GHR Foundation, the Swedish Research Council (2022-00775 and 2021-02219), ERA PerMed (ERAPERMED2021-184), the Knut and Alice Wallenberg Foundation (2022-0231), Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson’s Disease) at Lund University, the Swedish Alzheimer Foundation (AF-980907 and AF-994229), the Swedish Brain Foundation (FO2021-0293 and FO2023-0163), the Parkinson Foundation of Sweden (1412/22), the Cure Alzheimer’s Fund, the Rönström Family Foundation, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, the Skåne University Hospital Foundation (2020-O000028), the WASP and DDLS joint call for research projects (WASP/DDLS22-066), the Lilly Research Award Program, Regionalt Forskningsstöd (2022-1259) and the Swedish federal government under the ALF agreement (2022-Projekt0080 and 2022-Projekt0107). Additionally, this work was supported by the SciLifeLab & Wallenberg Data Driven Life Science Program (grant no. KAW 2020.0239), the Swedish Research Council (2024-03642), the NIA (U01 AG079847-02) and Gates Ventures. The CHARIOT-PRO study was funded by Johnson & Johnson, Merck, Takeda and Gates Ventures, and analysis was supported by the UKRI Future Leaders Fellowship (MR/S03532X/1 and MR/Y02012X/1) and the NIHR ARC Dementia Fellowship. The Emory ADRC participation was supported by the Emory Goizueta Alzheimer’s Research Disease Center (P50AG025688) and grants from Gates Ventures for the generation of proteomics data, and data collection was supported through funding by NIA grants R01AG053960, R01AG057911, R01AG061800, RF1AG057471, RF1AG057470, R01AG061800, R01AG057911 and R01AG057339. The Kansas ADRC participation was supported by the NIH (P30 AG072973, P30 AG072974 and R01 AG064227) and further supported by the Neil & Norma Hill Foundation, the Annemarie & Arturo Gandioli-Fumagalli Foundation, the Perpetual Foundation, the John Williams Endowment and the Hillcrest Foundation. The proteomic data included in this paper were funded by a grant from Gates Ventures. The Knight ADRC participation was supported by grants from the NIH (R01AG044546, RF1AG053303, RF1AG058501 and U01AG058922), the Michael J. Fox Foundation, the Alzheimer’s Association Zenith Fellows Award (ZEN-22-848604), Gates Ventures and an anonymous foundation. The recruitment and clinical characterization of research participants at Washington University were supported by NIH P30AG066444, P01AG03991 and P01AG026276. Additionally, this work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, the Neurogenomics and Informatics Center (https://neurogenomics.wustl.edu/) and the Departments of Neurology and Psychiatry at Washington University School of Medicine. The Whitehall II study was supported by the Wellcome Trust (221854/Z/20/Z), the UK Medical Research Council (Y014154, R024227, S011676 and K013351) and the NIA (R01AG056477 and R01AG062553).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Plasma and CSF biomarkers in a memory clinic: head-to-head comparison of phosphorylated tau immunoassays

  • Ashton, Nicholas J.
  • Puig-Pijoan, Albert
  • Milà Alomà, Marta
  • Fernández-Lebrero, Aida
  • Ortiz Romero, Paula, 1994-
  • Minguillón, Carolina
  • Navalpotro-Gómez, Irene
  • Grau, Oriol (Grau Rivera)
  • Manero, Rosa María
  • Puente Periz, Victor Manuel
  • Torre Fornell, Rafael de la
  • Roquer, Jaume
  • Suárez-Calvet, Marc
Introduction: Direct comparisons of the main blood phosphorylated tau immunoassays in memory clinic populations are needed to understand possible differences. Methods: In the BIODEGMAR study, 197 participants presenting with cognitive complaints were classified into an Alzheimer's disease (AD) or a non-AD cerebrospinal fluid (CSF) profile group, according to their amyloid beta 42/ phosphorylated tau (Aβ42/p-tau) ratio. We performed a head-to-head comparison of nine plasma and nine CSF tau immunoassays and determined their accuracy to discriminate abnormal CSF Aβ42/p-tau ratio. Results: All studied plasma tau biomarkers were significantly higher in the AD CSF profile group compared to the non-AD CSF profile group and significantly discriminated abnormal CSF Aβ42/p-tau ratio. For plasma p-tau biomarkers, the higher discrimination accuracy was shown by Janssen p-tau217 (r = 0.76; area under the curve [AUC] = 0.96), ADx p-tau181 (r = 0.73; AUC = 0.94), and Lilly p-tau217 (r = 0.73; AUC = 0.94). Discussion: Several plasma p-tau biomarkers can be used in a specialized memory clinic as a stand-alone biomarker to detect biologically-defined AD. Highlights: Patients with an Alzheimer's disease cerebrospinal fluid (AD CSF) profile have higher plasma phosphorylated tau (p-tau) levels than the non-AD CSF profile group. All plasma p-tau biomarkers significantly discriminate patients with an AD CSF profile from the non-AD CSF profile group. Janssen p-tau217, ADx p-tau181, and Lilly p-tau217 in plasma show the highest accuracy to detect biologically defined AD. Janssen p-tau217, ADx p-tau181, Lilly p-tau217, Lilly p-tau181, and UGot p-tau231 in plasma show performances that are comparable to their CSF counterparts., The authors would like to express their most sincere gratitude to the BIODEGMAR participants and relatives without whom this research would have not been possible. The authors thank Anna Boronat Rigol, Rachael Burchfield, and Nicholas Kyle Proctor for technical support. They also thank all the staff at University of Gothenburg, Department of Neurology at Hospital del Mar, and Barcelonaβeta Brain Research Center, who supported this project. Thomas K. Karikari was funded by the Swedish Research Council (Vetenskåpradet), the Alzheimer's Association Research Fellowship (#AARF-21-850325), the BrightFocus Foundation (#A2020812F), the International Society for Neurochemistry's Career Development Grant, the Swedish Alzheimer Foundation (Alzheimerfonden; #AF-930627), the Swedish Brain Foundation (Hjärnfonden; #FO2020-0240), the Swedish Dementia Foundation (Demensförbundet), the Swedish Parkinson Foundation (Parkinsonfonden), Gamla Tjänarinnor Foundation, the Aina (Ann) Wallströms and Mary-Ann Sjöbloms Foundation, the Agneta Prytz-Folkes & Gösta Folkes Foundation (#2020-00124), the Gun and Bertil Stohnes Foundation, and the Anna Lisa and Brother Björnsson's Foundation. Oriol Grau-Rivera is supported by the Spanish Ministry of Science, Innovation and Universities (IJC2020-043417-I), and receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568) and the Instituto de Salud Carlos III (PI19/00117). Irene Navalpotro-Gómez receives funding from the Spanish Instituto de Salud Carlos III (ISCIII-FEDER, PI21/00194). Jaume Roquer receives funding from the Spanish Instituto de Salud Carlos III (ISCIII-FEDER, PI21/00194). Jeff L. Dage is supported by the National Institutes of Health (U24AG021886, P30AG072976, and U01AG057195), Roche Diagnostics (RD005665), as well as the Stark Neurosciences Research Institute at Indiana University School of Medicine. Henrik Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer's Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019-0228), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), European Union Joint Program for Neurodegenerative Disorders (JPND2021-00694), and the UK Dementia Research Institute at UCL. Kaj Blennow is supported by the Swedish Research Council (#2017-00915), ADDF, USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-742881), Hjärnfonden, Sweden (#FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), and the NIH, USA (grant #1R01AG068398-01). Marc Suárez-Calvet receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Grant agreement No. 948677), Project “PI19/00155”, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

CSF synaptic biomarkers in the preclinical stage of Alzheimer disease and their association with MRI and PET: a cross-sectional study

  • Milà Alomà, Marta
  • Brinkmalm, Ann
  • Ashton, Nicholas J.
  • Kvartsberg, Hlin
  • Shekari, Mahnaz
  • Operto, Grégory
  • Salvadó, Gemma
  • Falcon, Carles
  • Gispert, Juan Domingo
  • Vilor Tejedor, Natàlia, 1988-
  • Arenaza Urquijo, Eider M.
  • Grau, Oriol (Grau Rivera)
  • Sala Vila, Aleix
  • Sánchez Benavides, Gonzalo
  • González de Echávarri, José Maria
  • Minguillón, Carolina
  • Fauria, Karine
  • Niñerola-Baizán, Aida
  • Perissinotti, Andrés
  • Kollmorgen, Gwendlyn
  • Suridjan, Ivonne
  • Zetterberg, Henrik
  • Molinuevo, José Luis
  • Blennow, Kaj
  • Suárez-Calvet, Marc
  • ALFA Study
Background and objectives: To determine whether CSF synaptic biomarkers are altered in the early preclinical stage of the Alzheimer continuum and associated with Alzheimer disease (AD) risk factors, primary pathology, and neurodegeneration markers. Methods: This cross-sectional study was performed in the Alzheimer's and Families (ALFA+) cohort, comprising middle-aged cognitively unimpaired participants. CSF neurogranin and growth-associated protein-43 (GAP-43) were measured with immunoassays, and synaptosomal-associated protein-25 (SNAP-25) and synaptotagmin-1 were measured with immunoprecipitation mass spectrometry. AD CSF biomarkers β-amyloid (Aβ)42/40, phosphorylated tau (p-tau), and total tau and the neurodegeneration biomarker neurofilament light chain (NfL) were also measured. Participants underwent structural MRI and fluorodeoxyglucose and Aβ PET imaging. General linear modeling was used to test the associations between CSF synaptic biomarkers and risk factors, Aβ pathology, tau pathology, and neurodegeneration markers. Results: All CSF synaptic biomarkers increased with age. CSF neurogranin was higher in females, while CSF SNAP-25 was higher in APOE ε4 carriers. All CSF synaptic biomarkers increased with higher Aβ load (as measured by CSF Aβ42/40 and Aβ PET Centiloid values), and it is important to note that the synaptic biomarkers were increased even in individuals in the earliest stages of Aβ deposition. Higher CSF synaptic biomarkers were also associated with higher CSF p-tau and NfL. Higher CSF neurogranin and GAP-43 were significantly associated with higher brain metabolism but lower cortical thickness in AD-related brain regions. Discussion: CSF synaptic biomarkers increase in the early preclinical stages of the Alzheimer continuum even when a low burden of Aβ pathology is present, and they differ in their association with age, sex, APOE ε4, and markers of neurodegeneration., The research leading to these results has received funding from “la Caixa” Foundation (LCF/PR/GN17/10300004) and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant 2017-SGR-892. J.D.G. holds a “Ramón y Cajal” fellowship (RYC-2013-13054). E. Arenaza-Urquijo is supported by the Spanish Ministry of Science, Innovation and Universities–Spanish State Research Agency (RYC2018-026053-I). N. Vilor-Tejedor is funded by a postdoctoral grant, Juan de la Cierva Programme (FJC2018-038085-I), Ministry of Science and Innovation– Spanish State Research Agency. Her research has received additional support of “la Caixa” Foundation (LCF/PR/GN17/10300004) and the Health Department of the Catalan Government (Health Research and Innovation Strategic Plan 2016–2020 grant SLT002/16/00201). All Centre for Genomic Regulation authors acknowledge the support of the Spanish Ministry of Science, Innovation and Universities to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. O. Grau-Rivera is supported by the Spanish Ministry of Science, Innovation and Universities (FJCI-2017-33437) and receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568). A. Sala-Vila is the recipient of an Instituto de Salud Carlos III Miguel Servet II fellowship (CP II 17/00029). H. Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (No. 2018-02532), European Research Council (No. 681712), Swedish State Support for Clinical Research (No. ALFGBG-720931), Alzheimer Drug Discovery Foundation (No. 201809-2016862), and the UK Dementia Research Institute at UCL. K. Blennow is supported by the Swedish Research Council (No. 2017-00915), Alzheimer Drug Discovery Foundation (No. RDAPB-201809-2016615), Swedish Alzheimer Foundation (No. AF-742881), Hjärnfonden, Sweden (No. FO2017-0243), the Swedish state under the agreement between the Swedish government and the county councils, the ALF agreement (No. ALFGBG-715986), European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), and NIH (No. 1R01AG068398-01). M. Suárez-Calvet receives funding from the European Research Council under the European Union's Horizon 2020 Research and Innovation Programme (grant agreement 948677). M. Suárez-Calvet also receives funding from the Instituto de Salud Carlos III (PI19/00155) and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva Programme grant IJC2018-037478-I)
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A novel ultrasensitive assay for plasma p-tau217: Performance in individuals with subjective cognitive decline and early Alzheimer's disease

  • González Ortiz, Fernando
  • González Escalante, Armand
  • Ortiz Romero, Paula, 1994-
  • Minguillón, Carolina
  • Contador, José
  • Suárez-Calvet, Marc
  • Blennow, Kaj
Introduction: Detection of Alzheimer's disease (AD) pathophysiology among individuals with mild cognitive changes and those experiencing subjective cognitive decline (SCD) remains challenging. Plasma phosphorylated tau 217 (p-tau217) is one of the most promising of the emerging biomarkers for AD. However, accessible methods are limited. Methods: We employed a novel p-tau217 immunoassay (University of Gothenburg [UGOT] p-tau217) in four independent cohorts (n = 308) including a cerebrospinal fluid (CSF) biomarker-classified cohort (Discovery), two cohorts consisting mostly of cognitively unimpaired (CU) and mild cognitively impaired (MCI) participants (MYHAT and Pittsburgh), and a population-based cohort of individuals with SCD (Barcelonaβeta Brain Research Center's Alzheimer's At-Risk Cohort [β-AARC]). Results: UGOT p-tau217 showed high accuracy (area under the curve [AUC] = 0.80-0.91) identifying amyloid beta (Aβ) pathology, determined either by Aβ positron emission tomography or CSF Aβ42/40 ratio. In individuals experiencing SCD, UGOT p-tau217 showed high accuracy identifying those with a positive CSF Aβ42/40 ratio (AUC = 0.91). Discussion: UGOT p-tau217 can be an easily accessible and efficient way to screen and monitor patients with suspected AD pathophysiology, even in the early stages of the continuum., This publication is part of the BBRC's β-AARC study, the MYHAT study, and the Pittsburgh study. The authors would like to express their most sincere gratitude to the project participants, without whom this research would have not been possible. The authors would like to thank Altoida for kindly supporting the CSF AD core biomarker characterisation of β-AARC study participants. F.G.-O. was funded by the Anna Lisa and Brother Björnsson's Foundation and Emil och Maria Palms Foundation. H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation ə under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation ə under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). K.B. is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721 and #AF-968270), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the Alzheimer's Association 2021 Zenith Award (ZEN-21-848495), and the Alzheimer's Association 2022-2025 Grant (SG-23-1038904 QC). M.S.C. receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Grant agreement No. 948677), Project “PI19/00155”, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). T.K.K. was supported by grants 1 R01 AG083874-01 and 1U24AG082930 from the National Institutes of Health (NIH), the Swedish Research Council (Vetenskåpradet; 2021-03244), the Alzheimer's Association (AARF-21-850325), the Swedish Alzheimer Foundation (Alzheimerfonden), the Aina (Ann) Wallströms and Mary-Ann Sjöbloms Stiftelsen, and the Emil och Wera Cornells stiftelsen. M.G. and the MYHAT study were funded by the NIH (grants AG052521 and R37 AG023651). The other Pittsburgh cohorts were financed by the NIH (grants P30 AG066468, P01AG025204, RF1AG025516, RF1AG052525, R01AG052446, and R01AG052446).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The CSF p-tau/ß-amyloid 42 ratio correlates with brain structure and fibrillary ß-amyloid deposition in cognitively unimpaired individuals at the earliest stages of pre-clinical Alzheimer's disease

  • Cacciaglia, Raffaele
  • Shekari, Mahnaz
  • Salvadó, Gemma
  • Milà Alomà, Marta
  • Falcón, Carles
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Fauria, Karine
  • Grau, Oriol (Grau Rivera)
  • Molinuevo, José Luis
  • Blennow, Kaj
  • Zetterberg, Henrik
  • Quevenco, Frances-Catherine
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • ALFA Study
CSF concentrations of β-amyloid 42 (Aβ42) and phosphorylated tau (p-tau) are well-established biomarkers of Alzheimer's disease and have been studied in relation to several neuropathological features both in patients and in cognitively unimpaired individuals. The CSF p-tau/Aβ42 ratio, a biomarker combining information from both pathophysiological processes, has emerged as a promising tool for monitoring disease progression, even at pre-clinical stages. Here, we studied the association between the CSF p-tau/Aβ42 ratio with downstream markers of pre-clinical Alzheimer's disease progression including brain structure, glucose metabolism, fibrillary Aβ deposition and cognitive performance in 234 cognitively unimpaired individuals, who underwent cognitive testing, a lumbar puncture, MRI, 18F-fluorodeoxyglucose and 18F-flutemetamol PET scanning. We evaluated both main effects and interactions with Alzheimer's disease risk factors, such as older age, female sex and the apoliporoptein E (APOE)-ɛ4 allele, in a priori defined regions of interest and further examined the associations on the whole-brain using voxel-wise regressions. In addition, as the association between CSF Alzheimer's disease biomarkers and brain structure and function may be non-linear, we tested the interaction between the CSF p-tau/Aβ42 ratio and stages of pre-clinical Alzheimer's disease defined using the amyloid (A) and tau (T) classification. We found significantly positive associations between CSF p-tau/Aβ42 and both cortical Aβ deposition and regional grey matter volume while no effect was observed for brain metabolism. A significant interaction with age indicated that, for the same level of CSF p-tau/Aβ42, older individuals displayed both increased Aβ deposition and lower grey matter volume, in widespread cortical areas. In addition, we found that women compared with men had a greater Aβ fibrillary accumulation in midline cortical areas and inferior temporal regions, for the same level of the CSF biomarker. The impact of CSF p-tau/Aβ42 on grey matter volume was modulated by AT stages, with A+T+ individuals displaying significantly less positive associations in areas of early atrophy in the Alzheimer's continuum. Finally, we found that sex and APOE-ɛ4 modulated the association between the CSF biomarker and episodic memory as well as abstract reasoning, respectively. Our data indicate that the CSF p-tau/Aβ42 ratio is strongly associated with multiple downstream neuropathological events in cognitively unimpaired individuals and may thus serve as a potent biomarker to investigate the earliest changes in pre-clinical Alzheimer's disease. Given that its impact on both Aβ deposition and grey matter volume is modulated by specific risk factors, our results highlight the need to take into account such predisposing variables in both clinical practice and prevention trials., The research leading to these results has received funding from ‘la Caixa’ Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. R.C. receives funding from ‘Ministerio de Ciencia, Innovación y Universidades—Agencia Estatal de Investigación’ MCIN/AEI/10.13039/501100011033/FEDER, EU, through project PID2021-125433OA-100 and support from grant RYC2021-031128-I, funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/Plan de Recuperación, Transformación y Resiliencia (PRTR). H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Union’s Horizon Europe research and innovation programme under grant agreement no. 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 860197 (MIRIADE), the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021-00694) and the UK Dementia Research Institute at University College London (UCL) (UKDRI-1003). K.B. is supported by the Swedish Research Council (#2017-00915), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721 and #AF-968270), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the Avtal om Läkarutbildning och Forskning (ALF) agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Programme for Neurodegenerative Disorders (JPND2019-466-236), the National Institutes of Health (NIH), USA, (grant #1R01AG068398-01), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495) and the Alzheimer’s Association 2022–25 Grant (SG-23-1038904 QC). M.S.-C. receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement no. 948677), Project ‘PI19/00155’, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 847648 (LCF/BQ/PR21/11840004). O.G.-R. is supported by the ‘Ministerio de Ciencia, Innovación y Universidades' (IJC2020-043417-I) and receives funding from the Alzheimer’s Association (2019-AARF-644568) and the Instituto de Salud Carlos III (PI19/00117).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Impact of gender on the willingness to participate in clinical trials and undergo related procedures in individuals from an Alzheimer's prevention research cohort

  • Canals-Gispert, Lidia
  • Cañas-Martínez, Alba
  • Huesa, Gema
  • Suárez-Calvet, Marc
  • Milà Alomà, Marta
  • Arenaza Urquijo, Eider M.
  • Cirillo, Davide
  • Schumacher Dimech, Annemarie
  • Iulita, Maria Florencia
  • Novakova Martinkova, Julie
  • Tartaglia, Maria Carmela
  • Quevenco, Frances-Catherine
  • Santuccione Chadha, Antonella
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Ferretti, Maria Teresa
  • Fauria, Karine
  • Brugulat Serrat, Anna, 1986-
  • ALFA Study
Background: Although there is growing evidence of the association between gender and early diagnosis of preclinical Alzheimer's disease, little attention has been given to the enrolment ratio of men and women in clinical trials and data reporting. Methods: This study aims to analyze gender differences in sociodemographic factors associated with the willingness to participate in clinical trials and undergo specific procedures in the context of an Alzheimer's disease prevention research cohort. 2544 cognitively unimpaired participants from the ALFA parent cohort (age 45-75 years) of the Barcelonaβeta Brain Research Center were contacted through a structured phone call to determine their willingness to participate in Alzheimer's disease clinical trials and undergo trial-related procedures (magnetic resonance imaging, lumbar puncture, positron emission tomography, and cognitive assessment). Sociodemographic data on education, occupational attainment, civil and caregiver status were gathered. Stepwise logistic regression models were performed in order to study the interaction between gender and sociodemographic factors in the willingness to participate in clinical trials and to undergo clinical trial-related procedures. Results: 1,606 out of the 2,544 participants were women (63.1%). Women were significantly younger and had lower educational attainment compared with men. In addition, women were more likely to be caregivers, single and unemployed. Women showed a significantly lower willingness than men to participate in a clinical trial (p = 0.003) and to undergo a lumbar puncture (p < 0.001). Single women were less willing to participate in clinical trials than single men (p = 0.041). Regarding clinical trial-related procedures, women with higher years of education were significantly less willing to undergo a lumbar puncture (p = 0.031). Conclusion: We found gender differences regarding the sociodemographic factors that predict the willingness to participate in clinical trials and to undergo clinical trial-related procedures. Our results highlight the urgent need to design recruitment strategies accounting for gender-related factors, particularly those related to marital status and education., The project leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/10300004. JNM is supported by project nr. LX22NPO5107 (MEYS): Financed by EU – Next Generation EU. MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (Grant agreement No. 948677), the Instituto de Salud Carlos III through the projects PI19/00155 and PI22/00456 (Co-funded by European Regional Development Fund (FEDER) "A way to make Europe"), and receives the support of a fellowship from”la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (fellowship code LCF/BQ/PR21/11840004). EMAU receives funding from the Alzheimer’s Association (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID), and from the Ministry of Science and Innovation (MCIN)/Spanish Research Agency (AEI) MCIN/AEI/https://doi.org/10.13039/501100011033 (PID2019-111514RA-I00 and RYC2018-026053-I, co-funded by the European Social Fund (FSE)). GSB receives funding from the Ministry of Science and Innovation/Spanish Research Agency (PID2020-119556RA-I00 funded by MCIN/AEI/https://doi.org/10.13039/501100011033/FEDER, UE). ABS receives funding from the Global Brain Health Institute (GBHI), Alzheimer's Association, Alzheimer's Society (GBHI ALZ UK-21–737797).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Diagnostic performance of plasma Aß42/40 ratio, p-tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non-AD dementias: an international multi-center study

  • Doecke, James D.
  • González Escalante, Armand
  • Contador, José
  • Suárez-Calvet, Marc
  • Fernández-Lebrero, Aida
  • Puig-Pijoan, Albert
  • Ortiz Romero, Paula, 1994-
  • Jiménez-Moyano, Esther
  • Minguillón, Carolina
  • Campo, Marta del
  • Teunissen, Charlotte E.
Introduction: Plasma phosphorylated tau (p-tau)181, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and amyloid beta ratio (Aß42/40) may have diagnostic and prognostic value in Alzheimer's disease (AD). Here we assess which markers can best identify AD from controls and other non-AD dementias in a large international multi-center study. Methods: Plasma samples (n = 1298) were collected from six international centers. Aß40, Aß42, GFAP, NfL, and p-tau181 were measured using single molecule array. In each group, AD diagnosis/co-pathology was defined according to cerebrospinal fluid biomarkers or amyloid positron emission tomography. Validations were performed in three separate cohorts via single and dual cut-off models. Results: p-tau181 showed the best area under the curve value to separate AD from frontotemporal dementia, controls, and Aß- dementia with Lewy bodies. However, this discriminative power could not be reproduced by applying pre-defined cut-offs. Discussion: p-tau181 was the best single plasma marker for detecting AD at any stage. Specific cut-offs are needed to maximize diagnostic performances. Highlights: Phosphorylated tau (p-tau)181 provided a clear differentiation between controls and Alzheimer's disease (AD) participants, with evidence of increased levels in the preclinical stage of AD. Plasma biomarkers demonstrated that when amyloid co-pathology is removed from dementia with Lewy bodies (DLB), only glial fibrillary acidic protein and neurofilament light chain remain to predict DLB. Given the low prevalence of amyloid co-pathology in frontotemporal dementia (FTD), p-tau181 and its ratio with amyloid beta 42 are strong biomarkers to differentiate FTD from AD., O.H. has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, C2N Diagnostics, Eli Lilly, Eisai, Fujirebio, GE Healthcare, and Roche. In the past 2 years, he has received consultancy/speaker fees from Alzpath, BioArctic, Biogen, Bristol Meyer Squibb, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi, and Siemens. L.G. participated on advisory boards for, and received writing honoraria and travel grants from, Almirall, Biogen, Euroimmun, Fujirebio, Lilly, Merck, Mylan, Novartis, Roche, Sanofi, Siemens Healthineers, and Teva. Work at Lund University was supported by the European Research Council (ADG-101096455), Alzheimer's Association (ZEN24-1069572, SG-23-1061717), GHR Foundation, Swedish Research Council (2022-00775), ERA PerMed (ERAPERMED2021-184), Knut and Alice Wallenberg foundation (2022-0231), Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, Swedish Alzheimer Foundation (AF-980907), Swedish Brain Foundation (FO2021-0293), Parkinson foundation of Sweden (1412/22), Cure Alzheimer's fund, Rönström Family Foundation, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Skåne University Hospital Foundation (2020-O000028), Regionalt Forskningsstöd (2022-1259), and Swedish federal government under the ALF agreement (2022-Projekt0080). The ALFA+ Study has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer's Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. M.S.-C. receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (Grant agreement No. 948677); ERA PerMed (ERAPERMED2021-184); Project “PI19/00155” and ‘‘PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). Research of C.E.T. is supported by the European Commission (Marie Curie International Training Network), grant agreement No 860197 (MIRIADE), Innovative Medicines Initiatives 3TR (Horizon 2020, grant no 831434) EPND (IMI 2 Joint Undertaking [JU], grant No. 101034344) and JPND (bPRIDE), European Partnership on Metrology, co-financed from the European Union's Horizon Europe Research and Innovation Programme and by the Participating States (22HLT07 NEuroBioStand), CANTATE project funded by the Alzheimer Drug Discovery Foundation, Alzheimer Association, Health Holland, the Dutch Research Council (ZonMW), Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands. C.T. is recipient of ABOARD, which is a public–private partnership receiving funding from ZonMW (#73305095007) and Health∼Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). C.T. is recipient of TAP-dementia, a ZonMw funded project (#10510032120003) in the context of the Dutch National Dementia Strategy.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Detecting amyloid-ß pathology in subjective cognitive decline using plasma and CSF biomarkers

  • Contador, José
  • Pozzi, Federico Emanuele
  • Sánchez Benavides, Gonzalo
  • Fernández-Arcos, Ana
  • Minguillón, Carolina
  • Fauria, Karine
  • González Escalante, Armand
  • Ortiz Romero, Paula, 1994-
  • Blasco-Forniés, Helena
  • Diego-Osaba, Marina de
  • Jiménez-Moyano, Esther
  • Torres-Torronteras, Javier
  • Gispert, Juan Domingo
  • Molinuevo, José Luis
  • Campo, Marta del
  • Grau, Oriol (Grau Rivera)
  • Suárez-Calvet, Marc
  • β-AARC Study collaborators
Background: Subjective cognitive decline (SCD) may represent an early stage of Alzheimer’s disease (AD), but biomarker studies in this population are limited. Therefore, we compared the performance of a comprehensive panel of novel cerebrospinal fluid (CSF) and blood biomarkers across different platforms for detecting amyloid-β (Aβ) pathology in SCD. Methods: 143 individuals with SCD (20% Aβ-positive) from the β-AARC cohort were included. Aβ status was determined by CSF Aβ42/40. CSF and blood biomarkers of Aβ, tau, synaptic function, neurodegeneration, and glial reactivity were measured cross-sectionally. Findings: In CSF, novel tau variants (p-tau205, p-tau217, p-tau231, p-tau235, NTA-tau) were elevated in Aβ-positive individuals with SCD. In plasma, p-tau217, p-tau217/Aβ42 (across multiple platforms), as well as p-tau181, p-tau181/Aβ42 and Aβ42/40 (platform-dependent) demonstrated strong discriminatory performance and high negative predictive value, but limited positive predictive value because of the low prevalence of Aβ pathology. Interpretation: In conclusion, several plasma biomarkers can exclude Aβ pathology in SCD, while some CSF and plasma markers indicate early AD-related changes. These plasma biomarkers could serve as accessible, cost-effective tools for early AD detection and risk stratification, and expedite the selection of candidates for disease-modifying treatments or preventive strategies., The research leading to these results has received funding from the Alzheimer’s Drug Discovery Foundation (ADDF) grants #RDADB-201906-2018897 and #201809-2016862. Additionally, the study has been funded by the Health Department of the Catalan Government, the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677), and PI22/00456, funded by Instituto de Salud Carlos III (ISCIII).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Decreased awareness of cognitive decline is associated with multimodal Alzheimer's disease biomarkers in cognitively unimpaired individuals

  • López-Martos, David
  • Suárez-Calvet, Marc
  • Cacciaglia, Raffaele
  • Shekari, Mahnaz
  • González Escalante, Armand
  • Brugulat Serrat, Anna, 1986-
  • Minguillón, Carolina
  • Gispert, Juan Domingo
  • Sánchez Benavides, Gonzalo
  • Grau, Oriol (Grau Rivera)
  • ALFA Study
Alzheimer's disease (AD) diagnostic guidelines emphasize subjective cognitive decline (SCD) preceding mild cognitive impairment (MCI), implicitly assuming awareness of cognitive decline (ACD) is preserved in preclinical AD. This study aimed to characterize a discrete clinical profile consistent with subtle amnestic anosognosia: decreased ACD, evaluating its association with multimodal core AD biomarkers in cognitively unimpaired (CU) individuals. We analyzed data from CU individuals with baseline CSF biomarkers and 3-year longitudinal neuropsychological assessment (ALFA+ cohort). Decreased ACD was defined by concurrent decline in episodic memory and cognitive awareness using robust longitudinal references (Free and Cued Selective Reminding Test, Memory Binding Test, Wechsler Memory Scale, and Subjective Cognitive Decline Questionnaire). Biomarker outcomes included plasma p-tau181, p-tau181/Aβ42, p-tau217; CSF p-tau181, Aβ42/40, p-tau181/Aβ42, p-tau217; Aβ ([¹⁸F]flutemetamol) and tau PET ([¹⁸F]RO948). Associations of ACD with AD biomarkers were evaluated using linear regression models. Sensitivity analysis was restricted to individuals with memory decline. 350 CU individuals were included (mean age 61 years; 60% female; mean education 14 years; 35% CSF Aβ-positive). Memory decline was identified in 61 (17%) individuals, of whom 25 (41%) exhibited concurrent awareness decline; meeting criteria for decreased ACD. This group demonstrated higher levels of AD pathology compared to the remaining sample. Among fluid biomarkers, CSF p-tau217 showed the strongest association. Neuroimaging revealed elevated frontoparietal Aβ PET, alongside temporal, insular, and frontal tau PET deposition. Sensitivity analysis confirmed that, although less pronounced, this pattern persists at the same threshold of memory decline. This study suggests that assessment of ACD may provide a crucial extension of current AD clinical frameworks., The research leading to these results has received funding from “la Caixa” Foundation under agreement LCF/PR/SC22/68000001, the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa−17–519007). RC received funding from the MCIN/AEI/10.13039/501100011033/FEDER, EU, through the project PID2021–125433OA−100 and from the grant RYC2021–031128-I, funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR; MS-C received funding from the ERC under the EU’s Horizon 2020 research and innovation program (grant no. 948677), ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through project no. SLD077/21/000001, projects PI19/00155 and PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the EU (FEDER), and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and the EU’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie (grant no. 847648 (LCF/BQ/PR21/11840004)); AB-S received funding from the Alzheimer's Association Clinician Scientist Fellowship (AACSF) Program, through the grant AACSF−23–1145154; HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023–00356, #2022–01018 and #2019–02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG−71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809–2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF−21–831376-C, #ADSF−21–831381-C, #ADSF−21–831377-C, and #ADSF−24–1284328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Familjen Beiglers Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022–0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021–00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, the UK Dementia Research Institute at UCL (UKDRI−1003), and an anonymous donor; KB is supported by the Swedish Research Council (#2017–00915 and #2022–00732), the Swedish Alzheimer Foundation (#AF−930351, #AF−939721, #AF−968270, and #AF−994551), Hjärnfonden, Sweden (#ALZ2022–0006, #FO2024–0048-TK−130 and FO2024–0048-HK−24), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG−965240 and #ALFGBG−1006418), the European Union Joint Program for Neurodegenerative Disorders (JPND2019–466–236), the Alzheimer’s Association 2021 Zenith Award (ZEN−21–848495), the Alzheimer’s Association 2022–2025 Grant (SG−23–1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, Familjen Rönströms Stiftelse, Stockholm, Sweden, and an anonymous philanthropist and donor; JDG was supported by the Spanish Ministry of Science and Innovation (RYC‑2013–13054), received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018–102261); OG-R received support from the grant IJC2020–043417-I, funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR, and receives funding from Instituto de Salud Carlos III (ISCIII) through the projects "PI19/00117" and "PI24/00116", co-funded by the European Union/FEDER, and through the project "CB16/10/00417"; GS-B receives support from the grant CP23/00039 (Miguel Servet), funded by the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union/FSE + , and receives funding from the MCIN/AEI/10.13039/501100011033 through the project PID2020–119556RA-I00 and through the project PID2024–163071OB-I00, funded by MICIU/AEI/10.13039/501100011033 and by the European Union FEDER.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Genetically predicted telomere length and Alzheimer's disease endophenotypes: a Mendelian randomization study

  • Rodríguez-Fernández, Blanca
  • Vilor Tejedor, Natàlia, 1988-
  • Arenaza Urquijo, Eider M.
  • Sánchez Benavides, Gonzalo
  • Suárez-Calvet, Marc
  • Operto, Grégory
  • Minguillón, Carolina
  • Navarro, Arcadi
  • Gispert, Juan Domingo
  • Sala Vila, Aleix
  • ALFA Study
Telomere length (TL) is associated with biological aging, consequently influencing the risk of age-related diseases such as Alzheimer's disease (AD). We aimed to evaluate the potential causal role of TL in AD endophenotypes (i.e., cognitive performance, N = 2233; brain age and AD-related signatures, N = 1134; and cerebrospinal fluid biomarkers (CSF) of AD and neurodegeneration, N = 304) through a Mendelian randomization (MR) analysis. Our analysis was conducted in the context of the ALFA (ALzheimer and FAmilies) study, a population of cognitively healthy individuals at risk of AD. A total of 20 single nucleotide polymorphisms associated with TL were used to determine the effect of TL on AD endophenotypes. Analyses were adjusted by age, sex, and years of education. Stratified analyses by APOE-ɛ4 status and polygenic risk score of AD were conducted. MR analysis revealed significant associations between genetically predicted longer TL and lower levels of CSF Aβ and higher levels of CSF NfL only in APOE-ɛ4 non-carriers. Moreover, inheriting longer TL was associated with greater cortical thickness in age and AD-related brain signatures and lower levels of CSF p-tau among individuals at a high genetic predisposition to AD. Further observational analyses are warranted to better understand these associations., The project leading to these results has received funding from the Alzheimer’s Association (Grant AARG-19-618265). This project has received funding from Instituto de Salud Carlos III (PI19/00119). Additional support has been received from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007), the Health Department of the Catalan Government (Health Research and Innovation Strategic Plan (PERIS) 2016-2020 grant# SLT002/16/00201), and the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2017-SGR-892. All CRG authors acknowledge the support of the Spanish Ministry of Science, Innovation and Universities to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. NV-T is funded by a post-doctoral grant, Juan de la Cierva Incorporación Programme (IJC2020-043216-I), Ministry of Science and Innovation–Spanish State Research Agency. EMAU is supported by the Spanish Ministry of Science, Innovation and Universities - Spanish State Research Agency (RYC2018-026053-I). MS-C receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement no. 948677). MS-C also receives funding from the Instituto de Salud Carlos III (PI19/00155) and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva Programme grant IJC2018-037478-I). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532); the European Research Council (#681712); Swedish State Support for Clinical Research (#ALFGBG-720931); the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862); the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C); the Olav Thon Foundation; the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019-0228); the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE); and the UK Dementia Research Institute at UCL. KB is supported by the Swedish Research Council (#2017-00915); the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615); the Swedish Alzheimer Foundation (#AF-742881); Hjärnfonden, Sweden (#FO2017-0243); the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986); the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236); and the National Institute of Health (NIH), USA, (grant #1R01AG068398-01). JDG is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054). AS-V. is the recipient of an Instituto de Salud Carlos III Miguel Servet II fellowship (CP II 17/00029).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Plasma p-tau212 identifies cognitively unimpaired individuals with emerging amyloid-ß pathology

  • Kac, Przemysław R.
  • González Escalante, Armand
  • Milà Alomà, Marta
  • Ashton, Nicholas J.
  • Shekari, Mahnaz
  • Ortiz Romero, Paula, 1994-
  • Turton, Michael
  • Harrison, Peter
  • Zetterberg, Henrik
  • Gispert, Juan Domingo
  • Karikari, Thomas K.
  • Suárez-Calvet, Marc
  • Blennow, Kaj
Plasma phosphorylated-tau (p-tau) biomarkers show high performance as first-in-line tests in the evaluation of patients with cognitive symptoms and have also found utility in clinical trials for anti-amyloid drug therapies for Alzheimer¿s disease (AD). Plasma p-tau212 is a novel blood biomarker that can discriminate cognitively unimpaired (CU) and subjective cognitive decline patients from mild cognitive impairment (MCI)-AD and AD dementia patients in clinical cohorts. Using Simoa technology, we evaluated plasma p-tau212 for its ability to detect emerging amyloid-beta (Aß) pathology in CU individuals with brain amyloidosis from CSF Aß42/40 ratio (n = 317) or Aß PET scans (n = 277). We benchmarked plasma p-tau212 against p-tau181, p-tau217, and p-tau231 by comparing their accuracies and fold changes for detecting brain amyloidosis. Our results showed that all the plasma p-tau biomarkers are increased in the CU CSF Aß + participants, with the highest median fold change observed for plasma p-tau212. Discrimination performance of the biomarkers to differentiate amyloid PET-positive from amyloid PET-negative participants differed between plasma p-tau biomarkers, being higher for plasma p-tau217 and p-tau212 compared to plasma p-tau181 and p-tau231. Furthermore, plasma p-tau212 was elevated in participants with low Aß burden (CSF Aß-positive, amyloid PET-negative), supporting its potential as a cost-effective, easily implemented biomarker for trial recruitment in early stages. Its further increase in Aß PET-positive participants suggests additional utility for monitoring anti-amyloid therapies., Open access funding provided by University of Gothenburg. Demensförbundet, Anna-Lisa och Bror Björnssons Stiftelse, Alzheimer’s Association, AARF-23-1141384,Marta Milà-Alomà, (#ADSF-21-831376-C,Henrik Zetterberg, #ADSF-21-831381-C, Henrik Zetterberg,#ADSF-21-831377-C, Henrik Zetterberg, #ADSF-24-1284328-C, Henrik Zetterberg, ZEN-21-848495, Kaj Blennow, #AARF-21-850325, Thomas K. Karikari, Vetenskapsrådet, #2023-00356, Henrik Zetterberg, #2022-01018, Henrik Zetterberg, #2019-02397, Henrik Zetterberg, #ALFGBG-71320, Henrik Zetterberg, #2017-00915,Kaj Blennow, (#ALFGBG-715986, Kaj Blennow, #ALFGBG-965240, Kaj Blennow, 2021-03244, Thomas K. Karikari, HORIZON EUROPE Reforming and enhancing the European Research and Innovation system, 101053962, Henrik Zetterberg, 948677, Marc Suárez-Calvet, Alzheimer’s Drug Discovery Foundation, 201809-2016862, Henrik Zetterberg, #RDAPB-201809-2016615, Kaj Blennow, European Partnership on Metrology, NEuroBioStand,Henrik Zetterberg, #22HLT07, Henrik Zetterberg, the Bluefield Project, Cure Alzheimer’s Fund, Olav Thon Stiftelsen, Familjen Erling-Perssons Stiftelse, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, #FO2022-0270, Henrik Zetterberg, #FO2017-0243,Kaj Blennow, #ALZ2022-0006, Kaj Blennow, HORIZON EUROPE Marie Sklodowska-Curie Actions, 860197 (MIRIADE), Henrik Zetterberg, No 847648 LCF/BQ/PR21/11840004, Marc Suárez-Calvet, EU Joint Programme – Neurodegenerative Disease Research, JPND2021-00694, Henrik Zetterberg, University College London Hospitals Biomedical Research Centre, UK Dementia Research Institute, UKDRI-1003, Henrik Zetterberg, Departament de Salut, Generalitat de Catalunya, SLD077/21/000001,Marc Suárez-Calvet, PI19/00155,Marc Suárez-Calvet, PI22/00456, Marc Suárez-Calvet,’la Caixa’ Foundation, ID 100010434, Marc Suárez-Calvet, Instituto de Salud Carlos III, Alzheimerfonden, #AF-930351, Kaj Blennow, #AF-939721,Kaj Blennow, #AF-968270, Kaj Blennow, European Union Joint Program for Neurodegenerative Disorders, JPND2019-466-236, Kaj Blennow, National Institute of Health (NIH), #1R01AG068398-01, Kaj Blennow, 1 RF1 AG052525-01A1, Thomas K. Karikari, 5 P30 AG066468-04, Thomas K. Karikari, 5 R01 AG053952-05, Thomas K. Karikari, 3 R01 MH121619-04S1, Thomas K. Karikari, 5 R37 AG023651-18, Thomas K. Karikari, 2 RF1 AG025516-12A1, Thomas K. Karikari, 5 R01 AG073267-02, Thomas K. Karikari, 2 R01 MH108509-06, Thomas K. Karikari, 5 R01 AG075336-02,Thomas K. Karikari, 5 R01 AG072641-02, Thomas K. Karikari, 2 P01 AG025204-16, Thomas K. Karikari, WaAina (Ann) llströms and Mary-Ann Sjöbloms stiftelsen, Emil och Wera Cornells Stiftelse.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Multimodal biomarker characterization of amnestic objective subtle cognitive decline in aging and preclinical Alzheimer's disease

  • López-Martos, David
  • Cacciaglia, Raffaele
  • Suárez-Calvet, Marc
  • Salvadó, Gemma
  • Shekari, Mahnaz
  • González Escalante, Armand
  • Milà Alomà, Marta
  • Brugulat Serrat, Anna, 1986-
  • Minguillón, Carolina
  • Tonietto, Matteo
  • Borroni, Edilio
  • Klein, Gregory
  • Quijano-Rubio, Clara
  • Kollmorgen, Gwendlyn
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Gispert, Juan Domingo
  • Grau, Oriol (Grau Rivera)
  • Sánchez Benavides, Gonzalo
  • ALFA Study
Background The objective of this study was to provide a multimodal biomarker characterization of amnestic objective subtle cognitive decline (obj-SCD) in aging and preclinical Alzheimer's disease (AD). Methods Prospective observational study; data from the Alzheimer's and Families+ (ALFAs+) cohort, including cognitively unimpaired (CU) individuals with available baseline CSF biomarkers (normal or AD continuum profiles) and longitudinal neuropsychological assessment (2 time points, 3-year follow-up). Amnestic obj-SCD was defined using robust longitudinal neuropsychological references with multivariate base rate thresholds of significant decline (Free and Cued Selective Reminding Test, Memory Binding Test, Wechsler Memory Scale IV: Logical Memory). Study outcomes included plasma p-tau217, NfL, and GFAP; CSF p-tau181/Aß42, NfL, and GFAP; Aß and tau PET; and MRI Grey Matter volume (GMv). The associations of amnestic obj-SCD with fluid (plasma and CSF) and neuroimaging biomarkers (PET and GMv) were evaluated using mixed-effects and voxel-wise linear regression models, respectively. Results 350 CU individuals were included (mean age 61 years; 60% female; mean education 14 years; 35% CSF Aß-positive). Amnestic obj-SCD was identified in 10% of the sample, associated with greater AD pathology (higher plasma p-tau217, CSF p-tau181/Aß42, global Aß PET, medial temporal tau PET), neurodegeneration (higher plasma and CSF NfL, reduced GMv in cingulate cortex, longitudinal GMv reductions in hippocampus) and inflammation (higher plasma and CSF GFAP, longitudinal GMv increases in neocortical brain regions). Discussion These findings highlight the need for standardized clinical staging criteria to enhance early detection and risk stratification in aging and preclinical AD., The research leading to these results has received funding from “la Caixa” Foundation under agreement LCF/PR/SC22/68000001, the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). R.C. received funding from the MCIN/AEI/10.13039/501100011033/FEDER, EU,through the project PID2021-125433OA-100 and from the grant RYC2021-031128-I, funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR; M.S.-C. received funding from the ERC under the EU’s Horizon 2020 research and innovation program (grant no. 948677), ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through project no. SLD077/21/000001, projects PI19/00155 and PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the EU (FEDER), and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and the EU’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie (grant no. 847648 (LCF/BQ/PR21/11840004)); A.B.-S. received funding from the Alzheimer's Association Clinician Scientist Fellowship (AACSF) Program, through the grant AACSF-23-1145154; H.Z. is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356, #2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Familjen Beiglers Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, the UK Dementia Research Institute at UCL (UKDRI-1003), and an anonymous donor; K.B. is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270, and #AF-994551), Hjärnfonden, Sweden (#ALZ2022-0006, #FO2024-0048-TK-130 and FO2024-0048-HK-24), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-965240 and #ALFGBG-1006418), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022-2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, Familjen Rönströms Stiftelse, Stockholm, Sweden, and an anonymous filantropist and donor; J.D.G. was supported by the Spanish Ministry of Science and Innovation (RYC‑2013‑13054), received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018‑102261); O.G.-R. was supported by the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva program IJC2020-043417-I), funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR, Instituto de Salud Carlos III (ISCIII) through the projects "PI19/00117" and "PI24/00116" and co-funded by the European Union/FEDER. OG-R also receives funding from F. Hoffmann-La Roche Ltd, and has given lectures in symposia sponsored by Roche Diagnostics, S.L.U; G.S.-B. was supported by the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union/FSE+, supported by MCIN/AEI/10.13039/501100011033, through the project PID2020-119556RA-I00 and grant CP23/00039.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Physical activity changes during midlife link to brain integrity and amyloid burden

  • Akinci, Muge
  • Aguilar Dominguez, Pablo
  • Palpatzis, Eleni
  • Shekari, Mahnaz
  • Garcia Prat, Marina
  • Deulofeu, Carme
  • Fauria, Karine
  • García Aymerich, Judith
  • Gispert, Juan Domingo
  • Suárez-Calvet, Marc
  • Grau, Oriol (Grau Rivera)
  • Sánchez Benavides, Gonzalo
  • Arenaza Urquijo, Eider M.
  • ALFA Study
Introduction: Evidence suggests that midlife physical activity may reduce Alzheimer's disease (AD) risk. In at-risk individuals, we investigated midlife physical activity changes in relation to AD-related pathologies. Methods: We included 337 cognitively unimpaired adults with baseline and follow-up physical activity evaluations within 4.07 ± 0.84 years. We performed multiple regressions considering follow-up amyloid-PET burden and MRI-based medial temporal lobe cortical thickness as outcomes. Independent variables encompassed changes in adherence to World Health Organization (WHO)-recommended physical activity levels, activity amounts, and sedentary behavior (no activity reported). Results: Remaining sedentary was associated with lower cortical thickness compared to doing limited physical activity, maintaining adherence, or becoming adherent to WHO recommendations. Becoming adherent to recommendations was linked to lower amyloid burden compared to becoming non-adherent. Increased activity amounts showed a dose-dependent association with lower amyloid burden. Discussion: Increasing physical activity and new adherence to WHO recommendations could be key objectives for preventive strategies during midlife. Clinical trial registration information: Registered at Clinicaltrials.gov (identifier: NCT02485730). Highlights: Boosting physical activity in midlife may have beneficial effects in preclinical AD. Physical activity increases relate to lower Aβ burden in a dose-dependent manner. Remaining sedentary links to lower cortical thickness in AD-vulnerable structures. New adherence to WHO-recommended physical activity levels may enhance brain health., This work was supported by ‘la Caixa’ Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer's Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Support has also been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant no. 2021 SGR 00913. EMA-U has received funding by the Ministry of Science and Innovation (PID2019-111514RA-I00) and the Alzheimer's Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID). EMA-U is supported by the Spanish Ministry of Science and Innovation—State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF) and EU Joint Programme-Neurodegenerative Disease Research (JPND2022-138). EP is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). MSC receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Grant agreement No. 948677), Project “PI19/00155”, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). We acknowledge support from the grant CEX2018-000806-S funded by MCIN/AEI/10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Program.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Blood pressure and Alzheimer's disease biomarkers in cognitively unimpaired adults: a multicenter study

  • Osset-Malla, Mariona
  • Martínez-Velasco, Aitana
  • Sánchez Benavides, Gonzalo
  • Buongiorno, Mariateresa
  • Sierra, Alejandro de la
  • Shekari, Mahnaz
  • Minguillón, Carolina
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Vállez García, David
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • Grau-Rivera, Oriol
  • ALFA Study
BACKGROUND: Hypertension is a modifiable risk factor for dementia, potentially influencing Alzheimer's disease (AD) pathology. Understanding this relationship is essential for developing interventions to reduce dementia risk. OBJECTIVES: We investigated cross-sectional and longitudinal associations between blood pressure and AD biomarkers in cerebrospinal fluid (CSF) and amyloid (Aß) positron emission tomography (PET) in cognitively unimpaired adults. DESIGN: Prospective observational study. SETTING: We analyzed data from cognitively unimpaired participants from three observational prospective European studies: ALFA+ (NCT02485730), EPAD-LCS (NCT02804789), and AMYPAD PNHS (EudraCT: 2018-002,277-22). MEASUREMENTS: ALFA+ participants had either CSF biomarkers (CSF Aß42, Aß40, p-tau181, t-tau) and/or Aß PET data. EPAD participants had CSF biomarkers (CSF Aß42, p-tau181, t-tau), and AMYPAD participants had Aß PET data. All participants had available data about diabetes, use of hypertensive medication, and waist-to-hip ratio. Multivariable linear regression models were used to analyze cross-sectional associations between systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure (PP) with CSF biomarkers or Aß PET (Centiloid units, CL); longitudinal associations were tested by means of delta CL scores between baseline and follow-up to assess Aß PET changes over time. RESULTS: We included 405 participants from ALFA+ (mean age 61.1 years; 60 % female), 1104 from EPAD (mean age 64.8 years; 59.1 % female), and 340 from AMYPAD (mean age 71.8 years; 60 % female). In ALFA+, DBP was negatively associated with CSF Aß40 (p = 0.016) and p-tau181 (p = 0.050), while there was a non-significant trend towards a positive association between SBP and CL over time (p = 0.058). In EPAD, DBP was negatively associated with CSF Aß42 (p < 0.001) and p-tau181 (p = 0.014), while PP was positively associated with CSF Aß42 (p = 0.024). In AMYPAD, SBP (p = 0.002) and PP (p = 0.003) were positively associated with CL at baseline, with a similar non-significant trend being found for DBP (p = 0.089). Higher DBP (p = 0.042) was significantly associated to increased CL over time, with a similar non-significant trend being found for SBP (p = 0.072). We did not find significant associations between blood pressure and longitudinal changes in CSF biomarkers. CONCLUSIONS: Elevated blood pressure was associated with increased Aß PET accumulation in cognitively unimpaired individuals. Further research is warranted to elucidate potential mechanisms underlying the negative associations between DBP and CSF biomarkers, which do not reflect the typical AD molecular signature. These findings highlight the relevance of high blood pressure as a potential risk factor for cognitive decline., The research leading to these results has received funding from “la Caixa” Foundation (ID 100,010,434), under agreement LCF/PR/GN17/50,300,004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17–519,007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00,913. OGR has received funding from the Alzheimer’s Association Research Fellowship Program (2019-AARF-644,568) and Instituto de Salud Carlos III (PI19/00,117) and receives funding from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva programme IJC2020–043,417-I). OG-R is supported by the Spanish Ministry of Science and Innovation –State Research Agency (IJC2020–043,417-I/MCIN/AEI/10.13039/501,100,011,033) and the European Union laquoNextGenerationEUraquo/PRTR. GSB receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency, PID2020–119556RA-I00. MS-C receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948,677); ERA PerMed (ERAPERMED2021–184); Project "PI19/00,155″ and “PI22/00,456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from ”la Caixa” Foundation (ID 100,010,434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847,648 (LCF/BQ/PR21/11,840,004). HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023–00,356; #2022–01,018 and #2019–02,397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101,053,962, Swedish State Support for Clinical Research (#ALFGBG-71,320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201,809–2016,862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21–831,376-C, #ADSF-21–831,381-C, #ADSF-21–831,377-C, and #ADSF-24–1284,328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022–0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860,197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021–00,694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (#2017–00,915 and #2022–00,732), the Swedish Alzheimer Foundation (#AF-930,351, #AF-939,721 and #AF-968,270), Hjärnfonden, Sweden (#FO2017–0243 and #ALZ2022–0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715,986 and #ALFGBG-965,240), the European Union Joint Program for Neurodegenerative Disorders (JPND2019–466–236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21–848,495), and the Alzheimer’s Association 2022–2025 Grant (SG-23–1038,904 QC). This work used data and/or samples from the EPAD project which received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement n° 115,736 and an Alzheimer’s Association Grant (SG-21–818,099-EPAD). This work also used data from AMYPAD PNHS that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115,952. This Joint Undertaking received support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. This communication reflects the views of the authors and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Awareness of episodic memory and meta-cognitive profiles: associations with cerebrospinal fluid biomarkers at the preclinical stage of the Alzheimer's continuum

  • López-Martos, David
  • Suárez-Calvet, Marc
  • Milà Alomà, Marta
  • Gispert, Juan Domingo
  • Minguillón, Carolina
  • Quijano-Rubio, Clara
  • Kollmorgen, Gwendlyn
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Grau, Oriol (Grau Rivera)
  • Sánchez Benavides, Gonzalo
Introduction: The lack of cognitive awareness, anosognosia, is a clinical deficit in Alzheimer's disease (AD) dementia. However, an increased awareness of cognitive function, hypernosognosia, may serve as a marker in the preclinical stage. Subjective cognitive decline (SCD) might correspond to the initial symptom in the dynamic trajectory of awareness, but SCD might be absent along with low awareness of actual cognitive performance in the preclinical stage. We hypothesized that distinct meta-cognitive profiles, both hypernosognosia and anosognosia, might be identified in preclinical-AD. This research evaluated the association between cerebrospinal fluid (CSF) AD biomarkers and the awareness of episodic memory, further exploring dyadic (participant-partner) SCD reports, in the preclinical Alzheimer's continuum. Methods: We analyzed 314 cognitively unimpaired (CU) middle-aged individuals (mean age: 60, SD: 4) from the ALFA+ cohort study. Episodic memory was evaluated with the delayed recall from the Memory Binding Test (MBT). Awareness of episodic memory, meta-memory, was defined as the normalized discrepancy between objective and subjective performance. SCD was defined using self-report, and dyadic SCD profiles incorporated the study partner's report using parallel SCD-Questionnaires. The relationship between CSF Aβ42/40 and CSF p-tau181 with meta-memory was evaluated with multivariable regression models. The role of SCD and the dyadic contingency was explored with the corresponding stratified analysis. Results: CSF Aβ42/40 was non-linearly associated with meta-memory, showing an increased awareness up to Aβ-positivity and a decreased awareness beyond this threshold. In the non-SCD subset, the non-linear association between CSF Aβ42/40 and meta-memory persisted. In the SCD subset, higher Aβ-pathology was linearly associated with increased awareness. Individuals presenting only study partner's SCD, defined as unaware decliners, exhibited higher levels of CSF p-tau181 correlated with lower meta-memory performance. Discussion: These results suggested that distinct meta-cognitive profiles can be identified in preclinical-AD. While most individuals might experience an increased awareness associated with the entrance in the AD continuum, hypernosognosia, some might be already losing insight and stepping into the anosognosic trajectory. This research reinforced that an early anosognosic profile, although at increased risk of AD-related decline, might be currently overlooked considering actual diagnostic criteria, and therefore its medical attention delayed., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The design and execution of the study were independent of any influence from funding sources. This includes data collection, analysis, interpretation, manuscript preparation, review, and approval. The research leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. DL-M was supported by Instituto de Salud Carlos III through the project PI19/00117 (Co-funded by European Regional Development Fund/European Social Fund “A way to make Europe”/”Investing in your future”). MS-C receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed (ERAPERMED2021-184); Project “PI19/00155” and “PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). JG receives funding from the European Comission Innovative Health Initiative (Grant Agreement: 101112145), the BrightFocus Foundation (Grant Reference ID: A2022034S), and La Marató de TV3 (Project: 202318 30-31-32). HZ was a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). KB was supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721 and #AF-968270), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), and the Alzheimer’s Association 2022-2025 Grant (SG-23-1038904 QC). OG-R was supported by the Spanish Ministry of Science and Innovation –State Research Agency (IJC2020-043417-I/MCIN/AEI/10.13039/501100011033) and the European Union laquoNextGenerationEUraquo/PRTR. GS-B was supported by the Agencia Estatal de Investigación AEI/10.13039/501100011033 through the project PID2020-119556RA-I00 and Instituto de Salud Carlos III (ISCIII) through the project CP23/00039 (Miguel Servet contract), co-funded by the European Union (FSE+).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Plasma phosphorylated tau 217 to identify preclinical Alzheimer disease

  • Salvadó, Gemma
  • Gispert, Juan Domingo
  • Suárez-Calvet, Marc
  • Hansson, Oskar
Importance: Advances in Alzheimer disease (AD) have shifted research focus to earlier disease stages, necessitating more scalable approaches to identify cognitively unimpaired individuals with amyloid β (Aβ) pathology. Objective: To assess the utility of plasma phosphorylated tau 217 (p-tau217) for classifying Aβ status in cognitively unimpaired individuals, both as a stand-alone test and in a 2-step approach where positive plasma results were confirmed using a second modality (Aβ positron emission tomography [PET] or cerebrospinal fluid [CSF]). Design, setting, and participants: This cross-sectional cohort study used data collected between June 2009 and March 2024. We included 2916 cognitively unimpaired participants from 12 international independent observational cohorts in the US, Europe, Australia, and Canada with available plasma p-tau217 levels and CSF or PET Aβ biomarkers. Performance comparisons between mass spectrometry and immunoassay-based p-tau217 measurements were also performed (n = 964). Exposures: Plasma p-tau217 levels measured by immunoassay. Main outcome and measures: Aβ status, determined by CSF or Aβ PET biomarkers. Results: Participants had a mean (SD) age of 66.9 (9.9) years; 971 (33.3%) were Aβ positive by either CSF or PET, 1667 (57.2%) were women, and 1108 (38.1%) carried at least 1 APOE ε4 allele. As a stand-alone test, plasma p-tau217 achieved a positive predictive value (PPV) of 79% (95% CI, 74-84) and an overall accuracy of 81% (95% CI, 80-82). In a 2-step workflow, the PPV and accuracy significantly increased to 91% (95% CI, 86-95). While this approach required screening of 677 individuals with plasma p-tau217 to identify 100 Aβ-positive individuals, compared to 536 participants when using PET alone, it reduced the need for PET testing to 124. Immunoassays demonstrated comparable PPVs to mass spectrometry (80% [95% CI, 74-86] vs 85% [95% CI, 81-90]; P = .12) but significantly lower overall accuracy (82% [95% CI, 79-84]% vs 88 [95% CI, 86-90]; P < .001) and true Aβ-positive detection rate (49% [95% CI, 43-55] vs 69% [95% CI, 64-75]; P < .001). Conclusions and relevance: The findings highlight the potential of plasma p-tau217 as a stand-alone test-or when used in a sequential 2-step approach alongside PET or CSF testing-as a cost-effective, scalable, and minimally burdensome strategy for identifying preclinical AD. Tailored screening workflows that incorporate p-tau217 can improve efficiency in participant selection for preclinical AD trials and, in the future, help guide access to disease-modifying treatments., Work at the authors’ research center (Lund University) was supported by the National Institute of Aging (R01AG083740), European Research Council (ADG-101096455), Alzheimer’s Association (ZEN24-1069572, SG-23-1061717), GHR Foundation, Swedish Research Council (2022-00775 and 2018-02052, 2021-02219), ERA PerMed (ERAPERMED2021-184), Knut and Alice Wallenberg Foundation (2022-0231), Strategic Research Area MultiPark (multidisciplinary research in Parkinson’s disease) at Lund University, Swedish Alzheimer Foundation (AF-980907, AF-994229), Swedish Brain Foundation (FO2021-0293, FO2023-0163), Parkinson Foundation of Sweden (1412/22), Cure Alzheimer’s Fund, Rönström Family Foundation, Berg Family Foundation, Greta och Johan Kock Foundation, WASP and DDLS joint call for research projects (WASP/DDLS22-066), Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Skåne University Hospital Foundation (2020-O000028), Regionalt Forskningsstöd (2022-1259), Bundy Academy at Lund University (2025-2026-2024-2428) and the Swedish federal government under the ALF agreement (2022-Projekt0080, 2022-Projekt0107). Dr Salvadó received funding from the European Union’s Horizon 2020 Research and Innovation Program under Marie Skłodowska-Curie action grant agreement number 101061836, an Alzheimer’s Association Research Fellowship (AARF-22-972612), the Brightfocus Foundation (A2024007F), the Alzheimerfonden (AF-980942, AF-994514, AF-1012218), Greta och Johan Kocks research grants and travel grants from the Strategic Research Area MultiPark (multidisciplinary research in Parkinson’s disease) at Lund University. This study was also funded by the Instituto de Salud Carlos III (Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España) through the projects INT21/00073, PI20/01473 and PI23/01786 to Dr Fortea) and the Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas Program 1, partly jointly funded by Fondo Europeo de Desarrollo Regional, Unión Europea, Una Manera de Hacer Europa, and cofunded by the European Regional Development Fund/European Social Fund. This work was also supported by National Institutes of Health grants R01 AG056850; R21 AG056974, R01 AG061566, R01 AG081394, and R61AG066543 to Dr Fortea. It was also supported by Fundación Tatiana Pérez de Guzmán el Bueno (IIBSP-DOW-2020-151 to Dr Fortea) and Horizon 2020–Research and Innovation Framework Programme from the European Union (H2020-SC1-BHC-2018-2020 to Dr Fortea). Dr Suárez-Calvet received funding from the European Research Council under the European Union’s Horizon 2020 research and innovation programme (grant agreement No. 948677); ERA PerMed (ERAPERMED2021-184); projects PI19/00155 and PI22/00456, funded by Instituto de Salud Carlos III and cofunded by the European Union; and from a fellowship from la Caixa Foundation (100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). The Translational Biomarkers in Aging and Dementia cohort is supported by the Weston Brain Institute, Canadian Institutes of Health Research (MOP-11-51-31; RFN 152985, 159815 and 162303), Canadian Consortium of Neurodegeneration and Aging (MOP-11-51-31-team 1), the Alzheimer’s Association (NIRG-12-92090 and NIRP-12-259245), Brain Canada Foundation (CFI Project 34874; 33397), the Fonds de Recherche du Québec–Santé (Chercheur Boursier, 2020-VICO-279314) and the Colin J. Adair Charitable Foundation. The Wisconsin Registry for Alzheimer's Prevention cohort was supported by R01AG027161, R01AG021155 and P30AG062715 from SC Johnson. The Australian Imaging Biomarkers and Lifestyle Study of Ageing study is funded by the Commonwealth Scientific and Industrial Research Organization, and the National Health and Medical Research Council. The Sant Pau Initiative on Neurodegeneration cohort received funding from the Fondo de Investigaciones Sanitario, Instituto de Salud Carlos III (PI21/00791, PI14/01126, PI17/01019, PI20/01473, PI13/01532, PI16/01825, PI18/00335, PI19/00882, PI18/00435, PI22/00611, INT19/00016, INT23/00048, PI17/01896, and AC19/00103), and the Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas program, jointly funded by Fondo Europeo de Desarrollo Regional, Unión Europea, Una manera de hacer Europa. The Sant Pau Initiative on Neurodegeneration cohort was also supported by the National Institutes of Health (grants 1R01AG056850-01A1; R21AG056974; and R01AG061566), by Generalitat de Catalunya (2017-SGR-547, SLT006/17/125, SLT006/17/119, SLT002/16/408), Marató TV3 Foundation grants 20141210, 044412 and 20142610, a grant from the Fundació Bancaria La Caixa (Down Alzheimer Barcelona Neuroimaging Initiative project), Fundació Catalana Síndrome de Down and Fundació Víctor Grífols i Lucas. Horizon 21 Consortium is partly funded by Jérôme Lejeune Foundation. PREVENT-AD was launched in 2011 as a $13.5 million, 7-year public-private partnership using funds provided by McGill University, the Fonds de Recherche du Québec–Santé, an unrestricted research grant from Pfizer Canada, the J.L. Levesque Foundation, the Lemaire Foundation, the Douglas Hospital Research Centre and Foundation, the Government of Canada, and the Canada Fund for Innovation. Additional funding sources include the Canadian Institutes of Health Research (438655), US National Institutes of Health (R01 AG068563), Alzheimer’s Association, Alzheimer Society of Canada and Brain Canada grants. Dr Blennow is supported by the Swedish Research Council (2017-00915 and 2022-00732), the Swedish Alzheimer Foundation (AF-930351, AF-939721, AF-968270, and AF-994551), Hjärnfonden, Sweden (ALZ2022-0006 and FO2024-0048-TK-130), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF agreement (ALFGBG-965240 and ALFGBG-1006418), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022-2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer, the Kirsten and Freddy Johansen Foundation, and Familjen Rönströms Stiftelse. Dr Teunissen is supported by the European Commission (Marie Curie International Training Network, grant agreement 860197) and TAME, Innovative Medicines Initiatives 3TR (Horizon 2020, grant no 831434) EPND (IMI 2 Joint Undertaking, grant 101034344) and JPND (bPRIDE, CCAD), European Partnership on Metrology, cofinanced from the European Union’s Horizon Europe Research and Innovation Programme and by the participating states (22HLT07 NEuroBioStand). The CANTATE project was funded by the Alzheimer Drug Discovery Foundation, Alzheimer Association, Michael J Fox Foundation, Health Holland, the Dutch Research Council, Alzheimer Drug Discovery Foundation, the Selfridges Group Foundation, and Alzheimer Netherlands. Dr Teunissen is also a recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (73305095007) and Health~Holland, Topsector Life Sciences & Health (LSHM20106), and of TAP-dementia, a ZonMw-funded project (10510032120003) in the context of the Dutch National Dementia Strategy.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Time-encoded ASL reveals lower cerebral blood flow in the early AD continuum

  • Falcón, Carles
  • Minguillón, Carolina
  • Fauria, Karine
  • Cascales Lahoz, Diego
  • Contador, José
  • Fernández-Lebrero, Aida
  • Navalpotro-Gómez, Irene
  • Puig-Pijoan, Albert
  • Grau, Oriol (Grau Rivera)
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
Introduction: Cerebral blood flow (CBF) is reduced in cognitively impaired (CI) Alzheimer's disease (AD) patients. We checked the sensitivity of time-encoded arterial spin labeling (te-ASL) in measuring CBF alterations in individuals with positive AD biomarkers and associations with relevant biomarkers in cognitively unimpaired (CU) individuals. Methods: We compared te-ASL with single-postlabel delay (PLD) ASL in measuring CBF in 59 adults across the AD continuum, classified as CU amyloid beta (Aβ) negative (-), CU Aβ positive (+), and CI Aβ+. We sought associations of CBF with biomarkers of AD, cerebrovascular disease, synaptic dysfunction, neurodegeneration, and cognition in CU participants. Results: te-ASL was more sensitive at detecting CBF reduction in the CU Aβ+ and CI Aβ+ groups. In CU participants, lower CBF was associated with altered biomarkers of Aβ, tau, synaptic dysfunction, and neurodegeneration. Discussion: CBF reduction occurs early in the AD continuum. te-ASL is more sensitive than single-PLD ASL at detecting CBF changes in AD. Highlights: Lower CBF can be detected in CU subjects in the early AD continuum. te-ASL is more sensitive than single-PLD ASL at detecting CBF alterations in AD. CBF is linked to biomarkers of AD, synaptic dysfunction, and neurodegeneration., We want to express our most sincere gratitude to the ALFA project participants and relatives, without whom this research would not have been possible. We thank Roche Diagnostics International Ltd for providing the NeuroToolKit kits to measure CSF biomarkers, Eli Lilly and Company for providing the measurements of the in-house assay for CSF and plasma p-tau217, and GE Healthcare for providing the doses of [18F] flutemetamol PET. Lastly, we would like to thank Valeria Di Giacomo, PhD, and Allison Clark, from ThePaperMill, for providing writing support, funded by The Fundació Pasqual Maragall. Marc Suárez-Calvet receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (Grant agreement No. 948677), the Instituto de Salud Carlos III (ISCIII) through projects PI19/00155 and PI22/00456 (cofunded by the European Union FEDER), the Department of Research and Universities of the Generalitat de Catalunya through the project 2021 SGR 01137, the HNA Foundation through the project PROAD, and the ERA PerMed ERA-NET and the Department of Health of the Generalitat de Catalunya (DS-CAT) through the project SLD077/21/000001. Moreover, Marc receives support from a fellowship provided by “la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant agreement No. 847648 (fellowship code LCF/BQ/PR21/11840004). Henrik Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (Nos. 2022-01018 and 2019-02397), the European Union's Horizon Europe research and innovation program under Grant agreement No. 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (No. 201809-2016862), the AD Strategic Fund and the Alzheimer's Association (Nos. ADSF-21-831376-C, ADSF-21-831381-C, and ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (FO2022-0270), the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant agreement No. 860197 (MIRIADE), the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). Oriol Grau-Rivera receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), the Instituto de Salud Carlos III (ISCIII) through the project PI19/00117 (cofunded by the European Unior FEDER), and the MCIN/AEI/10.13039/501100011033 through the project IJC2020-043417-I (cofunded by the European Union NextGenerationEU/PRTR).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Data-driven CSF biomarker profiling: imaging and clinical outcomes in a cohort at risk of Alzheimer's disease

  • Argiris, Georgette
  • Akinci, Muge
  • Peña-Gómez, Cleofé
  • Palpatzis, Eleni
  • Garcia Prat, Marina
  • Shekari, Mahnaz
  • Blennow, Kaj
  • Zetterberg, Henrik
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Ashton, Nicholas J.
  • Karikari, Thomas K.
  • Brinkmalm-Westman, Ann
  • Lantero Rodriguez, Juan
  • Fauria, Karine
  • Sánchez Benavides, Gonzalo
  • Grau, Oriol (Grau Rivera)
  • Suárez-Calvet, Marc
  • Arenaza Urquijo, Eider M.
  • ALFA Study
Background: Cerebrospinal fluid (CSF) biomarkers of synaptic dysfunction, neuroinflammation, and glial response, complementing Alzheimer's disease (AD) core biomarkers, have improved the pathophysiological characterization of the disease. Here, we tested the hypothesis that the co-expression of multiple CSF biomarkers will help the identification of AD-like phenotypes when biomarker positivity thresholds are not met yet. Methods: Two hundred and seventy cognitively unimpaired adults with family history (FH) of sporadic AD (mean age = 60.6 ± 4.85 years, 64.8% women) underwent lumbar puncture, magnetic resonance imaging (n = 266) and positron emission tomography imaging (n = 239) protocols, and clinical evaluations. CSF Aβ42, Aβ40, p-tau181, p-tau217, p-tau231, NfL, neurogranin, sTREM2, YKL40, GFAP, S100, α-Synuclein, SYT1, and SNAP25 were measured. Participants were clustered based on CSF biomarker co-expression with an agglomerative algorithm. The predictive value of the classification against brain and cognitive outcomes was evaluated. Results: Three clusters (C) were identified. Higher Aβ burden and CSF p-tau was the hallmark of C1. The other two clusters showed lower Aβ burden but higher expression of glial (C2) or synaptic markers (C3). Participants in C1 showed an AD-like clinical phenotype, comprising participants with the overall highest percentage of two parent FH and APOE-ε4 carriers, in addition to comprising more females compared to C2. C3 displayed better vascular health compared to C1. C2 were older and comprised a lower percentage of females compared to C3. C1 showed an AD-like gray matter reduction in medial temporal (notably hippocampus) and frontal regions that were not observed in Aβ42/40 + compared with Aβ42/40 - . Furthermore, Aβ42/40 - participants in C1 showed GM reduction in inferior temporal areas compared with Aβ42/40 + participants overall. C1 membership also predicted cognitive decline in executive function, but not memory, beyond Aβ + status, overall suggesting a better prognosis in Aβ42/40 + participants without C1 membership. Additionally, C1 displayed a higher rate of conversion to Aβ + (25%) over time. Conclusions: Our results suggest that examining multiple CSF biomarkers reflecting diverse pathological pathways may complement and/or outperform AD core biomarkers and thresholding approaches to identify individuals showing a clinical and cognitive AD-like phenotype, including higher conversion to Aβ + , GM reductions and cognitive decline. The clinical utility of this approach warrants further investigation and replication in other cohorts., The research leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17–519007). Support has also been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant no. 2021 SGR 00913. The research leading to these results has received funding by the Ministry of Science and Innovation (PID2019-111514RA-I00) and the Alzheimer’s Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID), to EMA-U. EMA-U is supported by the Spanish Ministry of Science and Innovation—State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF). EMA-U receives support from EU Joint Programme-Neurodegenerative Disease Research (JPND2022-138). E.P is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). GA receives support from the Alzheimer’s Association research fellowship (23AARF-1028873). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022–01018 and #2019–02397), the European Union’s Horizon Europe research and innovation program under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201,809–2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21–831,376-C, #ADSF-21–831,381-C, and #ADSF-21–831,377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Program – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677), Project "PI19/00155″, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).
Repisalud
Publication Artículo científico (JournalArticle)

Genetically predicted telomere length and Alzheimer's disease endophenotypes: a Mendelian randomization study.

  • Rodríguez-Fernández, Blanca
  • Vilor-Tejedor, Natalia
  • Arenaza-Urquijo, Eider M
  • Sánchez-Benavides, Gonzalo
  • Suárez-Calvet, Marc
  • Operto, Grégory
  • Minguillón, Carolina
  • Fauria, Karine
  • Kollmorgen, Gwendlyn
  • Suridjan, Ivonne
  • de Moura, Manuel Castro
  • Piñeyro, David
  • Esteller, Manel
  • Blennow, Kaj
  • Zetterberg, Henrik
  • De Vivo, Immaculata
  • Molinuevo, José Luis
  • Navarro, Arcadi
  • Gispert, Juan Domingo
  • Sala-Vila, Aleix
  • Crous-Bou, Marta
Telomere length (TL) is associated with biological aging, consequently influencing the risk of age-related diseases such as Alzheimer's disease (AD). We aimed to evaluate the potential causal role of TL in AD endophenotypes (i.e., cognitive performance, N = 2233; brain age and AD-related signatures, N = 1134; and cerebrospinal fluid biomarkers (CSF) of AD and neurodegeneration, N = 304) through a Mendelian randomization (MR) analysis. Our analysis was conducted in the context of the ALFA (ALzheimer and FAmilies) study, a population of cognitively healthy individuals at risk of AD. A total of 20 single nucleotide polymorphisms associated with TL were used to determine the effect of TL on AD endophenotypes. Analyses were adjusted by age, sex, and years of education. Stratified analyses by APOE-ɛ4 status and polygenic risk score of AD were conducted. MR analysis revealed significant associations between genetically predicted longer TL and lower levels of CSF Aβ and higher levels of CSF NfL only in APOE-ɛ4 non-carriers. Moreover, inheriting longer TL was associated with greater cortical thickness in age and AD-related brain signatures and lower levels of CSF p-tau among individuals at a high genetic predisposition to AD. Further observational analyses are warranted to better understand these associations.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Genetically predicted telomere length and Alzheimer’s disease endophenotypes: a Mendelian randomization study

  • Rodríguez-Fernández, Blanca
  • Vilor-Tejedor, Natalia
  • Arenaza-Urquijo, Eider M.
  • Sánchez-Benavides, Gonzalo
  • Suárez-Calvet, Marc
  • Operto, Grégory
  • Minguillón, Carolina
  • Fauria, Karine
  • Kollmorgen, Gwendlyn
  • Suridjan, Ivonne
  • Castro de Moura, Manuel
  • Piñeyro, David
  • Esteller, Manel
  • Blennow, Kaj
  • Zetterberg, Henrik
  • De Vivo, Immaculata
  • Molinuevo, José Luis
  • Navarro, Arcadi
  • Gispert, Juan Domingo
  • Sala-Vila, Aleix
  • Crous-Bou, Marta
  • ALFA study
Telomere length (TL) is associated with biological aging, consequently influencing the risk of age-related diseases such as Alzheimer’s disease (AD). We aimed to evaluate the potential causal role of TL in AD endophenotypes (i.e., cognitive performance, N = 2233; brain age and AD-related signatures, N = 1134; and cerebrospinal fluid biomarkers (CSF) of AD and neurodegeneration, N = 304) through a Mendelian randomization (MR) analysis. Our analysis was conducted in the context of the ALFA (ALzheimer and FAmilies) study, a population of cognitively healthy individuals at risk of AD. A total of 20 single nucleotide polymorphisms associated with TL were used to determine the effect of TL on AD endophenotypes. Analyses were adjusted by age, sex, and years of education. Stratified analyses by APOE-ɛ4 status and polygenic risk score of AD were conducted. MR analysis revealed significant associations between genetically predicted longer TL and lower levels of CSF Aβ and higher levels of CSF NfL only in APOE-ɛ4 non-carriers. Moreover, inheriting longer TL was associated with greater cortical thickness in age and AD-related brain signatures and lower levels of CSF p-tau among individuals at a high genetic predisposition to AD. Further observational analyses are warranted to better understand these associations., The project leading to these results has received funding from the Alzheimer’s Association (Grant AARG-19-618265). This project has received funding from Instituto de Salud Carlos III (PI19/00119). Additional support has been received from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007), the Health Department of the Catalan Government (Health Research and Innovation Strategic Plan (PERIS) 2016-2020 grant# SLT002/16/00201), and the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2017-SGR-892. All CRG authors acknowledge the support of the Spanish Ministry of Science, Innovation and Universities to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. NV-T is funded by a post-doctoral grant, Juan de la Cierva Incorporación Programme (IJC2020-043216-I), Ministry of Science and Innovation–Spanish State Research Agency. EMAU is supported by the Spanish Ministry of Science, Innovation and Universities - Spanish State Research Agency (RYC2018-026053-I). MS-C receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement no. 948677). MS-C also receives funding from the Instituto de Salud Carlos III (PI19/00155) and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva Programme grant IJC2018-037478-I). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532); the European Research Council (#681712); Swedish State Support for Clinical Research (#ALFGBG-720931); the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862); the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C); the Olav Thon Foundation; the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019-0228); the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE); and the UK Dementia Research Institute at UCL. KB is supported by the Swedish Research Council (#2017-00915); the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615); the Swedish Alzheimer Foundation (#AF-742881); Hjärnfonden, Sweden (#FO2017-0243); the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986); the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236); and the National Institute of Health (NIH), USA, (grant #1R01AG068398-01). JDG is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054). AS-V. is the recipient of an Instituto de Salud Carlos III Miguel Servet II fellowship (CP II 17/00029).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Proteomic polygenic risk scores of age-related plasma protein levels reveal a role for Metalloproteinase inhibitor 2 (TIMP2) in cognitive performance

  • Anastasi, Federica
  • Genius, Patricia
  • Rodriguez-Fernandez, Blanca
  • Yang, Chengran
  • Gorijala, Priyanka
  • Timsina, Jigyasha
  • Hernández-Villamizar, Felipe
  • Lorenzini, Luigi
  • Del Campo, Marta
  • Sánchez-Benavides, Gonzalo
  • Minguillon, Carolina
  • Navarro, Arcadi
  • Cruchaga, Carlos
  • Suárez-Calvet, Marc
  • Vilor-Tejedor, Natalia
Several studies in mice have identified blood proteins that influence brain aging, yet translating these findings into humans remains challenging. To address this gap, we conducted a systematic review that identified 12 proteins reported to have an aging or rejuvenating effect in murine brains. Using protein quantitative trait loci data, we computed proteomic polygenic risk scores (protPRSs) capturing the lifelong genetic predisposition to higher or lower plasma protein levels and their regulation. We first validated the prediction accuracy of these protPRSs in two independent cohorts: 10 protPRSs in the Knight-ADRC and 7 protPRSs in the ALFA+ cohort significantly predicted their corresponding protein levels, although effect sizes were modest. We then examined their association with cognitive performance in cognitively unimpaired individuals at risk of Alzheimer's disease of the ALFA+ cohort. Among the protPRSs tested, the metalloproteinase inhibitor 2 (TIMP2) protPRS was significantly associated with better global cognition and episodic memory. These associations were consistent across stratifications by sex, APOE-ε4, and amyloid-β status, although some did not survive multiple testing corrections. TIMP2 protPRS correlated with measured TIMP2 levels, but actual plasma concentrations were not significantly related to cognition. This finding aligns with murine evidence of TIMP2's brain-rejuvenating role. By leveraging genetic predisposition to protein abundance and regulation, protPRSs may provide complementary insight into long-term biological processes not captured by single protein measurements. Our results support TIMP2 as a candidate for further investigation in the context of brain aging and cognitive decline., The research leading to these results has received funding from “la Caixa” Foundation, under agreement LCF/PR/SC22/68000001, the Health Department of the Catalan Government (Health Research and Innovation Strategic Plan (PERIS) 2016–2020 grant# SLT002/16/00201) and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17–519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant no. 2021 SGR 00913 and 2021 SGR 01137. FA receives funding from the JDC2022–049347-I grant, funded by the MCIU/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR. This work was supported in part by grants from the National Institutes of Health (R01AG044546 (CC), P01AG003991(CC), RF1AG053303 (CC), RF1AG058501 (CC), U01AG058922 (CC), the Chan Zuckerberg Initiative (CZI), the Alzheimer’s Association Zenith Fellows Award (ZEN-22–848604, awarded to CC), and an Anonymous foundation. The recruitment and clinical characterization of research participants at Washington University were supported by NIH P30AG066444 (JCM), P01AG03991(JCM), and P01AG026276(JCM). This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, the Neurogenomics and Informatics Center (NGI: https://neurogenomics.wustl.edu/)and the Departments of Neurology and Psychiatry at Washington University School of Medicine. MS-C receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed (ERAPERMED2021–184); Project "PI19/00155" and “PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from ”la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). NV-T was supported by the Spanish Ministry of Science and Innovation - State Research Agency (IJC2020–043216-I/MCIN/AEI/10.13039/501100011033) and the European Union «NextGenerationEU» /PRTR and currently receives funding from the Spanish Research Agency MICIU/AEI/10.13039/501100011033 (grant RYC2022–038136-I cofunded by the European Union FSE+ and grant PID2022–143106OA-I00 cofunded by the European Union FEDER). Additionally, NV-T is supported in part by the William H. Gates Sr. Fellowship from the Alzheimer’s Disease Data Initiative. All CRG authors acknowledge the support of the Spanish Ministry of Science, Innovation, and Universities to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Time-encoded ASL reveals lower cerebral blood flow in the early AD continuum

  • Falcón, Carles
  • Minguillón, Carolina
  • Fauria, Karine
  • Cascales Lahoz, Diego
  • Contador, Jose
  • Fernández-Lebrero, Aida
  • Navalpotro-Gómez, Irene
  • Puig-Pijoan, Albert
  • Grau-Rivera, Oriol
  • Suárez-Calvet, Marc
  • Gispert López, Juan Domingo
Introduction: Cerebral blood flow (CBF) is reduced in cognitively impaired (CI) Alzheimer's disease (AD) patients. We checked the sensitivity of time-encoded arterial spin labeling (te-ASL) in measuring CBF alterations in individuals with positive AD biomarkers and associations with relevant biomarkers in cognitively unimpaired (CU) individuals. Methods: We compared te-ASL with single-postlabel delay (PLD) ASL in measuring CBF in 59 adults across the AD continuum, classified as CU amyloid beta (Aβ) negative (-), CU Aβ positive (+), and CI Aβ+. We sought associations of CBF with biomarkers of AD, cerebrovascular disease, synaptic dysfunction, neurodegeneration, and cognition in CU participants. Results: te-ASL was more sensitive at detecting CBF reduction in the CU Aβ+ and CI Aβ+ groups. In CU participants, lower CBF was associated with altered biomarkers of Aβ, tau, synaptic dysfunction, and neurodegeneration. Discussion: CBF reduction occurs early in the AD continuum. te-ASL is more sensitive than single-PLD ASL at detecting CBF changes in AD. Highlights: Lower CBF can be detected in CU subjects in the early AD continuum. te-ASL is more sensitive than single-PLD ASL at detecting CBF alterations in AD. CBF is linked to biomarkers of AD, synaptic dysfunction, and neurodegeneration., We want to express our most sincere gratitude to the ALFA project participants and relatives, without whom this research would not have been possible. We thank Roche Diagnostics International Ltd for providing the NeuroToolKit kits to measure CSF biomarkers, Eli Lilly and Company for providing the measurements of the in-house assay for CSF and plasma p-tau217, and GE Healthcare for providing the doses of [18F] flutemetamol PET. Lastly, we would like to thank Valeria Di Giacomo, PhD, and Allison Clark, from ThePaperMill, for providing writing support, funded by The Fundació Pasqual Maragall. Marc Suárez-Calvet receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (Grant agreement No. 948677), the Instituto de Salud Carlos III (ISCIII) through projects PI19/00155 and PI22/00456 (cofunded by the European Union FEDER), the Department of Research and Universities of the Generalitat de Catalunya through the project 2021 SGR 01137, the HNA Foundation through the project PROAD, and the ERA PerMed ERA-NET and the Department of Health of the Generalitat de Catalunya (DS-CAT) through the project SLD077/21/000001. Moreover, Marc receives support from a fellowship provided by “la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant agreement No. 847648 (fellowship code LCF/BQ/PR21/11840004). Henrik Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (Nos. 2022-01018 and 2019-02397), the European Union's Horizon Europe research and innovation program under Grant agreement No. 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (No. 201809-2016862), the AD Strategic Fund and the Alzheimer's Association (Nos. ADSF-21-831376-C, ADSF-21-831381-C, and ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (FO2022-0270), the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant agreement No. 860197 (MIRIADE), the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). Oriol Grau-Rivera receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), the Instituto de Salud Carlos III (ISCIII) through the project PI19/00117 (cofunded by the European Unior FEDER), and the MCIN/AEI/10.13039/501100011033 through the project IJC2020-043417-I (cofunded by the European Union NextGenerationEU/PRTR).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: an international overview

  • Delaby, Constance
  • Grau, Oriol (Grau Rivera)
  • Puig-Pijoan, Albert
  • Suárez-Calvet, Marc
  • Lehmann, Sylvain
Introduction: the current practice of quantifying cerebrospinal fluid (CSF) biomarkers as an aid in the diagnosis of Alzheimer's disease (AD) varies from center to center. For a same biochemical profile, interpretation and reporting of results may differ, which can lead to misunderstandings and raises questions about the commutability of tests. Methods: We obtained a description of (pre-)analytical protocols and sample reports from 40 centers worldwide. A consensus approach allowed us to propose harmonized comments corresponding to the different CSF biomarker profiles observed in patients. Results: the (pre-)analytical procedures were similar between centers. There was considerable heterogeneity in cutoff definitions and report comments. We therefore identified and selected by consensus the most accurate and informative comments regarding the interpretation of CSF biomarkers in the context of AD diagnosis. Discussion: this is the first time that harmonized reports are proposed across worldwide specialized laboratories involved in the biochemical diagnosis of AD., This manuscript was facilitated by the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART), through the Biofluid Based Biomarkers Professional Interest Area (BBB-PIA). The views and opinions expressed in this publication represent those of the authors and do not necessarily reflect those of the BBB-PIA membership, ISTAART, or the Alzheimer's Association. The authors thank the French Society of Clinical Biology, the ISTAART BBB-PIA, and the Society for Neurochemistry and Clinical CSF analysis for their help in initiating this work. Constance Delaby received no support for the present manuscript. Charlotte Teunissen received the following grants during the last 36 months: Research of CET is supported by the European Commission (Marie Curie International Training Network, grant agreement No 860197 [MIRIADE], and JPND), Health Holland, the Dutch Research Council (ZonMw), Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands, Alzheimer Association. CT and WF are recipients of ABOARD, which is a public-private partnership receiving funding from ZonMw (#73305095007) and Health∼Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). More than 30 partners participate in ABOARD. ABOARD also receives funding from Edwin Bouw Fonds and Gieskes-Strijbisfonds. IV is appointed on a research grant by Alzheimer Nederland (NL-17004). She received no support for the present manuscript. Kaj Blennow is supported by the Swedish Alzheimer Foundation (#AF-742881) and Hjärnfonden, Sweden (#FO2017-0243). He received no support for the present manuscript. Daniel Alcolea received funding from Institute of Health Carlos III (ISCIII), Spain PI18/00435 and INT19/00016, and by the Department of Health Generalitat de Catalunya PERIS program SLT006/17/125. He received no support for the present manuscript. Ivan Arisi was partly supported by: Fondo Ordinario Enti (FOE D.M 865/2019) funds in the framework of a collaboration agreement between the Italian National Research Council and EBRI (2019-2021); POR (Operative Program Lazio Region, Italy) FESR (European Program Regional Development) 2014-2020, Public Notice “LIFE 2020” MODIAG Project. Elodie Bouaziz-Amar received no support for the present manuscript. Anne Beaume received no support for the present manuscript. Aurélie Bedel received no support for the present manuscript. Giovanni Bellomo is supported by University of Perugia, CIRMMP, IRST Istituto Romagnolo per lo Studio e la Cura dei Tumori, Innuvatech srl. He received no support for the present manuscript. Edith Bigot-Corbel received no support for the present manuscript. Maria Bjerke received no support for the present manuscript. Marie-Céline Blanc-Quintin received no support for the present manuscript. Mercè Boada received support from LA CAIXA, IMI, ISCIII H2020 the European Union/EFPIA Innovative Medicines Initiative Joint Undertaking MOPEAD project (Grants No. 115985) and is also supported by national grant, PI17/01474 from Acción Estratégica en Salud, integrated into the Spanish National Plan of R+D+I and founded by ISCIII (Instituto de Salud Carlos III)-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER- “Una manera de Hacer Europa”). She received no support for the present manuscript. Olivier Bousigues is supported by A2MCL Alsace Alzheimer. He received no support for the present manuscript. Miles D. Chapman received no support for the present manuscript. Mari L. DeMarco is supported by the Michael Smith Foundation for Health Research, Brain Canada (Canada Brain Research Fund), Health Canada, Women's Brain Health Initiative, Alzheimer Society of Canada, St. Paul's Foundation, Djavad Mowafaghian Centre for Brain Health at the University of British Columbia and the Canadian Consortium for Neurodegeneration and Aging; with all funds provided to the University of British Columbia. Mara D'Onofrio was partly supported by Fondo Ordinario Enti (FOE D.M 865/2019) funds in the framework of a collaboration agreement between the Italian National Research Council POR (Operative Program Lazio Region, Italy) FESR (European Program Regional Development) 2014-2020, Public Notice “LIFE 2020″, MODIAG Project. She received no support for the present manuscript. Julien Dumurgier received no support for the present manuscript. Diane Dufour received no support for the present manuscript. Sebastiaan Engelborghs is supported for various projects: Research Project GSKE/FMRE, Research Project FWO Vlaanderen, PhD fellowship FWO Vlaanderen (n = 3), VLAIO PhD fellowship. He received no support for the present manuscript. Hermann Esselmann received no support for the present manuscript. Anne Fogli received no support for the present manuscript. Audrey Gabelle received no support for the present manuscript. Elisabetta Galloni received no support for the present manuscript. Clémentine Gondolf received no support for the present manuscript. Frédérique Grandhomme received no support for the present manuscript. Oriol Grau-Rivera receives grants from the Spanish Ministry of Science, Innovation and Universities (FJCI-2017-33437), and from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568). He received no support for the present manuscript. Melanie Hart receives UCLH Biomedical Research Centre support from NIHR (Neurosciences). She received no support for the present manuscript. Takeshi Ikeuchi received the following grants to his institution AMED: 21dk0207049, 21dk0207045, 21ek0109545, 20ek0109350, 20ek0109392. He received no support for the present manuscript. Andreas Jeromin received no support for the present manuscript. Kensaku Kasuga received no support for the present manuscript. Ashvini Keshavan is supported by the Weston Brain Institute/Selfridges Foundation grant UB170045. She received no support for the present manuscript. Michael Khalil received unrestricted research grants from Biogen and Novartis. He received no support for the present manuscript. Peter Körtvelyessy received no support for the present manuscript. Agnieszka Kulczynska-Przybik received no support for the present manuscript. Jean-Louis Laplanche received no support for the present manuscript. Qiao-Xin Li received no support for the present manuscript. Alberto Lleó is supported by grants from Generalitat de Catalunya (PERIS SLT002/16/00408), Instituto de Salud Carlos III (PI17/01896), Instituto de Salud Carlos III CIBERNED. He received no support for the present manuscript. Catherine Malaplate received no support for the present manuscript. Marta Marquié is supported by the Instituto de Salud Carlos III (ISCIII) Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER-Una manera de hacer Europa) grant PI19/00335. She received no support for the present manuscript. Colin M. Masters received no support for the present manuscript. Barbara Mroczko received a grant from The Binding Site Group and Biokom Diagnostyka. She received no support for the present manuscript. Léonor Nogueira received no support for the present manuscript. Adelina Orellana received no support for the present manuscript. Markus Otto is supported by BMBF, Thierry Latran foundation, EU, DFG. He received no support for the present manuscript. Jean-Baptiste Oudart is supported by Astrazeneca grant for a research program on EGFR targeted therapy resistance in NSCLC. He received no support for the present manuscript. Claire Paquet received no support for the present manuscript. Federico Paolini received no support for the present manuscript. Lucilla Parnetti received no support for the present manuscript. Armand Perret-Liaudet received no support for the present manuscript. Katell Peoc'h is supported by contract with Siemens Healthineers. She received no support for the present manuscript. Koen Poesen received no support for the present manuscript. Albert Puig-Pijoan received no support for the present manuscript. Isabelle Quadrio received no support for the present manuscript. Murielle Quillard-Muraine received no support for the present manuscript. Benoît Rucheton received no support for the present manuscript. Susanne Schraen received no support for the present manuscript. Jonathan M. Schott is supported by the Medical Research Council, Alzheimer's Research UK, Weston Brain Institute, British Heart Foundation, Alzheimer's Association. He received no support for the present manuscript. Leslie M. Shaw is supported by NIA for ADNI Biomarker Core, UPENN ADRC Biomarker Corr, MJ Fox PPMI for CSF Biomarker measurements, Roche for IIS study of AD biomarkers. He received no support for the present manuscript. Marc Suárez-Calvet receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (Grant agreement No. 948677). He also receives funding from the Instituto de Salud Carlos III (PI19/00155) and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva Programme grant IJC2018-037478-I). He received no support for the present manuscript. Magda Tsolaki received no support for the present manuscript. Hayrettin Tumani is supported by Alexion, Bayer, Biogen, Celgene, Genzyme-Sanofi, Merck, Novartis, Roche, Teva. He received no support for the present manuscript. Chinedu T Udeh-Momoh is supported by Alzheimer research UK (Project Grant). He received no support for the present manuscript. Lucie Vaudran received no support for the present manuscript. Marcel M. Verbeek is supported by the BIONIC project (no. 733050822, which has been made possible by ZonMw within the framework of “Memorabel,” the research and innovation program for dementia, as part of the Dutch national “Deltaplan for Dementia”: zonmw.nl/dementiaresearch), and the CAFÉ project (the National Institutes of Health, USA, grant number 5R01NS104147-02). The BIONIC project is a consortium of Radboudumc, LUMC, ADX Neurosciences, and University of Rhode Island University. MM Verbeek is also supported by a grant from the Selfridges Group Foundation. He received no support for the present manuscript. Federico Verde received no support for the present manuscript. Lisa Vermunt is supported by Alzheimer Nederland. She received no support for the present manuscript. Jonathan Volgesgang is supported by Clinician Scientist Research Fellowship, German Research Foundation (Deutsche Forschungsgesellschaft, project number: 413501650; 09/01/2019-02/28/2021); Eric Dorris Memorial Fellowship (McLean Hospital; 07/01/2020-06/30/2021). He received no support for the present manuscript. Jens Wiltfang is supported by Federal Ministry of Education and Research (BMBF) State of Lower Saxony; He received no support for the present manuscript. Henrik Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019-0228), the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), and the UK Dementia Research Institute at UCL. He received no support for the present manuscript. Sylvain Lehmann received no support for the present manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer's disease progression

  • Pelkmans, Wiesje
  • Shekari, Mahnaz
  • Brugulat Serrat, Anna, 1986-
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Fauria, Karine
  • Molinuevo, José Luis
  • Grau, Oriol (Grau Rivera)
  • González Escalante, Armand
  • Kollmorgen, Gwendlyn
  • Carboni, Margherita
  • Ashton, Nicholas J.
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • ALFA Study
Introduction: We studied how biomarkers of reactive astrogliosis mediate the pathogenic cascade in the earliest Alzheimer's disease (AD) stages. Methods: We performed path analysis on data from 384 cognitively unimpaired individuals from the ALzheimer and FAmilies (ALFA)+ study using structural equation modeling to quantify the relationships between biomarkers of reactive astrogliosis and the AD pathological cascade. Results: Cerebrospinal fluid (CSF) amyloid beta (Aβ)42/40 was associated with Aβ aggregation on positron emission tomography (PET) and with CSF p-tau181 , which was in turn directly associated with CSF neurofilament light (NfL). Plasma glial fibrillary acidic protein (GFAP) mediated the relationship between CSF Aβ42/40 and Aβ-PET, and CSF YKL-40 partly explained the association between Aβ-PET, p-tau181 , and NfL. Discussion: Our results suggest that reactive astrogliosis, as indicated by different fluid biomarkers, influences the pathogenic cascade during the preclinical stage of AD. While plasma GFAP mediates the early association between soluble and insoluble Aβ, CSF YKL-40 mediates the latter association between Aβ and downstream Aβ-induced tau pathology and tau-induced neuronal injury. Highlights: Lower CSF Aβ42/40 was directly linked to higher plasma GFAP concentrations. Plasma GFAP partially explained the relationship between soluble Aβ and insoluble Aβ. CSF YKL-40 mediated Aβ-induced tau phosphorylation and tau-induced neuronal injury., The ALFA+ study receives funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa‑17‑519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan government under grant no. 2017-SGR-892. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (2022-01018 and 2019-02397), the European Union's Horizon Europe research and innovation program under grant agreement 101053962, Swedish State Support for Clinical Research (ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (201809-2016862), the AD Strategic Fund and the Alzheimer's Association (ADSF-21-831376-C, ADSF-21-831381-C, and ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (FO2022-0270), the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (2017‑00915); the Alzheimer Drug Discovery Foundation (ADDF), USA (RDAPB‑201809‑2016615); the Swedish Alzheimer Foundation (AF‑742881); Hjärnfonden, Sweden (FO2017‑0243); the Swedish state under the agreement between the Swedish government and the county councils, the ALF‑agreement (ALFGBG‑715986); the European Union Joint Programme for Neurodegenerative Disorders (JPND2019‑466‑236); the National Institute of Health (NIH), USA (grant 1R01AG068398‑01); and the Alzheimer's Association 2021 Zenith Award (ZEN‑21‑848495). MSC receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement 948677), the Instituto de Salud Carlos III (PI19/00155, PI22/00456), and the ERC under the EU's ‘la Caixa’ Foundation (ID 100010434) and from the EU's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant (847648, LCF/BQ/PR21/11840004). JDG is supported by the Spanish Ministry of Science and Innovation (RYC‑2013‑13054). JDG has also received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018‑102261). GS-B receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency, PID2020-119556RA-I00. OGR receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117), and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva programme IJC2020-043417-I).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Data-driven CSF biomarker profiling: imaging and clinical outcomes in a cohort at risk of Alzheimer's disease

  • Argiris, Georgette
  • Akinci, Muge
  • Peña-Gómez, Cleofé
  • Palpatzis, Eleni
  • Garcia Prat, Marina
  • Shekari, Mahnaz
  • Blennow, Kaj
  • Zetterberg, Henrik
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Ashton, Nicholas J.
  • Karikari, Thomas K.
  • Brinkmalm-Westman, Ann
  • Lantero Rodriguez, Juan
  • Fauria, Karine
  • Sánchez Benavides, Gonzalo
  • Grau, Oriol (Grau Rivera)
  • Suárez-Calvet, Marc
  • Arenaza Urquijo, Eider M.
  • ALFA Study
Background: Cerebrospinal fluid (CSF) biomarkers of synaptic dysfunction, neuroinflammation, and glial response, complementing Alzheimer's disease (AD) core biomarkers, have improved the pathophysiological characterization of the disease. Here, we tested the hypothesis that the co-expression of multiple CSF biomarkers will help the identification of AD-like phenotypes when biomarker positivity thresholds are not met yet. Methods: Two hundred and seventy cognitively unimpaired adults with family history (FH) of sporadic AD (mean age = 60.6 ± 4.85 years, 64.8% women) underwent lumbar puncture, magnetic resonance imaging (n = 266) and positron emission tomography imaging (n = 239) protocols, and clinical evaluations. CSF Aβ42, Aβ40, p-tau181, p-tau217, p-tau231, NfL, neurogranin, sTREM2, YKL40, GFAP, S100, α-Synuclein, SYT1, and SNAP25 were measured. Participants were clustered based on CSF biomarker co-expression with an agglomerative algorithm. The predictive value of the classification against brain and cognitive outcomes was evaluated. Results: Three clusters (C) were identified. Higher Aβ burden and CSF p-tau was the hallmark of C1. The other two clusters showed lower Aβ burden but higher expression of glial (C2) or synaptic markers (C3). Participants in C1 showed an AD-like clinical phenotype, comprising participants with the overall highest percentage of two parent FH and APOE-ε4 carriers, in addition to comprising more females compared to C2. C3 displayed better vascular health compared to C1. C2 were older and comprised a lower percentage of females compared to C3. C1 showed an AD-like gray matter reduction in medial temporal (notably hippocampus) and frontal regions that were not observed in Aβ42/40 + compared with Aβ42/40 - . Furthermore, Aβ42/40 - participants in C1 showed GM reduction in inferior temporal areas compared with Aβ42/40 + participants overall. C1 membership also predicted cognitive decline in executive function, but not memory, beyond Aβ + status, overall suggesting a better prognosis in Aβ42/40 + participants without C1 membership. Additionally, C1 displayed a higher rate of conversion to Aβ + (25%) over time. Conclusions: Our results suggest that examining multiple CSF biomarkers reflecting diverse pathological pathways may complement and/or outperform AD core biomarkers and thresholding approaches to identify individuals showing a clinical and cognitive AD-like phenotype, including higher conversion to Aβ + , GM reductions and cognitive decline. The clinical utility of this approach warrants further investigation and replication in other cohorts., The research leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17–519007). Support has also been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant no. 2021 SGR 00913. The research leading to these results has received funding by the Ministry of Science and Innovation (PID2019-111514RA-I00) and the Alzheimer’s Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID), to EMA-U. EMA-U is supported by the Spanish Ministry of Science and Innovation—State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF). EMA-U receives support from EU Joint Programme-Neurodegenerative Disease Research (JPND2022-138). E.P is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). GA receives support from the Alzheimer’s Association research fellowship (23AARF-1028873). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022–01018 and #2019–02397), the European Union’s Horizon Europe research and innovation program under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201,809–2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21–831,376-C, #ADSF-21–831,381-C, and #ADSF-21–831,377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Program – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677), Project "PI19/00155″, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The potential dual role of tau phosphorylation: plasma phosphorylated-tau217 in newborns and Alzheimer’s disease

  • González Ortiz, Fernando
  • Vávra, Jakub
  • Payne, Emma
  • Kirsebom, Bjørn-Eivind
  • Sjöbom, Ulrika
  • Santos, Cristiano
  • Júlvez Calvo, Jordi
  • Kramer, Kaitlin
  • Zalcberg, David
  • Montoliu-Gaya, Laia
  • Turton, Michael
  • Harrison, Peter
  • Hellström, Ann
  • Zetterberg, Henrik
  • Fladby, Tormod
  • Sanders, Robert D.
  • Blennow, Kaj
Tau phosphorylation plays an important role in brain physiology and pathology. During foetal development, it supports microtubule dynamics and neuroplasticity, whereas in Alzheimer’s disease (AD), it drives pathological tau aggregation and tangle formation. In this multicentre study (n = 462), we measured plasma phosphorylated-tau217 in healthy newborns, premature infants, patients with AD and healthy controls across various age groups. Plasma phosphorylated-tau217 levels were significantly higher in newborns compared to healthy individuals of any age group and even exceeded levels observed in patients with AD. In newborns, plasma phosphorylated-tau217 levels inversely correlated with perinatal factors such as gestational age. Longitudinal analysis of preterm infants demonstrated a decline in serum phosphorylated-tau217 levels over the first months of life, approaching levels observed in young adults. In contrast, elevated plasma phosphorylated-tau217 in older individuals was associated with AD pathology. Our findings corroborate the crucial role of tau phosphorylation in early brain development. However, in AD, tau phosphorylation transitions into a pathological mechanism. The high levels of blood-based phosphorylated-tau217 observed at birth and subsequent clearance might indicate distinct regulatory mechanisms that prevent tau aggregation in early life. Further studies are needed to explore the shared mechanisms of tau phosphorylation in newborns and AD., K.B. is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270 and #AF-994551), Hjärnfonden, Sweden (#ALZ2022-0006 and #FO2024-0048-TK-130), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-965240 and #ALFGBG-1006418), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022-2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark and Familjen Rönströms Stiftelse, Stockholm, Sweden. The project was funded by the Norwegian Research Council, JPND/PMI-AD (NRC 311993), the National Institute of Health (R01 AG083874-01). F.G.-O. was funded by the Anna Lisa and Brother Björnsson’s Foundation and Emil och Maria Palms Foundation. M.S.-C. receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement no. 948677), Project ‘PI19/00155’, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 847648 (LCF/BQ/PR21/11840004). B.-E.K. was supported by a grant from Helse-Nord (HNF1540-20). H.Z. is a Wallenberg scholar and a distinguished professor at the Swedish Research Council and receives funding from the Swedish Research Council (#2023-00356, #2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement no. 101053962 and Swedish State Support for Clinical Research (#ALFGBG-71320).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Detecting amyloid-ß pathology in subjective cognitive decline using plasma and CSF biomarkers

  • Contador, José
  • Pozzi, Federico Emanuele
  • Sánchez Benavides, Gonzalo
  • Fernández-Arcos, Ana
  • Minguillón, Carolina
  • Fauria, Karine
  • González Escalante, Armand
  • Ortiz Romero, Paula, 1994-
  • Blasco-Forniés, Helena
  • Diego-Osaba, Marina de
  • Jiménez-Moyano, Esther
  • Torres-Torronteras, Javier
  • Gispert, Juan Domingo
  • Molinuevo, José Luis
  • Campo, Marta del
  • Grau, Oriol (Grau Rivera)
  • Suárez-Calvet, Marc
  • β-AARC Study collaborators
Background: Subjective cognitive decline (SCD) may represent an early stage of Alzheimer’s disease (AD), but biomarker studies in this population are limited. Therefore, we compared the performance of a comprehensive panel of novel cerebrospinal fluid (CSF) and blood biomarkers across different platforms for detecting amyloid-β (Aβ) pathology in SCD. Methods: 143 individuals with SCD (20% Aβ-positive) from the β-AARC cohort were included. Aβ status was determined by CSF Aβ42/40. CSF and blood biomarkers of Aβ, tau, synaptic function, neurodegeneration, and glial reactivity were measured cross-sectionally. Findings: In CSF, novel tau variants (p-tau205, p-tau217, p-tau231, p-tau235, NTA-tau) were elevated in Aβ-positive individuals with SCD. In plasma, p-tau217, p-tau217/Aβ42 (across multiple platforms), as well as p-tau181, p-tau181/Aβ42 and Aβ42/40 (platform-dependent) demonstrated strong discriminatory performance and high negative predictive value, but limited positive predictive value because of the low prevalence of Aβ pathology. Interpretation: In conclusion, several plasma biomarkers can exclude Aβ pathology in SCD, while some CSF and plasma markers indicate early AD-related changes. These plasma biomarkers could serve as accessible, cost-effective tools for early AD detection and risk stratification, and expedite the selection of candidates for disease-modifying treatments or preventive strategies., The research leading to these results has received funding from the Alzheimer’s Drug Discovery Foundation (ADDF) grants #RDADB-201906-2018897 and #201809-2016862. Additionally, the study has been funded by the Health Department of the Catalan Government, the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677), and PI22/00456, funded by Instituto de Salud Carlos III (ISCIII).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A plasma biomarker panel for detecting early amyloid-β accumulation and its changes in middle-aged cognitively unimpaired individuals at risk for Alzheimer's disease

  • González Escalante, Armand
  • Milà Alomà, Marta
  • Brum, Wagner S.
  • Ashton, Nicholas J.
  • Ortiz Romero, Paula, 1994-
  • Shekari, Mahnaz
  • Campo, Marta del
  • Anastasi, Federica
  • Quijano-Rubio, Clara
  • Kollmorgen, Gwendlyn
  • Minguillón, Carolina
  • Sánchez Benavides, Gonzalo
  • Grau, Oriol (Grau Rivera)
  • Gispert, Juan Domingo
  • Zetterberg, Henrik
  • Vilor Tejedor, Natàlia, 1988-
  • Blennow, Kaj
  • Suárez-Calvet, Marc
Background: Plasma biomarkers of Alzheimer's disease (AD) change during preclinical stages, indicating potential for detecting amyloid-β (Aβ) pathology in cognitively unimpaired (CU) individuals. Given the need for accurate, scalable biomarkers, we evaluated a fully automated plasma panel to detect and monitor longitudinal Aβ accumulation in CU individuals. Methods: In this longitudinal study, we examined a plasma panel (Aβ42/40, p-tau181, GFAP, NfL, p-tau217 and ApoE4) in CU participants at risk for AD. We assessed the biomarkers' performance to detect Aβ pathology and the cross-sectional and longitudinal relationships between the biomarkers and Aβ accumulation, neurodegeneration and cognition. Findings: We included 400 middle-aged CU participants, of whom 135 (33.8%) were CSF Aβ-positive. All plasma biomarkers differed between Aβ-positive and -negative individuals, with plasma Aβ42/40, p-tau217, p-tau181/Aβ42, and p-tau217/Aβ42 showing the best performance in detecting A+ CU individuals. However, plasma Aβ42/40 was sensitive to random variability. Plasma p-tau217/Aβ42 had the highest performance in detecting PET A+ individuals (AUC = 0.94). All baseline plasma biomarkers were associated with longitudinal increases in Aβ deposition (mean follow-up [SD]: 3.27 ± 0.5). Longitudinal changes in plasma p-tau217 and p-tau217/Aβ42 were associated with concurrent changes in Aβ (both CSF and PET) and soluble tau pathology. Interpretation: In CU individuals, several plasma biomarkers at baseline detect Aβ accumulation and are associated with its short-term change. Plasma p-tau217, and p-tau217/Aβ42 longitudinal changes reflect concurrent Aβ accumulation during this period. These findings help enrich studies in CU individuals at risk of progressing to AD. Funding: ERC-2020-STG (Grant agreement No. 948677); ERA PerMed-ERA NET and the Generalitat de Catalunya (SLD077/21/000001); PI19/00155; PI22/00456, LCF/BQ/PR21/11840004., This publication is part of the ALFA study (ALzheimers and Families). The authors would like to express their most sincere gratitude to the ALFA project participants and relatives without whom this research would not have been possible. The authors thank Roche Diagnostics International Ltd for providing the kits to measure Plasma and CSF biomarkers and GE Healthcare for providing the doses of [18F]flutemetamol PET. The NeuroToolKit is a panel of exploratory prototype assays designed to robustly evaluate biomarkers associated with key pathologic events characteristic of AD and other neurological disorders, used for research purposes only and not approved for clinical use (Roche Diagnostics International Ltd, Rotkreuz, Switzerland). Elecsys Phospho-Tau (181P) CSF and Elecsys Total-Tau CSF assays are approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. We thank the collaborators of the ALFA Study: Alba Cañas, Albina Polo, Ana Fernández-Arcos, Annabella Beteta, Anna Brugulat-Serrat, Anna Soteras, Blanca Rodríguez-Fernández, Carme Deulofeu, Ferran Lugo, Irene Cumplido-Mayoral, Jordi Huguet, Laura Hernández, Maria Emilio, Patricia Genius, Paula Marne, Sandra Pradas, Sherezade Fuentes, and Wiesje Pelkmans. MMA receives funding from the Alzheimer’s Association Research Fellowship Program (AARF-23-1141384). FA receives funding from the JDC2022-049347-I grant, funded by the MCIU/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR. GSB is supported by the Agencia Estatal de Investigación AEI/10.13039/501100011033 through the project PID2020-119556RA-I00 and by Instituto de Salud Carlos III (ISCIII) through the project CP23/00039 (Miguel Servet contract), co-funded by the European Union (FSE+). OGR’s institution is supported by Roche Pharmaceuticals and Spanish Ministry of Science, Innovation and Universities (IJC2020-043417-I). HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer’s Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). NVT is supported by the Spanish Ministry of Science and Innovation - State Research Agency (grant RYC2022-038136-I, cofunded by the European Union FSE+ and grant PID2022-143106OA-I00 cofunded by the European Union FEDER). Additionally, NVT is supported by the William H. Gates Sr. Fellowship from the Alzheimer’s Disease Data Initiative. KB is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270, and #AF-994551), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022–2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, and Familjen Rönströms Stiftelse, Stockholm, Sweden. MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through the project SLD077/21/000001; Project “PI19/00155” and “PI22/00456”, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Genetically predicted telomere length and Alzheimer's disease endophenotypes: a Mendelian randomization study

  • Rodríguez-Fernández, Blanca
  • Vilor Tejedor, Natàlia, 1988-
  • Arenaza Urquijo, Eider M.
  • Sánchez Benavides, Gonzalo
  • Suárez-Calvet, Marc
  • Operto, Grégory
  • Minguillón, Carolina
  • Navarro, Arcadi
  • Gispert, Juan Domingo
  • Sala Vila, Aleix
  • ALFA Study
Telomere length (TL) is associated with biological aging, consequently influencing the risk of age-related diseases such as Alzheimer's disease (AD). We aimed to evaluate the potential causal role of TL in AD endophenotypes (i.e., cognitive performance, N = 2233; brain age and AD-related signatures, N = 1134; and cerebrospinal fluid biomarkers (CSF) of AD and neurodegeneration, N = 304) through a Mendelian randomization (MR) analysis. Our analysis was conducted in the context of the ALFA (ALzheimer and FAmilies) study, a population of cognitively healthy individuals at risk of AD. A total of 20 single nucleotide polymorphisms associated with TL were used to determine the effect of TL on AD endophenotypes. Analyses were adjusted by age, sex, and years of education. Stratified analyses by APOE-ɛ4 status and polygenic risk score of AD were conducted. MR analysis revealed significant associations between genetically predicted longer TL and lower levels of CSF Aβ and higher levels of CSF NfL only in APOE-ɛ4 non-carriers. Moreover, inheriting longer TL was associated with greater cortical thickness in age and AD-related brain signatures and lower levels of CSF p-tau among individuals at a high genetic predisposition to AD. Further observational analyses are warranted to better understand these associations., The project leading to these results has received funding from the Alzheimer’s Association (Grant AARG-19-618265). This project has received funding from Instituto de Salud Carlos III (PI19/00119). Additional support has been received from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007), the Health Department of the Catalan Government (Health Research and Innovation Strategic Plan (PERIS) 2016-2020 grant# SLT002/16/00201), and the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2017-SGR-892. All CRG authors acknowledge the support of the Spanish Ministry of Science, Innovation and Universities to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. NV-T is funded by a post-doctoral grant, Juan de la Cierva Incorporación Programme (IJC2020-043216-I), Ministry of Science and Innovation–Spanish State Research Agency. EMAU is supported by the Spanish Ministry of Science, Innovation and Universities - Spanish State Research Agency (RYC2018-026053-I). MS-C receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement no. 948677). MS-C also receives funding from the Instituto de Salud Carlos III (PI19/00155) and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva Programme grant IJC2018-037478-I). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532); the European Research Council (#681712); Swedish State Support for Clinical Research (#ALFGBG-720931); the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862); the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C); the Olav Thon Foundation; the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019-0228); the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE); and the UK Dementia Research Institute at UCL. KB is supported by the Swedish Research Council (#2017-00915); the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615); the Swedish Alzheimer Foundation (#AF-742881); Hjärnfonden, Sweden (#FO2017-0243); the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986); the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236); and the National Institute of Health (NIH), USA, (grant #1R01AG068398-01). JDG is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054). AS-V. is the recipient of an Instituto de Salud Carlos III Miguel Servet II fellowship (CP II 17/00029).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The mediating role of neuroimaging-derived biological brain age in the association between risk factors for dementia and cognitive decline in middle-aged and older individuals without cognitive impairment: a cohort study

  • Cumplido-Mayoral, Irene
  • Brugulat Serrat, Anna, 1986-
  • Sánchez Benavides, Gonzalo
  • González Escalante, Armand
  • Anastasi, Federica
  • Milà Alomà, Marta
  • López-Martos, David
  • Akinci, Muge
  • Falcón, Carles
  • Shekari, Mahnaz
  • Cacciaglia, Raffaele
  • Arenaza Urquijo, Eider M.
  • Minguillón, Carolina
  • Fauria, Karine
  • Molinuevo, José Luis
  • Suárez-Calvet, Marc
  • Grau, Oriol (Grau Rivera)
  • Vilaplana, Verónica
  • Gispert, Juan Domingo
  • ALFA Study
Background: Neuroimaging-based brain-age delta has been shown to be a mediator linking cardiovascular risk factors to cognitive function. We aimed to assess the mediating role of brain-age delta in the association between modifiable risk factors of dementia and longitudinal cognitive decline in middle-aged and older individuals who are asymptomatic, stratified by Alzheimer's disease pathology. We also explored whether the mediation effect is specific to cognitive domain. Methods: In this cohort study, we included participants from the ALFA+ cohort aged between 45 years and 65 years who were cognitively unimpaired and who had available structural MRI, cerebrospinal fluid β-amyloid (Aβ)42 and Aβ40 measurements obtained within 1 year of each other, modifiable risk factors assessment, and cognitive evaluation over 3 years. Participants were recruited from the Barcelonaβeta Brain Research Center (Barcelona, Spain). Included individuals underwent a first assessment between Oct 25, 2016, and Jan 28, 2020, and a follow-up cognitive assessment 3·28 (SD 0·27) years later. We computed brain-age delta and composites of different cognitive function domains (preclinical Alzheimer's cognitive composite [PACC], attention, executive function, episodic memory, visual processing, and language). We used partial least squares path modelling to explore mediation effects in the associations between modifiable risk factors (including cardiovascular, mental health, mood, metabolic or endocrine history, and alcohol use) and changes in cognitive composites. To assess the role of Alzheimer's disease pathology, we computed separate models for Aβ-negative and Aβ-positive individuals. Findings: Of the 419 participants enrolled in ALFA+, 302 met our inclusion criteria, of which 108 participants were classified as Aβ-positive and 194 as Aβ-negative. In Aβ-positive individuals, brain-age delta partially mediated (percent mediation proportion 15·73% [95% CI 14·22-16·66]) the association between modifiable risk factors and decline in overall cognition (across cognitive domains). Brain-age delta fully mediated (mediation proportion 28·03% [26·25-29·21]) the effect of modifiable risk factors on the PACC, wherein increased values for risk factors correlated with an older brain-age delta, and, consequently, an older brain-age delta was linked to greater PACC decline. This effect appears to be primarily driven by memory decline. Mediation was not significant in Aβ-negative individuals (3·52% [0·072-4·17]) on PACC, although path coefficients were not significantly different from those in the Aβ-positive group. Interpretation: Our findings suggest that brain-age delta captures the association between modifiable risk factors and longitudinal cognitive decline in middle-aged and older people. In asymptomatic middle-aged and older individuals who are Aβ-positive, the pathology might be the strongest driver of cognitive decline, whereas the effect of risk factors is smaller. Our results highlight the potential of brain-age delta as an objective outcome measure for preventive lifestyle interventions targeting cognitive decline. Funding: La Caixa Foundation, the TriBEKa Imaging Platform, and the Universities and Research Secretariat of the Catalan Government. Translation: For the Spanish translation of the abstract see Supplementary Materials section., This publication is part of the ALFA study. We thank the ALFA project participants and relatives, without whom this research would not have been possible. We thank Kaj Blennow and Henrik Zetterberg for performing the measurements of cerebrospinal fluid Aβ42:Aβ40 ratio. We thank Roche Diagnostics International for providing the kits to measure cerebrospinal fluid biomarkers. The Roche NeuroToolKit is a panel of exploratory prototype assays designed to evaluate biomarkers associated with key pathological events characteristic of Alzheimer's disease and other neurological disorders, used for research purposes only and not approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. The ALFA+ study receives funding from La Caixa Foundation (100010434; LCF/PR/GN17/50300004) and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa 17 519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government (2021 SGR 009132017-SGR-892). MS-C receives funding from the European Research Council under the EU Horizon 2020 research and innovation programme (948677; project PI19/00155), funded by Instituto de Salud Carlos III and co-funded by the EU, and from a fellowship from La Caixa Foundation (100010434) and from the EU Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant (847648; LCF/BQ/PR21/11840004). DL-M is supported by Instituto de Salud Carlos III (PI19/00117; co-funded by European Regional Development Fund, European Social Fund A Way to Make Europe, and Investing in your Future). EMA-U is supported by the Spanish Ministry of Science and Innovation State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund and the Spanish Ministry of Science and Innovation (PID2019-111514RA-I00). VV has been supported by the Spanish Research Agency (PID2020-116907RB-I00 of the call MCIN/AEI/10.13039/501100011033). JDG is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054). JDG has also received research support from the EU and European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative Joint Undertaking AMYPAD (115952), European Institute of Innovation and Technology Digital (2021), and from Ministerio de Ciencia y Universidades (RTI2018-102261). GS-B receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency (PID2020-119556RA-I00). OG-R receives funding from the Alzheimer's Association Research Fellowship (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117), and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva programme IJC2020-043417-I).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Proteomic polygenic risk scores of age-related plasma protein levels reveal a role for Metalloproteinase inhibitor 2 (TIMP2) in cognitive performance

  • Anastasi, Federica
  • Genius, Patricia
  • Rodríguez-Fernández, Blanca
  • Yang, Chengran
  • Gorijala, Priyanka
  • Timsina, Jigyasha
  • Hernández-Villamizar, Felipe
  • Lorenzini, Luigi
  • Campo, Marta del
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Cruchaga, Carlos
  • Suárez-Calvet, Marc
  • Vilor Tejedor, Natàlia, 1988-
Several studies in mice have identified blood proteins that influence brain aging, yet translating these findings into humans remains challenging. To address this gap, we conducted a systematic review that identified 12 proteins reported to have an aging or rejuvenating effect in murine brains. Using protein quantitative trait loci data, we computed proteomic polygenic risk scores (protPRSs) capturing the lifelong genetic predisposition to higher or lower plasma protein levels and their regulation. We first validated the prediction accuracy of these protPRSs in two independent cohorts: 10 protPRSs in the Knight-ADRC and 7 protPRSs in the ALFA+ cohort significantly predicted their corresponding protein levels, although effect sizes were modest. We then examined their association with cognitive performance in cognitively unimpaired individuals at risk of Alzheimer's disease of the ALFA+ cohort. Among the protPRSs tested, the metalloproteinase inhibitor 2 (TIMP2) protPRS was significantly associated with better global cognition and episodic memory. These associations were consistent across stratifications by sex, APOE-ε4, and amyloid-β status, although some did not survive multiple testing corrections. TIMP2 protPRS correlated with measured TIMP2 levels, but actual plasma concentrations were not significantly related to cognition. This finding aligns with murine evidence of TIMP2's brain-rejuvenating role. By leveraging genetic predisposition to protein abundance and regulation, protPRSs may provide complementary insight into long-term biological processes not captured by single protein measurements. Our results support TIMP2 as a candidate for further investigation in the context of brain aging and cognitive decline., This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, the Neurogenomics and Informatics Center (NGI: https://neurogenomics.wustl.edu/)and the Departments of Neurology and Psychiatry at Washington University School of Medicine. MS-C receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed (ERAPERMED2021-184); Project "PI19/00155" and "PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from "la Caixa" Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). NV-T was supported by the Spanish Ministry of Science and Innovation - State Research Agency (IJC2020-043216-I/MCIN/AEI/10.13039/501100011033) and the European Union «NextGenerationEU»/PRTR and currently receives funding from the Spanish Research Agency MICIU/AEI/10.13039/501100011033 (grant RYC2022-038136-I cofunded by the European Union FSE+ and grant PID2022-143106OA-I00 cofunded by the European Union FEDER). Additionally, NV-T is supported in part by the William H. Gates Sr. Fellowship from the Alzheimer's Disease Data Initiative. All CRG authors acknowledge the support of the Spanish Ministry of Science, Innovation, and Universities to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

CSF glial biomarkers are associated with cognition in individuals at risk of Alzheimer's disease

  • Warmenhoven, Noëlle
  • Sánchez Benavides, Gonzalo
  • González Escalante, Armand
  • Milà Alomà, Marta
  • Shekari, Mahnaz
  • López-Martos, David
  • Ortiz Romero, Paula, 1994-
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Minguillón, Carolina
  • Gispert, Juan Domingo
  • Vilor Tejedor, Natàlia, 1988-
  • Arenaza Urquijo, Eider M.
  • Palpatzis, Eleni
  • Ashton, Nicholas J.
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Suárez-Calvet, Marc
  • Grau, Oriol (Grau Rivera)
  • ALFA Study
Introduction: We examined whether baseline glial markers soluble triggering receptor expressed on myeloid cell 2 (sTREM2), chitinase 3-like protein 1 (YKL-40), and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF), and plasma GFAP are associated with cognitive change in cognitively unimpaired (CU) individuals at risk of Alzheimer's disease (AD). Methods: A total of 353 CU (mean age 60.9 years) participants were included (mean follow-up time 3.28 years). Linear regression models with cognition as outcome were used. We also tested whether amyloid beta (Aβ) status modified these associations. Results: Higher baseline CSF sTREM2 was associated with a positive global cognition (Preclinical Alzheimer's Cognitive Composite) rate of change, and better memory and executive outcomes, independently of AD pathology. Higher baseline plasma GFAP was associated with a decline on attention rate of change. Stratified analyses by Aβ status showed that CSF sTREM2 and YKL-40 were positively associated with executive functioning in amyloid negative (Aβ-) individuals. Discussion: Our results suggest that a TREM2-mediated microglial response may be associated with better longitudinal cognitive performance. Highlights: Higher cerebrospinal fluid (CSF) soluble triggering receptor expressed on myeloid cell 2 (sTREM2) relates to better longitudinal cognitive performance. The association between CSF sTREM2 and cognition is independent of Alzheimer's disease (AD) pathology. Targeting microglial reactivity may be a therapeutic strategy for AD prevention., This publication is part of the ALFA study (ALzheimers and Families). The authors would like to thank the collaborators of the ALFA study. Additionally, the authors would like to express their most sincere gratitude to the ALFA project participants and relatives without whom this research would not have been possible. The authors thank Roche Diagnostics International Ltd for providing the kits to measure CSF biomarkers and GE Healthcare for providing the doses of [18F]flutemetamol PET. The Roche NeuroToolKit is a panel of exploratory prototype assays designed to robustly evaluate biomarkers associated with key pathologic events characteristic of AD and other neurological disorders, used for research purposes only and not approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. The ALFA+ study receives funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa17519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. GSB is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project PID2020-119556RA-I00 and by the Instituto de Salud Carlos III (ISCIII) through the project CP23/00039 (Miguel Servet Contract), so-funded by the European Union (FSE+). DLM is supported by the Instituto de Salud Carlos III (ISCIII) through the project PI19/00117 (co-funded by European Regional Development Fund/European Social Fund “A way to make Europe”/“Investing in your future”). CM received funding within the context of EURO-FINGERS, a EU Joint Programme – Neurodegenerative Disease Research (JPND) project. The EURO-FINGERS project is supported through the following funding organizations under the aegis of JPND—www.jpnd.eu: Finland: Academy of Finland; Germany: Federal Ministry of Education and Research; Spain: National Institute of Health Carlos III; Luxembourg: National Research Fund; Hungary: National Research, Development and Innovation Office; and The Netherlands: Netherlands Organisation for Health Research and Development (ZonMW-Memorabel no. 733051102). JDG has received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), Innovative Health Initiative PROMINENT (grant agreement 101112145), EIT Digital (Grant 2021), and from the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project RTI2018102261. EAU has received funding by the Ministry of Science and Innovation (PID2019-111514RA-I00), the Alzheimer's Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID), and the European Union Joint Program for Neurodegenerative Disorders (JPND2022-138, AC22/00060). EAU is also supported by the Spanish Ministry of Science and Innovation—State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF). EP is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (#201700915); the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB2018092016615); the Swedish Alzheimer Foundation (#AF742881); Hjärnfonden, Sweden (#FO20170243); the Swedish state under the agreement between the Swedish government and the County Councils, the ALFagreement (#ALFGBG715986); the European Union Joint Program for Neurodegenerative Disorders (JPND2019466236); the National Institute of Health (NIH), USA (grant #1R01AG06839801); and the Alzheimer's Association 2021 Zenith Award (ZEN21848495). MSC receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (Grant agreement No. 948677), the Instituto de Salud Carlos III (ISCIII) through the projects PI19/00155 and PI22/00456 (Co-funded by European Regional Development Fund (FEDER) “A way to make Europe”), and receives the support of a fellowship funded by “la Caixa” Foundation (ID 100010434), and the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (fellowship code LCF/BQ/PR21/11840004). OGR receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (ISCIII) through the project PI19/00117 co-funded by the European Union (FEDER), and from Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project IJC2020-043417-I, co-funded by the European Union “Next GenerationEU”/PRTR. NVT is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project IJDC2020-043216-I, co-funded by the European Union “Next GenerationEU”/PRTR) and project PID2022-143106OA-I00, co-funded by the European Union (FEDER). In addition, NVT receives funding from the Alzheimer's Disease Data Initiative (ADDI) through the Williams H. Gates Sr. Fellowship Program and the Ajuntament de Barcelona in collaboration with “la Caixa” Foundation though the project 23S06083-001.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Subjective cognitive decline and anxious/depressive symptoms during the COVID-19 pandemic: what is the role of stress perception, stress resilience, and β-amyloid?

  • Akinci, Muge
  • Sánchez Benavides, Gonzalo
  • Brugulat Serrat, Anna, 1986-
  • Peña-Gómez, Cleofé
  • Palpatzis, Eleni
  • Shekari, Mahnaz
  • Deulofeu, Carme
  • Fuentes-Julian, Sherezade
  • Salvadó, Gemma
  • González de Echávarri, José Maria
  • Suárez-Calvet, Marc
  • Minguillón, Carolina
  • Fauria, Karine
  • Molinuevo, José Luis
  • Gispert, Juan Domingo
  • Grau, Oriol (Grau Rivera)
  • Arenaza Urquijo, Eider M.
  • ALFA Study
Background: the COVID-19 pandemic may worsen the mental health of people reporting subjective cognitive decline (SCD) and therefore their clinical prognosis. We aimed to investigate the association between the intensity of SCD and anxious/depressive symptoms during confinement and the underlying mechanisms. Methods: two hundred fifty cognitively unimpaired participants completed the Hospital Anxiety and Depression Scale (HADS) and SCD-Questionnaire (SCD-Q) and underwent amyloid-β positron emission tomography imaging with [18F] flutemetamol (N = 205) on average 2.4 (± 0.8) years before the COVID-19 confinement. During the confinement, participants completed the HADS, Perceived Stress Scale (PSS), Brief Resilience Scale (BRS), and an ad hoc questionnaire on worries (access to primary products, self-protection materials, economic situation) and lifestyle changes (sleep duration, sleep quality, eating habits). We investigated stress-related measurements, worries, and lifestyle changes in relation to SCD. We then conducted an analysis of covariance to investigate the association of SCD-Q with HADS scores during the confinement while controlling for pre-confinement anxiety/depression scores and demographics. Furthermore, we introduced amyloid-β positivity, PSS, and BRS in the models and performed mediation analyses to explore the mechanisms explaining the association between SCD and anxiety/depression. Results: in the whole sample, the average SCD-Q score was 4.1 (± 4.4); 70 (28%) participants were classified as SCD, and 26 (12.7%) were amyloid-β-positive. During the confinement, participants reporting SCD showed higher PSS (p = 0.035) but not BRS scores (p = 0.65) than those that did not report SCD. No differences in worries or lifestyle changes were observed. Higher SCD-Q scores showed an association with greater anxiety/depression scores irrespective of pre-confinement anxiety/depression levels (p = 0.002). This association was not significant after introducing amyloid-β positivity and stress-related variables in the model (p = 0.069). Amyloid-β positivity and PSS were associated with greater HADS irrespective of pre-confinement anxiety/depression scores (p = 0.023; p < 0.001). The association of SCD-Q with HADS was mediated by PSS (p = 0.01). Conclusions: higher intensity of SCD, amyloid-β positivity, and stress perception showed independent associations with anxious/depressive symptoms during the COVID-19 confinement irrespective of pre-confinement anxiety/depression levels. The association of SCD intensity with anxiety/depression was mediated by stress perception, suggesting stress regulation as a potential intervention to reduce affective symptomatology in the SCD population in the face of stressors., This research was supported by Alzheimer’s Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID) to EMAU. EMAU holds a “Ramón y Cajal” fellowship (RYC2018-026053-I). EMAU holds a grant from the Ministry of Science and Innovation (PID2019-111514RA-I00). The research leading to these results has received funding from the “la Caixa” Foundation (LCF/PR/GN17/10300004), the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project. Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant 2017-SGR-892. MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant Agreement No. 948677) and the Instituto de Salud Carlos III (PI19/00155) and a fellowship from “la Caixa” Foundation (ID 100010434) and the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 847648 (LCF/BQ/PR21/11840004).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Memory performance mediates subjective sleep quality associations with cerebrospinal fluid Alzheimer's disease biomarker levels and hippocampal volume among individuals with mild cognitive symptoms

  • Stankeviciute, Laura
  • Blackman, Jonathan
  • Tort-Colet, Núria
  • Fernández-Arcos, Ana
  • Sánchez Benavides, Gonzalo
  • Suárez-Calvet, Marc
  • Iranzo, Álex
  • Molinuevo, José Luis
  • Gispert, Juan Domingo
  • Coulthard, Elizabeth
  • Grau, Oriol (Grau Rivera)
Sleep disturbances are prevalent in Alzheimer's disease (AD), affecting individuals during its early stages. We investigated associations between subjective sleep measures and cerebrospinal fluid (CSF) biomarkers of AD in adults with mild cognitive symptoms from the European Prevention of Alzheimer's Dementia Longitudinal Cohort Study, considering the influence of memory performance. A total of 442 participants aged >50 years with a Clinical Dementia Rating (CDR) score of 0.5 completed the Pittsburgh Sleep Quality Index questionnaire and underwent neuropsychological assessment, magnetic resonance imaging acquisition, and CSF sampling. We analysed the relationship of sleep quality with CSF AD biomarkers and cognitive performance in separated multivariate linear regression models, adjusting for covariates. Poorer cross-sectional sleep quality was associated with lower CSF levels of phosphorylated tau and total tau alongside better immediate and delayed memory performance. After adjustment for delayed memory scores, associations between CSF biomarkers and sleep quality became non-significant, and further analysis revealed that memory performance mediated this relationship. In post hoc analyses, poorer subjective sleep quality was associated with lesser hippocampal atrophy, with memory performance also mediating this association. In conclusion, worse subjective sleep quality is associated with less altered AD biomarkers in adults with mild cognitive symptoms (CDR score 0.5). These results could be explained by a systematic recall bias affecting subjective sleep assessment in individuals with incipient memory impairment. Caution should therefore be exercised when interpreting subjective sleep quality measures in memory-impaired populations, emphasising the importance of complementing subjective measures with objective assessments., Data used in the preparation of this article were obtained from the Longitudinal Cohort Study (LCS), delivered by the European Prevention of Alzheimer's Disease (EPAD) Consortium. As such investigators within the EPAD-LCS and EPAD Consortium contributed to the design and implementation of EPAD and/or provided data but did not participate in the analysis or writing of this report. A complete list of EPAD Investigators can be found at: https://ep-ad.org/wp-content/uploads/2020/12/202010_List-of-epadistas.pdf. The EPAD-LCS was launched in 2015 as a public–private partnership, led by Chief Investigator Professor Craig Ritchie MB BS. This work used data and/or samples from the EPAD project which received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement number 115736 and an Alzheimer's Association Grant (SG21-818099-EPAD).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Intracellular fluid accumulation underlies brain volume increases in early Alzheimer's disease

  • Kassinopoulos, Michalis
  • Montesinos, Paula
  • Falcon, Carles
  • Huguet, Jordi
  • Minguillón, Carolina
  • Fauria, Karine
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Molinuevo, José Luis
  • Grau, Oriol (Grau Rivera)
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Suárez-Calvet, Marc
  • Sánchez González, Javier
  • Gispert, Juan Domingo
  • ALFA Study
Abstract In the preclinical stages of Alzheimer's disease, increased brain volume has been associated with amyloid-beta pathology, particularly in regions that undergo volume reductions as the disease progresses. Glial reactivity and water diffusion alterations have been linked to such macroscopic volumetric changes. Brain volume reductions have also been reported following amyloid-beta removal with anti-amyloid therapies with beneficial clinical effects, but it remains unclear whether these changes result from resolving amyloid-triggered neuroinflammation or neurodegeneration. Intravoxel incoherent motion modelling based on multi-shell diffusion-weighted imaging may provide a better understanding of the processes underlying these paradoxical changes. This study used intravoxel incoherent motion diffusion MRI to examine how alterations in cerebral water pools contribute to increased brain volume linked to amyloid-beta deposition and neuroinflammation in cognitively unimpaired individuals. We developed a three-compartment diffusion MRI model with four parameters of cerebral water diffusion: slow diffusion coefficient, fast diffusion coefficient, slow signal portion, and perfusion fraction. We computed these diffusion parameters in 297 cognitively unimpaired late middle-aged adults, 35% of whom showed evidence of amyloid deposition. We examined their correlation with demographic factors (age, sex, apolipoprotein E status), markers of Alzheimer's disease pathology, neurodegeneration, neuroinflammation, and mean diffusivity. Then, we identified regions showing grey matter volume increases related to amyloid burden and examined the association between grey matter volume and diffusion parameters within these regions. We did not find evidence of associations between diffusion parameters and amyloid-related biomarkers, whether assessed by PET or cerebrospinal fluid measures. In contrast, the four diffusion parameters showed strong and widespread associations with biomarkers of neuroinflammation and neurodegeneration, particularly in frontoparietal and cingulate regions. Additionally, in grey matter regions where volume increases were related to amyloid levels, volumes were negatively correlated with the slow diffusion coefficient (P = 0.001), perfusion fraction (P = 0.036) and mean diffusivity (P = 0.047). These findings indicate that diffusion-derived measures are more sensitive to neuroinflammatory and neurodegenerative processes than to amyloid pathology in cognitively unimpaired individuals. Furthermore, the observed negative association between grey matter volume and slow diffusion coefficient in amyloid-related regions may reflect increased cellular complexity rather than intracellular water accumulation. This interpretation suggests that glial remodelling or microstructural changes could underlie brain volume increases in amyloid-positive individuals without overt neurodegeneration. These results underscore the value of intravoxel incoherent motion-derived metrics for gaining deeper insights into the pathophysiological mechanisms of Alzheimer's disease, influencing brain volume changes as well as those resulting from the response to anti-amyloid therapies., The research leading to these results has received funding from 'la Caixa' Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Health Department of the Catalan Government (Health Research and Innovation Strategic Plan (PERIS) 2016–2020 grant# SLT002/16/00201), and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. Henrik Zetterberg is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). Oriol Grau Rivera receives funding from the Alzheimer’s Association Research Fellowship Program (2019-AARF-644568) and is supported by the Spanish Ministry of Science, Innovation and Universities (IJC2020-043417-I). Kaj Blennow is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270, and #AF-994551), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022-2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, and Familjen Rönströms Stiftelse, Stockholm, Sweden. Marc Suárez-Calvet receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (Grant agreement No. 948677) and the Instituto de Salud Carlos III through the projects PI19/00155 and PI22/00456 (Co-funded by European Regional Development Fund, FEDER, ‘A way to make Europe’). Moreover, Marc Suárez-Calvet receives the support of a fellowship from ‘la Caixa’ Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 847648 (fellowship code LCF/BQ/PR21/11840004).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The CSF p-tau/ß-amyloid 42 ratio correlates with brain structure and fibrillary ß-amyloid deposition in cognitively unimpaired individuals at the earliest stages of pre-clinical Alzheimer's disease

  • Cacciaglia, Raffaele
  • Shekari, Mahnaz
  • Salvadó, Gemma
  • Milà Alomà, Marta
  • Falcón, Carles
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Fauria, Karine
  • Grau-Rivera, Oriol
  • Molinuevo, José Luis
  • Blennow, Kaj
  • Zetterberg, Henrik
  • Quevenco, Frances-Catherine
  • Suárez-Calvet, Marc
  • Gispert López, Juan Domingo
  • ALFA Study
CSF concentrations of β-amyloid 42 (Aβ42) and phosphorylated tau (p-tau) are well-established biomarkers of Alzheimer's disease and have been studied in relation to several neuropathological features both in patients and in cognitively unimpaired individuals. The CSF p-tau/Aβ42 ratio, a biomarker combining information from both pathophysiological processes, has emerged as a promising tool for monitoring disease progression, even at pre-clinical stages. Here, we studied the association between the CSF p-tau/Aβ42 ratio with downstream markers of pre-clinical Alzheimer's disease progression including brain structure, glucose metabolism, fibrillary Aβ deposition and cognitive performance in 234 cognitively unimpaired individuals, who underwent cognitive testing, a lumbar puncture, MRI, 18F-fluorodeoxyglucose and 18F-flutemetamol PET scanning. We evaluated both main effects and interactions with Alzheimer's disease risk factors, such as older age, female sex and the apoliporoptein E (APOE)-ɛ4 allele, in a priori defined regions of interest and further examined the associations on the whole-brain using voxel-wise regressions. In addition, as the association between CSF Alzheimer's disease biomarkers and brain structure and function may be non-linear, we tested the interaction between the CSF p-tau/Aβ42 ratio and stages of pre-clinical Alzheimer's disease defined using the amyloid (A) and tau (T) classification. We found significantly positive associations between CSF p-tau/Aβ42 and both cortical Aβ deposition and regional grey matter volume while no effect was observed for brain metabolism. A significant interaction with age indicated that, for the same level of CSF p-tau/Aβ42, older individuals displayed both increased Aβ deposition and lower grey matter volume, in widespread cortical areas. In addition, we found that women compared with men had a greater Aβ fibrillary accumulation in midline cortical areas and inferior temporal regions, for the same level of the CSF biomarker. The impact of CSF p-tau/Aβ42 on grey matter volume was modulated by AT stages, with A+T+ individuals displaying significantly less positive associations in areas of early atrophy in the Alzheimer's continuum. Finally, we found that sex and APOE-ɛ4 modulated the association between the CSF biomarker and episodic memory as well as abstract reasoning, respectively. Our data indicate that the CSF p-tau/Aβ42 ratio is strongly associated with multiple downstream neuropathological events in cognitively unimpaired individuals and may thus serve as a potent biomarker to investigate the earliest changes in pre-clinical Alzheimer's disease. Given that its impact on both Aβ deposition and grey matter volume is modulated by specific risk factors, our results highlight the need to take into account such predisposing variables in both clinical practice and prevention trials., The research leading to these results has received funding from ‘la Caixa’ Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. R.C. receives funding from ‘Ministerio de Ciencia, Innovación y Universidades—Agencia Estatal de Investigación’ MCIN/AEI/10.13039/501100011033/FEDER, EU, through project PID2021-125433OA-100 and support from grant RYC2021-031128-I, funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/Plan de Recuperación, Transformación y Resiliencia (PRTR). H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Union’s Horizon Europe research and innovation programme under grant agreement no. 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 860197 (MIRIADE), the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021-00694) and the UK Dementia Research Institute at University College London (UCL) (UKDRI-1003). K.B. is supported by the Swedish Research Council (#2017-00915), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721 and #AF-968270), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the Avtal om Läkarutbildning och Forskning (ALF) agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Programme for Neurodegenerative Disorders (JPND2019-466-236), the National Institutes of Health (NIH), USA, (grant #1R01AG068398-01), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495) and the Alzheimer’s Association 2022–25 Grant (SG-23-1038904 QC). M.S.-C. receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement no. 948677), Project ‘PI19/00155’, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 847648 (LCF/BQ/PR21/11840004). O.G.-R. is supported by the ‘Ministerio de Ciencia, Innovación y Universidades' (IJC2020-043417-I) and receives funding from the Alzheimer’s Association (2019-AARF-644568) and the Instituto de Salud Carlos III (PI19/00117).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profile

  • Milà Alomà, Marta
  • Shekari, Mahnaz
  • Salvadó, Gemma
  • Gispert, Juan Domingo
  • Arenaza Urquijo, Eider M.
  • Operto, Grégory
  • Falcón, Carles
  • Vilor Tejedor, Natàlia, 1988-
  • Grau, Oriol (Grau Rivera)
  • Sala Vila, Aleix
  • Sánchez Benavides, Gonzalo
  • González de Echávarri, José Maria
  • Minguillón, Carolina
  • Suárez-Calvet, Marc
  • Molinuevo, José Luis
  • ALFA Study
Background: Understanding the changes that occur in the transitional stage between absent and overt amyloid-β (Aβ) pathology within the Alzheimer's continuum is crucial to develop therapeutic and preventive strategies. The objective of this study is to test whether cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF, structural, and functional neuroimaging biomarker profile. Methods: Cross-sectional study of 318 middle-aged, cognitively unimpaired individuals from the ALFA+ cohort. We measured CSF Aβ42/40, phosphorylated tau (p-tau), total tau (t-tau), neurofilament light (NfL), neurogranin, sTREM2, YKL40, GFAP, IL6, S100B, and α-synuclein. Participants also underwent cognitive assessments, APOE genotyping, structural MRI, [18F]-FDG, and [18F]-flutemetamol PET. To ensure the robustness of our results, we used three definitions of low burden of Aβ pathology: (1) positive CSF Aβ42/40 and < 30 Centiloids in Aβ PET, (2) positive CSF Aβ42/40 and negative Aβ PET visual read, and (3) 20-40 Centiloid range in Aβ PET. We tested CSF and neuroimaging biomarker differences between the low burden group and the corresponding Aβ-negative group, adjusted by age and sex. Results: The prevalence and demographic characteristics of the low burden group differed between the three definitions. CSF p-tau and t-tau were increased in the low burden group compared to the Aβ-negative in all definitions. CSF neurogranin was increased in the low burden group definitions 1 and 3, while CSF NfL was only increased in the low burden group definition 1. None of the defined low burden groups showed signs of atrophy or glucose hypometabolism. Instead, we found slight increases in cortical thickness and metabolism in definition 2. Conclusions: There are biologically meaningful Aβ-downstream effects in individuals with a low burden of Aβ pathology, while structural and functional changes are still subtle or absent. These findings support considering individuals with a low burden of Aβ pathology for clinical trials. Trial registration: NCT02485730., The research leading to these results has received funding from “la Caixa” Foundation (LCF/PR/GN17/10300004) and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2017-SGR-892. JDG holds a “Ramón y Cajal” fellowship (RYC-2013-13054). EMA-U is supported by the Spanish Ministry of Science, Innovation and Universities - Spanish State Research Agency (RYC2018-026053-I). NV-T is funded by a post-doctoral grant, Juan de la Cierva Programme (FJC2018-038085-I), Ministry of Science and Innovation–Spanish State Research Agency. OG-R is supported by the Spanish Ministry of Science, Innovation and Universities (FJCI-2017-33437), and receives funding from the Alzheimer’s Association Research Fellowship Program (2019-AARF-644568). ASV is the recipient of an Instituto de Salud Carlos III Miguel Servet II fellowship (CP II 17/00029). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), and the UK Dementia Research Institute at UCL. KB is supported by the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-742881), Hjärnfonden, Sweden (#FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986), and European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236). MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (Grant agreement No. 948677). MSC also receives funding from the Instituto de Salud Carlos III (PI19/00155) and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva Programme grant IJC2018-037478-I).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Decreased awareness of cognitive decline is associated with multimodal Alzheimer's disease biomarkers in cognitively unimpaired individuals

  • López-Martos, David
  • Suárez-Calvet, Marc
  • Cacciaglia, Raffaele
  • Shekari, Mahnaz
  • González Escalante, Armand
  • Brugulat Serrat, Anna, 1986-
  • Minguillón, Carolina
  • Gispert, Juan Domingo
  • Sánchez Benavides, Gonzalo
  • Grau, Oriol (Grau Rivera)
  • ALFA Study
Alzheimer's disease (AD) diagnostic guidelines emphasize subjective cognitive decline (SCD) preceding mild cognitive impairment (MCI), implicitly assuming awareness of cognitive decline (ACD) is preserved in preclinical AD. This study aimed to characterize a discrete clinical profile consistent with subtle amnestic anosognosia: decreased ACD, evaluating its association with multimodal core AD biomarkers in cognitively unimpaired (CU) individuals. We analyzed data from CU individuals with baseline CSF biomarkers and 3-year longitudinal neuropsychological assessment (ALFA+ cohort). Decreased ACD was defined by concurrent decline in episodic memory and cognitive awareness using robust longitudinal references (Free and Cued Selective Reminding Test, Memory Binding Test, Wechsler Memory Scale, and Subjective Cognitive Decline Questionnaire). Biomarker outcomes included plasma p-tau181, p-tau181/Aβ42, p-tau217; CSF p-tau181, Aβ42/40, p-tau181/Aβ42, p-tau217; Aβ ([¹⁸F]flutemetamol) and tau PET ([¹⁸F]RO948). Associations of ACD with AD biomarkers were evaluated using linear regression models. Sensitivity analysis was restricted to individuals with memory decline. 350 CU individuals were included (mean age 61 years; 60% female; mean education 14 years; 35% CSF Aβ-positive). Memory decline was identified in 61 (17%) individuals, of whom 25 (41%) exhibited concurrent awareness decline; meeting criteria for decreased ACD. This group demonstrated higher levels of AD pathology compared to the remaining sample. Among fluid biomarkers, CSF p-tau217 showed the strongest association. Neuroimaging revealed elevated frontoparietal Aβ PET, alongside temporal, insular, and frontal tau PET deposition. Sensitivity analysis confirmed that, although less pronounced, this pattern persists at the same threshold of memory decline. This study suggests that assessment of ACD may provide a crucial extension of current AD clinical frameworks., The research leading to these results has received funding from “la Caixa” Foundation under agreement LCF/PR/SC22/68000001, the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa−17–519007). RC received funding from the MCIN/AEI/10.13039/501100011033/FEDER, EU, through the project PID2021–125433OA−100 and from the grant RYC2021–031128-I, funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR; MS-C received funding from the ERC under the EU’s Horizon 2020 research and innovation program (grant no. 948677), ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through project no. SLD077/21/000001, projects PI19/00155 and PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the EU (FEDER), and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and the EU’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie (grant no. 847648 (LCF/BQ/PR21/11840004)); AB-S received funding from the Alzheimer's Association Clinician Scientist Fellowship (AACSF) Program, through the grant AACSF−23–1145154; HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023–00356, #2022–01018 and #2019–02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG−71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809–2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF−21–831376-C, #ADSF−21–831381-C, #ADSF−21–831377-C, and #ADSF−24–1284328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Familjen Beiglers Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022–0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021–00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, the UK Dementia Research Institute at UCL (UKDRI−1003), and an anonymous donor; KB is supported by the Swedish Research Council (#2017–00915 and #2022–00732), the Swedish Alzheimer Foundation (#AF−930351, #AF−939721, #AF−968270, and #AF−994551), Hjärnfonden, Sweden (#ALZ2022–0006, #FO2024–0048-TK−130 and FO2024–0048-HK−24), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG−965240 and #ALFGBG−1006418), the European Union Joint Program for Neurodegenerative Disorders (JPND2019–466–236), the Alzheimer’s Association 2021 Zenith Award (ZEN−21–848495), the Alzheimer’s Association 2022–2025 Grant (SG−23–1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, Familjen Rönströms Stiftelse, Stockholm, Sweden, and an anonymous philanthropist and donor; JDG was supported by the Spanish Ministry of Science and Innovation (RYC‑2013–13054), received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018–102261); OG-R received support from the grant IJC2020–043417-I, funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR, and receives funding from Instituto de Salud Carlos III (ISCIII) through the projects "PI19/00117" and "PI24/00116", co-funded by the European Union/FEDER, and through the project "CB16/10/00417"; GS-B receives support from the grant CP23/00039 (Miguel Servet), funded by the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union/FSE + , and receives funding from the MCIN/AEI/10.13039/501100011033 through the project PID2020–119556RA-I00 and through the project PID2024–163071OB-I00, funded by MICIU/AEI/10.13039/501100011033 and by the European Union FEDER.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

CSF synaptic biomarkers in the preclinical stage of Alzheimer disease and their association with MRI and PET: a cross-sectional study

  • Milà Alomà, Marta
  • Brinkmalm, Ann
  • Ashton, Nicholas J.
  • Kvartsberg, Hlin
  • Shekari, Mahnaz
  • Operto, Grégory
  • Salvadó, Gemma
  • Falcon, Carles
  • Gispert, Juan Domingo
  • Vilor Tejedor, Natàlia, 1988-
  • Arenaza Urquijo, Eider M.
  • Grau, Oriol (Grau Rivera)
  • Sala Vila, Aleix
  • Sánchez Benavides, Gonzalo
  • González de Echávarri, José Maria
  • Minguillón, Carolina
  • Fauria, Karine
  • Niñerola-Baizán, Aida
  • Perissinotti, Andrés
  • Kollmorgen, Gwendlyn
  • Suridjan, Ivonne
  • Zetterberg, Henrik
  • Molinuevo, José Luis
  • Blennow, Kaj
  • Suárez-Calvet, Marc
  • ALFA Study
Background and objectives: To determine whether CSF synaptic biomarkers are altered in the early preclinical stage of the Alzheimer continuum and associated with Alzheimer disease (AD) risk factors, primary pathology, and neurodegeneration markers. Methods: This cross-sectional study was performed in the Alzheimer's and Families (ALFA+) cohort, comprising middle-aged cognitively unimpaired participants. CSF neurogranin and growth-associated protein-43 (GAP-43) were measured with immunoassays, and synaptosomal-associated protein-25 (SNAP-25) and synaptotagmin-1 were measured with immunoprecipitation mass spectrometry. AD CSF biomarkers β-amyloid (Aβ)42/40, phosphorylated tau (p-tau), and total tau and the neurodegeneration biomarker neurofilament light chain (NfL) were also measured. Participants underwent structural MRI and fluorodeoxyglucose and Aβ PET imaging. General linear modeling was used to test the associations between CSF synaptic biomarkers and risk factors, Aβ pathology, tau pathology, and neurodegeneration markers. Results: All CSF synaptic biomarkers increased with age. CSF neurogranin was higher in females, while CSF SNAP-25 was higher in APOE ε4 carriers. All CSF synaptic biomarkers increased with higher Aβ load (as measured by CSF Aβ42/40 and Aβ PET Centiloid values), and it is important to note that the synaptic biomarkers were increased even in individuals in the earliest stages of Aβ deposition. Higher CSF synaptic biomarkers were also associated with higher CSF p-tau and NfL. Higher CSF neurogranin and GAP-43 were significantly associated with higher brain metabolism but lower cortical thickness in AD-related brain regions. Discussion: CSF synaptic biomarkers increase in the early preclinical stages of the Alzheimer continuum even when a low burden of Aβ pathology is present, and they differ in their association with age, sex, APOE ε4, and markers of neurodegeneration., The research leading to these results has received funding from “la Caixa” Foundation (LCF/PR/GN17/10300004) and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant 2017-SGR-892. J.D.G. holds a “Ramón y Cajal” fellowship (RYC-2013-13054). E. Arenaza-Urquijo is supported by the Spanish Ministry of Science, Innovation and Universities–Spanish State Research Agency (RYC2018-026053-I). N. Vilor-Tejedor is funded by a postdoctoral grant, Juan de la Cierva Programme (FJC2018-038085-I), Ministry of Science and Innovation– Spanish State Research Agency. Her research has received additional support of “la Caixa” Foundation (LCF/PR/GN17/10300004) and the Health Department of the Catalan Government (Health Research and Innovation Strategic Plan 2016–2020 grant SLT002/16/00201). All Centre for Genomic Regulation authors acknowledge the support of the Spanish Ministry of Science, Innovation and Universities to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. O. Grau-Rivera is supported by the Spanish Ministry of Science, Innovation and Universities (FJCI-2017-33437) and receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568). A. Sala-Vila is the recipient of an Instituto de Salud Carlos III Miguel Servet II fellowship (CP II 17/00029). H. Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (No. 2018-02532), European Research Council (No. 681712), Swedish State Support for Clinical Research (No. ALFGBG-720931), Alzheimer Drug Discovery Foundation (No. 201809-2016862), and the UK Dementia Research Institute at UCL. K. Blennow is supported by the Swedish Research Council (No. 2017-00915), Alzheimer Drug Discovery Foundation (No. RDAPB-201809-2016615), Swedish Alzheimer Foundation (No. AF-742881), Hjärnfonden, Sweden (No. FO2017-0243), the Swedish state under the agreement between the Swedish government and the county councils, the ALF agreement (No. ALFGBG-715986), European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), and NIH (No. 1R01AG068398-01). M. Suárez-Calvet receives funding from the European Research Council under the European Union's Horizon 2020 Research and Innovation Programme (grant agreement 948677). M. Suárez-Calvet also receives funding from the Instituto de Salud Carlos III (PI19/00155) and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva Programme grant IJC2018-037478-I)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

P-tau235: a novel biomarker for staging preclinical Alzheimer's disease

  • Lantero Rodriguez, Juan
  • Snellman, Anniina
  • Benedet, Andrea L.
  • Milà Alomà, Marta
  • Camporesi, Elena
  • Montoliu-Gaya, Laia
  • Ashton, Nicholas J.
  • Vrillon, Agathe
  • Karikari, Thomas K.
  • Gispert, Juan Domingo
  • Salvadó, Gemma
  • Shekari, Mahnaz
  • Toomey, Christina E.
  • Lashley, Tammaryn L.
  • Zetterberg, Henrik
  • Suárez-Calvet, Marc
  • Brinkmalm, Gunnar
  • Rosa-Neto, Pedro
  • Blennow, Kaj
Alzheimer's disease (AD) is characterised by a long preclinical phase. Although phosphorylated tau (p-tau) species such as p-tau217 and p-tau231 provide accurate detection of early pathological changes, other biomarkers capable of staging disease progression during preclinical AD are still needed. Combining exploratory and targeted mass spectrometry methods in neuropathologically confirmed brain tissue, we observed that p-tau235 is a prominent feature of AD pathology. In addition, p-tau235 seemed to be preceded by p-tau231, in what appeared to be a sequential phosphorylation event. To exploit its biomarker potential in cerebrospinal fluid (CSF), we developed and validated a new p-tau235 Simoa assay. Using three clinical cohorts, we demonstrated that (i) CSF p-235 increases early in AD continuum, and (ii) changes in CSF p-tau235 and p-tau231 levels during preclinical AD are consistent with the sequential phosphorylation evidence in AD brain. In conclusion, CSF p-tau235 appears to be not only a highly specific biomarker of AD but also a promising staging biomarker for the preclinical phase. Thus, it could prove useful tracking disease progression and help enriching clinical trial recruitment.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: the NeuroToolKit

  • Johnson, Sterling C.
  • Suárez-Calvet, Marc
  • Suridjan, Ivonne
  • Minguillón, Carolina
  • Gispert, Juan Domingo
  • Jonaitis, Erin
  • Michna, Agatha
  • Carboni, Margherita
  • Bittner, Tobias
  • Rabe, Christina
  • Kollmorgen, Gwendlyn
  • Zetterberg, Henrik
  • Blennow, Kaj
Background: Alzheimer's disease (AD) is a complex and heterogeneous disease, which requires reliable biomarkers for diagnosis and monitoring disease activity. Preanalytical protocol and technical variability associated with biomarker immunoassays makes comparability of biomarker data across multiple cohorts difficult. This study aimed to compare cerebrospinal fluid (CSF) biomarker results across independent cohorts, including participants spanning the AD continuum. Methods: Measured on the NeuroToolKit (NTK) prototype panel of immunoassays, 12 CSF biomarkers were evaluated from three cohorts (ALFA+, Wisconsin, and Abby/Blaze). A correction factor was applied to biomarkers found to be affected by preanalytical procedures (amyloid-β1-42, amyloid-β1-40, and alpha-synuclein), and results between cohorts for each disease stage were compared. The relationship between CSF biomarker concentration and cognitive scores was evaluated. Results: Biomarker distributions were comparable across cohorts following correction. Correlations of biomarker values were consistent across cohorts, regardless of disease stage. Disease stage differentiation was highest for neurofilament light (NfL), phosphorylated tau, and total tau, regardless of the cohort. Correlation between biomarker concentration and cognitive scores was comparable across cohorts, and strongest for NfL, chitinase-3-like protein-1 (YKL40), and glial fibrillary acidic protein. Discussion: The precision of the NTK enables merging of biomarker datasets, after correction for preanalytical confounders. Assessment of multiple cohorts is crucial to increase power in future studies into AD pathogenesis., The ALFA+ study receives funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). For the Wisconsin studies, CSF assay kits were provided by Roche Diagnostics GmbH. Data were collected under the following grants from the NIH National Institute of Aging: R01 AG027161, R01 AG037639, R01AG054059 UF1AG051216, P50 AG033514, and P30 AG062715. Support was also provided by the NIH National Center for Advancing Translational Sciences (NCATS), grant UL1TR000427 (Clinical and Translational Sciences). MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 Research and Innovation Programme (grant agreement No. 948677), the Instituto de Salud Carlos III (PI19/00155), and a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie (grant agreement No. 847648; LCF/BQ/PR21/11840004). JDG is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054). JDG has also received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (Grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018-102261). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532); the European Research Council (#681712); Swedish State Support for Clinical Research (#ALFGBG-720931); the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862); the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C); the Olav Thon Foundation; the Erling-Persson Family Foundation; Stiftelsen för Gamla Tjänarinnor; Hjärnfonden, Sweden (#FO2019-0228); the European Union’s Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE); and the UK Dementia Research Institute at UCL. KB is supported by the Swedish Research Council (#2017-00915); the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615); the Swedish Alzheimer Foundation (#AF-742881); Hjärnfonden, Sweden (#FO2017-0243); the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986); the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236); the National Institute of Health (NIH), USA (grant #1R01AG068398-01); and the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Longitudinal interplay between subclinical atherosclerosis, cardiovascular risk factors, and cerebral glucose metabolism in midlife: results from the PESA prospective cohort study

  • Tristão Pereira, Catarina
  • Fuster, Valentín
  • Oliva, Belén
  • Moreno Arciniegas, Andrea
  • Garcia-Lunar, Ines
  • Perez-Herreras, Cristina
  • Schöll, Michael
  • Suárez-Calvet, Marc
  • Moro, Maria Angeles
  • Garcia-Alvarez, Ana
  • Fernández Ortiz, Antonio
  • Sánchez González, Javier
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Ibáñez, Borja
  • Gispert, Juan Domingo
  • Cortes-Canteli, Marta
Background: Cardiovascular disease and dementia often coexist at advanced stages. Yet, longitudinal studies examining the interplay between atherosclerosis and its risk factors on brain health in midlife are scarce. We aimed to characterise the longitudinal associations between cerebral glucose metabolism, subclinical atherosclerosis, and cardiovascular risk factors in middle-aged asymptomatic individuals. Methods: The Progression of Early Subclinical Atherosclerosis (PESA) study is a Spanish longitudinal observational cohort study of 4184 asymptomatic individuals aged 40-54 years (NCT01410318). Participants with subclinical atherosclerosis underwent longitudinal cerebral [18F]fluorodeoxyglucose ([18F]FDG)-PET, and annual percentage change in [18F]FDG uptake was assessed (primary outcome). Cardiovascular risk was quantified with SCORE2 and subclinical atherosclerosis with three-dimensional vascular ultrasound (exposures). Multivariate regression and linear mixed effects models were used to assess associations between outcomes and exposures. Additionally, blood-based biomarkers of neuropathology were quantified and mediation analyses were performed. Secondary analyses were corrected for multiple comparisons using the false discovery rate (FDR) approach. Findings: This longitudinal study included a PESA subcohort of 370 participants (median age at baseline 49·8 years [IQR 46·1-52·2]; 309 [84%] men, 61 [16%] women; median follow-up 4·7 years [IQR 4·2-5·2]). Baseline scans took place between March 6, 2013, and Jan 21, 2015, and follow-up scans between Nov 24, 2017, and Aug 7, 2019. Persistent high risk of cardiovascular disease was associated with an accelerated decline of cortical [18F]FDG uptake compared with low risk (β=-0·008 [95% CI -0·013 to -0·002]; pFDR=0·040), with plasma neurofilament light chain, a marker of neurodegeneration, mediating this association by 20% (β=0·198 [0·008 to 0·740]; pFDR=0·050). Moreover, progression of subclinical carotid atherosclerosis was associated with an additional decline in [18F]FDG uptake in Alzheimer's disease brain regions, not explained by cardiovascular risk (β=-0·269 [95% CI -0·509 to -0·027]; p=0·029). Interpretation: Middle-aged asymptomatic individuals with persistent high risk of cardiovascular disease and subclinical carotid atherosclerosis already present brain metabolic decline, suggesting that maintenance of cardiovascular health during midlife could contribute to reductions in neurodegenerative disease burden later in life. Funding: Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III, Santander Bank, Pro-CNIC Foundation, BrightFocus Foundation, BBVA Foundation, "la Caixa" Foundation., We thank the PESA participants and the imaging, administrative, and medical PESA teams. The PESA study is equally co-funded by the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) and Santander Bank (Madrid, Spain) and also receives funding from the Instituto de Salud Carlos III (ISCIII), Madrid, Spain (PI15/02019), the European Regional Development Fund (ERDF—A Way to Build Europe), and the European Social Fund (ESF—Investing in Your Future). CNIC is a Severo Ochoa Center of Excellence (CEX2020-001041-S) and is supported by the ISCIII, the Spanish Ministry for Science and Innovation, and the Pro-CNIC Foundation. CT-P was supported by a “la Caixa” Foundation fellowship (ID 100010434, LCF/BQ/DI19/11730052). MC-C was supported by a Miguel Servet type II research contract (ISCIII, CPII21/00007) and the Fondo de Investigación Sanitaria (ISCIII, PI20/00819). We acknowledge the Sephardic Foundation on Aging and other donors of the Alzheimer's Disease Research (grant number A2022034S), a programme of the BrightFocus Foundation, for support of this research. This work was also partially produced with the support of a 2021 Leonardo Grant for Researchers and Cultural Creators from the BBVA Foundation awarded to MC-C (the Foundation takes no responsibility for the opinions, statements, and contents of this project, which are entirely the responsibility of its authors). BI was supported by the European Research Council (ERC-2018-CoG 819775-MATRIX). MS is supported by the Knut and Alice Wallenberg Foundation (Wallenberg Centre for Molecular and Translational Medicine; KAW2014.0363), the Swedish Research Council (2017-02869, 2021-02678, 2021-06545), the Swedish state under the agreement between the Swedish Government and the County Councils, the ALF-agreement (ALFGBG-813971, ALFGBG-965326), the Swedish Brain Foundation (FO2021-0311), and the Swedish Alzheimer Foundation (AF-740191). MS-C receives funding from the European Research Council (grant agreement number 948677), project “PI19/00155”, funded by ISCIII and co-funded by the EU, and a fellowship from “la Caixa” Foundation (ID 100010434) and from the EU's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement number 847648 (LCF/BQ/PR21/11840004). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018), the EU's Horizon Europe research and innovation programme under grant agreement number 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation, USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the EU's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement number 860197 (MIRIADE), the EU Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (#2017-00915, #2022-00732), the Swedish state under the agreement between the Swedish Government and the County Councils, the ALF-agreement (#ALFGBG-715986, #ALFGBG-965240), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270), Hjärnfonden, Sweden (#FO2017-0243, #ALZ2022-0006), the Alzheimer's Association 2021 Zenith Award (ZEN-21-848495), and the Alzheimer's Association 2022–2025 grant (SG-23-1038904 QC).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Diagnostic performance of plasma Aß42/40 ratio, p-tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non-AD dementias: an international multi-center study

  • Doecke, James D.
  • González Escalante, Armand
  • Contador, José
  • Suárez-Calvet, Marc
  • Fernández-Lebrero, Aida
  • Puig-Pijoan, Albert
  • Ortiz Romero, Paula, 1994-
  • Jiménez-Moyano, Esther
  • Minguillón, Carolina
  • Campo, Marta del
  • Teunissen, Charlotte E.
Introduction: Plasma phosphorylated tau (p-tau)181, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and amyloid beta ratio (Aß42/40) may have diagnostic and prognostic value in Alzheimer's disease (AD). Here we assess which markers can best identify AD from controls and other non-AD dementias in a large international multi-center study. Methods: Plasma samples (n = 1298) were collected from six international centers. Aß40, Aß42, GFAP, NfL, and p-tau181 were measured using single molecule array. In each group, AD diagnosis/co-pathology was defined according to cerebrospinal fluid biomarkers or amyloid positron emission tomography. Validations were performed in three separate cohorts via single and dual cut-off models. Results: p-tau181 showed the best area under the curve value to separate AD from frontotemporal dementia, controls, and Aß- dementia with Lewy bodies. However, this discriminative power could not be reproduced by applying pre-defined cut-offs. Discussion: p-tau181 was the best single plasma marker for detecting AD at any stage. Specific cut-offs are needed to maximize diagnostic performances. Highlights: Phosphorylated tau (p-tau)181 provided a clear differentiation between controls and Alzheimer's disease (AD) participants, with evidence of increased levels in the preclinical stage of AD. Plasma biomarkers demonstrated that when amyloid co-pathology is removed from dementia with Lewy bodies (DLB), only glial fibrillary acidic protein and neurofilament light chain remain to predict DLB. Given the low prevalence of amyloid co-pathology in frontotemporal dementia (FTD), p-tau181 and its ratio with amyloid beta 42 are strong biomarkers to differentiate FTD from AD., O.H. has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, C2N Diagnostics, Eli Lilly, Eisai, Fujirebio, GE Healthcare, and Roche. In the past 2 years, he has received consultancy/speaker fees from Alzpath, BioArctic, Biogen, Bristol Meyer Squibb, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi, and Siemens. L.G. participated on advisory boards for, and received writing honoraria and travel grants from, Almirall, Biogen, Euroimmun, Fujirebio, Lilly, Merck, Mylan, Novartis, Roche, Sanofi, Siemens Healthineers, and Teva. Work at Lund University was supported by the European Research Council (ADG-101096455), Alzheimer's Association (ZEN24-1069572, SG-23-1061717), GHR Foundation, Swedish Research Council (2022-00775), ERA PerMed (ERAPERMED2021-184), Knut and Alice Wallenberg foundation (2022-0231), Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, Swedish Alzheimer Foundation (AF-980907), Swedish Brain Foundation (FO2021-0293), Parkinson foundation of Sweden (1412/22), Cure Alzheimer's fund, Rönström Family Foundation, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Skåne University Hospital Foundation (2020-O000028), Regionalt Forskningsstöd (2022-1259), and Swedish federal government under the ALF agreement (2022-Projekt0080). The ALFA+ Study has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer's Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. M.S.-C. receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (Grant agreement No. 948677); ERA PerMed (ERAPERMED2021-184); Project “PI19/00155” and ‘‘PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). Research of C.E.T. is supported by the European Commission (Marie Curie International Training Network), grant agreement No 860197 (MIRIADE), Innovative Medicines Initiatives 3TR (Horizon 2020, grant no 831434) EPND (IMI 2 Joint Undertaking [JU], grant No. 101034344) and JPND (bPRIDE), European Partnership on Metrology, co-financed from the European Union's Horizon Europe Research and Innovation Programme and by the Participating States (22HLT07 NEuroBioStand), CANTATE project funded by the Alzheimer Drug Discovery Foundation, Alzheimer Association, Health Holland, the Dutch Research Council (ZonMW), Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands. C.T. is recipient of ABOARD, which is a public–private partnership receiving funding from ZonMW (#73305095007) and Health∼Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). C.T. is recipient of TAP-dementia, a ZonMw funded project (#10510032120003) in the context of the Dutch National Dementia Strategy.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Plasma p-tau212 identifies cognitively unimpaired individuals with emerging amyloid-ß pathology

  • Kac, Przemysław R.
  • González Escalante, Armand
  • Milà Alomà, Marta
  • Ashton, Nicholas J.
  • Shekari, Mahnaz
  • Ortiz Romero, Paula, 1994-
  • Turton, Michael
  • Harrison, Peter
  • Zetterberg, Henrik
  • Gispert, Juan Domingo
  • Karikari, Thomas K.
  • Suárez-Calvet, Marc
  • Blennow, Kaj
Plasma phosphorylated-tau (p-tau) biomarkers show high performance as first-in-line tests in the evaluation of patients with cognitive symptoms and have also found utility in clinical trials for anti-amyloid drug therapies for Alzheimer¿s disease (AD). Plasma p-tau212 is a novel blood biomarker that can discriminate cognitively unimpaired (CU) and subjective cognitive decline patients from mild cognitive impairment (MCI)-AD and AD dementia patients in clinical cohorts. Using Simoa technology, we evaluated plasma p-tau212 for its ability to detect emerging amyloid-beta (Aß) pathology in CU individuals with brain amyloidosis from CSF Aß42/40 ratio (n = 317) or Aß PET scans (n = 277). We benchmarked plasma p-tau212 against p-tau181, p-tau217, and p-tau231 by comparing their accuracies and fold changes for detecting brain amyloidosis. Our results showed that all the plasma p-tau biomarkers are increased in the CU CSF Aß + participants, with the highest median fold change observed for plasma p-tau212. Discrimination performance of the biomarkers to differentiate amyloid PET-positive from amyloid PET-negative participants differed between plasma p-tau biomarkers, being higher for plasma p-tau217 and p-tau212 compared to plasma p-tau181 and p-tau231. Furthermore, plasma p-tau212 was elevated in participants with low Aß burden (CSF Aß-positive, amyloid PET-negative), supporting its potential as a cost-effective, easily implemented biomarker for trial recruitment in early stages. Its further increase in Aß PET-positive participants suggests additional utility for monitoring anti-amyloid therapies., Open access funding provided by University of Gothenburg. Demensförbundet, Anna-Lisa och Bror Björnssons Stiftelse, Alzheimer’s Association, AARF-23-1141384,Marta Milà-Alomà, (#ADSF-21-831376-C,Henrik Zetterberg, #ADSF-21-831381-C, Henrik Zetterberg,#ADSF-21-831377-C, Henrik Zetterberg, #ADSF-24-1284328-C, Henrik Zetterberg, ZEN-21-848495, Kaj Blennow, #AARF-21-850325, Thomas K. Karikari, Vetenskapsrådet, #2023-00356, Henrik Zetterberg, #2022-01018, Henrik Zetterberg, #2019-02397, Henrik Zetterberg, #ALFGBG-71320, Henrik Zetterberg, #2017-00915,Kaj Blennow, (#ALFGBG-715986, Kaj Blennow, #ALFGBG-965240, Kaj Blennow, 2021-03244, Thomas K. Karikari, HORIZON EUROPE Reforming and enhancing the European Research and Innovation system, 101053962, Henrik Zetterberg, 948677, Marc Suárez-Calvet, Alzheimer’s Drug Discovery Foundation, 201809-2016862, Henrik Zetterberg, #RDAPB-201809-2016615, Kaj Blennow, European Partnership on Metrology, NEuroBioStand,Henrik Zetterberg, #22HLT07, Henrik Zetterberg, the Bluefield Project, Cure Alzheimer’s Fund, Olav Thon Stiftelsen, Familjen Erling-Perssons Stiftelse, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, #FO2022-0270, Henrik Zetterberg, #FO2017-0243,Kaj Blennow, #ALZ2022-0006, Kaj Blennow, HORIZON EUROPE Marie Sklodowska-Curie Actions, 860197 (MIRIADE), Henrik Zetterberg, No 847648 LCF/BQ/PR21/11840004, Marc Suárez-Calvet, EU Joint Programme – Neurodegenerative Disease Research, JPND2021-00694, Henrik Zetterberg, University College London Hospitals Biomedical Research Centre, UK Dementia Research Institute, UKDRI-1003, Henrik Zetterberg, Departament de Salut, Generalitat de Catalunya, SLD077/21/000001,Marc Suárez-Calvet, PI19/00155,Marc Suárez-Calvet, PI22/00456, Marc Suárez-Calvet,’la Caixa’ Foundation, ID 100010434, Marc Suárez-Calvet, Instituto de Salud Carlos III, Alzheimerfonden, #AF-930351, Kaj Blennow, #AF-939721,Kaj Blennow, #AF-968270, Kaj Blennow, European Union Joint Program for Neurodegenerative Disorders, JPND2019-466-236, Kaj Blennow, National Institute of Health (NIH), #1R01AG068398-01, Kaj Blennow, 1 RF1 AG052525-01A1, Thomas K. Karikari, 5 P30 AG066468-04, Thomas K. Karikari, 5 R01 AG053952-05, Thomas K. Karikari, 3 R01 MH121619-04S1, Thomas K. Karikari, 5 R37 AG023651-18, Thomas K. Karikari, 2 RF1 AG025516-12A1, Thomas K. Karikari, 5 R01 AG073267-02, Thomas K. Karikari, 2 R01 MH108509-06, Thomas K. Karikari, 5 R01 AG075336-02,Thomas K. Karikari, 5 R01 AG072641-02, Thomas K. Karikari, 2 P01 AG025204-16, Thomas K. Karikari, WaAina (Ann) llströms and Mary-Ann Sjöbloms stiftelsen, Emil och Wera Cornells Stiftelse.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts

  • Lantero Rodríguez, Juan
  • Vrillon, Agathe
  • Fernández-Lebrero, Aida
  • Ortiz Romero, Paula, 1994-
  • Snellman, Anniina
  • Montoliu-Gaya, Laia
  • Brum, Wagner S.
  • Cognat, Emmanuel
  • Dumurgier, Julien
  • Puig-Pijoan, Albert
  • Navalpotro-Gómez, Irene
  • García-Escobar, Greta
  • Karikari, Thomas K.
  • Vanmechelen, Eugeen
  • Ashton, Nicholas J.
  • Zetterberg, Henrik
  • Suárez-Calvet, Marc
  • Paquet, Claire
  • Blennow, Kaj
Background Cerebrospinal fluid (CSF) p-tau235 is a novel biomarker highly specific of Alzheimer’s disease (AD). However, CSF p-tau235 has only been studied in well-characterized research cohorts, which do not fully reflect the patient landscape found in clinical settings. Therefore, in this multicentre study, we investigated the performance of CSF p-tau235 to detect symptomatic AD in clinical settings and compared it with CSF p-tau181, p-tau217 and p-tau231. Methods CSF p-tau235 was measured using an in-house single molecule array (Simoa) assay in two independent memory clinic cohorts: Paris cohort (Lariboisière Fernand-Widal University Hospital Paris, France; n=212) and BIODEGMAR cohort (Hospital del Mar, Barcelona, Spain; n=175). Patients were classified by the syndromic diagnosis (cognitively unimpaired [CU], mild cognitive impairment [MCI] or dementia) and their biological diagnosis (amyloid-beta [Aβ]+ or Aβ ). Both cohorts included detailed cognitive assessments and CSF biomarker measurements (clinically validated core AD biomarkers [Lumipulse CSF Aβ1–42/40 ratio, p-tau181 and t-tau] and in-house developed Simoa CSF p-tau181, p-tau217 and p-tau231). Results High CSF p-tau235 levels were strongly associated with CSF amyloidosis regardless of the clinical diagnosis, being significantly increased in MCI Aβ+ and dementia Aβ+ when compared with all other Aβ− groups (Paris cohort: P ˂0.0001 for all; BIODEGMAR cohort: P ˂0.05 for all). CSF p-tau235 was pronouncedly increased in the A+T+ profile group compared with A−T− and A+T− groups (P ˂0.0001 for all). Moreover, CSF p-tau235 demonstrated high diagnostic accuracies identifying CSF amyloidosis in symptomatic cases (AUCs=0.86 to 0.96) and discriminating AT groups (AUCs=0.79 to 0.98). Overall, CSF p-tau235 showed similar performances to CSF p-tau181 and CSF p-tau231 when discriminating CSF amyloidosis in various scenarios, but lower than CSF p-tau217. Finally, CSF p-tau235 associated with global cognition and memory domain in both cohorts. Conclusions CSF p-tau235 was increased with the presence of CSF amyloidosis in two independent memory clinic cohorts. CSF p-tau235 accurately identified AD in both MCI and dementia patients. Overall, the diagnostic performance of CSF p-tau235 was comparable to that of other CSF p-tau measurements, indicating its suitability to support a biomarker-based AD diagnosis in clinical settings., Open access funding provided by University of Gothenburg. This study was funded by the Swedish Research Council (#2017-00915 and #2022-00732), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-742881), Hjärnfonden, Sweden (#FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236) and the National Institute of Health (NIH), USA, (grant #1R01AG068398-01). AV is supported by Fondation Ophtalmologique Adolphe de Rothschild and Fondation Vaincre Alzheimer. AES was supported by the Paulo Foundation, the Orion Research Foundation sr, and currently holds a postdoctoral fellowship from the Academy of Finland (#341059). TKK was funded by the Swedish Research Council (Vetenskapsrådet #2021-03244), the Alzheimer’s Association Research Fellowship (#AARF-21-850325), the Aina (Ann) Wallströms and Mary-Ann Sjöbloms stiftelsen and the Emil och Wera Cornells stiftelsen. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694) and the UK Dementia Research Institute at UCL (UKDRI-1003). MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677), Project “PI19/00155”, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Plasma and CSF biomarkers in a memory clinic: head-to-head comparison of phosphorylated tau immunoassays

  • Ashton, Nicholas J.
  • Puig-Pijoan, Albert
  • Milà Alomà, Marta
  • Fernández-Lebrero, Aida
  • Ortiz Romero, Paula, 1994-
  • Minguillón, Carolina
  • Navalpotro-Gómez, Irene
  • Grau, Oriol (Grau Rivera)
  • Manero, Rosa María
  • Puente Periz, Victor Manuel
  • Torre Fornell, Rafael de la
  • Roquer, Jaume
  • Suárez-Calvet, Marc
Introduction: Direct comparisons of the main blood phosphorylated tau immunoassays in memory clinic populations are needed to understand possible differences. Methods: In the BIODEGMAR study, 197 participants presenting with cognitive complaints were classified into an Alzheimer's disease (AD) or a non-AD cerebrospinal fluid (CSF) profile group, according to their amyloid beta 42/ phosphorylated tau (Aβ42/p-tau) ratio. We performed a head-to-head comparison of nine plasma and nine CSF tau immunoassays and determined their accuracy to discriminate abnormal CSF Aβ42/p-tau ratio. Results: All studied plasma tau biomarkers were significantly higher in the AD CSF profile group compared to the non-AD CSF profile group and significantly discriminated abnormal CSF Aβ42/p-tau ratio. For plasma p-tau biomarkers, the higher discrimination accuracy was shown by Janssen p-tau217 (r = 0.76; area under the curve [AUC] = 0.96), ADx p-tau181 (r = 0.73; AUC = 0.94), and Lilly p-tau217 (r = 0.73; AUC = 0.94). Discussion: Several plasma p-tau biomarkers can be used in a specialized memory clinic as a stand-alone biomarker to detect biologically-defined AD. Highlights: Patients with an Alzheimer's disease cerebrospinal fluid (AD CSF) profile have higher plasma phosphorylated tau (p-tau) levels than the non-AD CSF profile group. All plasma p-tau biomarkers significantly discriminate patients with an AD CSF profile from the non-AD CSF profile group. Janssen p-tau217, ADx p-tau181, and Lilly p-tau217 in plasma show the highest accuracy to detect biologically defined AD. Janssen p-tau217, ADx p-tau181, Lilly p-tau217, Lilly p-tau181, and UGot p-tau231 in plasma show performances that are comparable to their CSF counterparts., The authors would like to express their most sincere gratitude to the BIODEGMAR participants and relatives without whom this research would have not been possible. The authors thank Anna Boronat Rigol, Rachael Burchfield, and Nicholas Kyle Proctor for technical support. They also thank all the staff at University of Gothenburg, Department of Neurology at Hospital del Mar, and Barcelonaβeta Brain Research Center, who supported this project. Thomas K. Karikari was funded by the Swedish Research Council (Vetenskåpradet), the Alzheimer's Association Research Fellowship (#AARF-21-850325), the BrightFocus Foundation (#A2020812F), the International Society for Neurochemistry's Career Development Grant, the Swedish Alzheimer Foundation (Alzheimerfonden; #AF-930627), the Swedish Brain Foundation (Hjärnfonden; #FO2020-0240), the Swedish Dementia Foundation (Demensförbundet), the Swedish Parkinson Foundation (Parkinsonfonden), Gamla Tjänarinnor Foundation, the Aina (Ann) Wallströms and Mary-Ann Sjöbloms Foundation, the Agneta Prytz-Folkes & Gösta Folkes Foundation (#2020-00124), the Gun and Bertil Stohnes Foundation, and the Anna Lisa and Brother Björnsson's Foundation. Oriol Grau-Rivera is supported by the Spanish Ministry of Science, Innovation and Universities (IJC2020-043417-I), and receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568) and the Instituto de Salud Carlos III (PI19/00117). Irene Navalpotro-Gómez receives funding from the Spanish Instituto de Salud Carlos III (ISCIII-FEDER, PI21/00194). Jaume Roquer receives funding from the Spanish Instituto de Salud Carlos III (ISCIII-FEDER, PI21/00194). Jeff L. Dage is supported by the National Institutes of Health (U24AG021886, P30AG072976, and U01AG057195), Roche Diagnostics (RD005665), as well as the Stark Neurosciences Research Institute at Indiana University School of Medicine. Henrik Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer's Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019-0228), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), European Union Joint Program for Neurodegenerative Disorders (JPND2021-00694), and the UK Dementia Research Institute at UCL. Kaj Blennow is supported by the Swedish Research Council (#2017-00915), ADDF, USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-742881), Hjärnfonden, Sweden (#FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), and the NIH, USA (grant #1R01AG068398-01). Marc Suárez-Calvet receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Grant agreement No. 948677), Project “PI19/00155”, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease

  • Milà Alomà, Marta
  • Shekari, Mahnaz
  • Salvadó, Gemma
  • Ortiz Romero, Paula, 1994-
  • González Escalante, Armand
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Gispert, Juan Domingo
  • Suárez-Calvet, Marc
  • Blennow, Kaj
Blood biomarkers indicating elevated amyloid-β (Aβ) pathology in preclinical Alzheimer's disease are needed to facilitate the initial screening process of participants in disease-modifying trials. Previous biofluid data suggest that phosphorylated tau231 (p-tau231) could indicate incipient Aβ pathology, but a comprehensive comparison with other putative blood biomarkers is lacking. In the ALFA+ cohort, all tested plasma biomarkers (p-tau181, p-tau217, p-tau231, GFAP, NfL and Aβ42/40) were significantly changed in preclinical Alzheimer's disease. However, plasma p-tau231 reached abnormal levels with the lowest Aβ burden. Plasma p-tau231 and p-tau217 had the strongest association with Aβ positron emission tomography (PET) retention in early accumulating regions and associated with longitudinal increases in Aβ PET uptake in individuals without overt Aβ pathology at baseline. In summary, plasma p-tau231 and p-tau217 better capture the earliest cerebral Aβ changes, before overt Aβ plaque pathology is present, and are promising blood biomarkers to enrich a preclinical population for Alzheimer's disease clinical trials., The research leading to these results received funding from ‘la Caixa’ Foundation (ID 100010434), under agreement LCF/PR/GN17/10300004 and the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). E.V. was supported by Flanders Innovation and Entrepreneurship (VLAIO grant no. 140105). C.M. received funding within the context of EURO-FINGERS, a EU Joint Programme–Neurodegenerative Disease Research (JPND) project. The EURO-FINGERS project is supported through the following funding organizations under the aegis of JPND—www.jpnd.eu: Finland: Academy of Finland; Germany: Federal Ministry of Education and Research; Spain: National Institute of Health Carlos III; Luxembourg: National Research Fund; Hungary: National Research, Development and Innovation Office; and The Netherlands: Netherlands Organisation for Health Research and Development (ZonMW-Memorabel no. 733051102). H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (grant no. 2018-02532), the European Research Council (ERC, grant no. 681712), Swedish State Support for Clinical Research (grant no. ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (grant no. 201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (grant nos. ADSF-21-831376-C, ADSF-21-831381-C and ADSF-21-831377-C), the Olav Thon Foundation, the Erling–Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (grant no. FO2019-0228), the EU’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement no. 860197 (MIRIADE) and the UK Dementia Research Institute at University College London (UCL). J.D.G. is supported by the Spanish Ministry of Economy and Competitiveness (RYC-2013-13054) and received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant no. 115952) and from Ministerio de Ciencia, Innovación y Universidades (grant no. RTI2018-102261). M.S.C. receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 948677), the Instituto de Salud Carlos III (PI19/00155), and from the ERC under the EU’s ‘la Caixa’ Foundation (ID 100010434) and from the EU’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant (no. 847648, LCF/BQ/PR21/11840004). K.B. is supported by the Swedish Research Council (grant no. 2017-00915), the ADDF, USA (grant no. RDAPB-201809-2016615), the Swedish Alzheimer Foundation (grant no. AF-742881) (grant nos. AF-930351, AF-939721 and AF-968270), Hjärnfonden, Sweden (grant nos. FO2017-0243 and ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF agreement (grant nos. ALFGBG-715986 and ALFGBG-965240), the EU Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the National Institutes of Health (grant no. 1R01AG068398-01) and the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Impact of gender on the willingness to participate in clinical trials and undergo related procedures in individuals from an Alzheimer's prevention research cohort

  • Canals-Gispert, Lidia
  • Cañas-Martínez, Alba
  • Huesa, Gema
  • Suárez-Calvet, Marc
  • Milà Alomà, Marta
  • Arenaza Urquijo, Eider M.
  • Cirillo, Davide
  • Schumacher Dimech, Annemarie
  • Iulita, Maria Florencia
  • Novakova Martinkova, Julie
  • Tartaglia, Maria Carmela
  • Quevenco, Frances-Catherine
  • Santuccione Chadha, Antonella
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Ferretti, Maria Teresa
  • Fauria, Karine
  • Brugulat Serrat, Anna, 1986-
  • ALFA Study
Background: Although there is growing evidence of the association between gender and early diagnosis of preclinical Alzheimer's disease, little attention has been given to the enrolment ratio of men and women in clinical trials and data reporting. Methods: This study aims to analyze gender differences in sociodemographic factors associated with the willingness to participate in clinical trials and undergo specific procedures in the context of an Alzheimer's disease prevention research cohort. 2544 cognitively unimpaired participants from the ALFA parent cohort (age 45-75 years) of the Barcelonaβeta Brain Research Center were contacted through a structured phone call to determine their willingness to participate in Alzheimer's disease clinical trials and undergo trial-related procedures (magnetic resonance imaging, lumbar puncture, positron emission tomography, and cognitive assessment). Sociodemographic data on education, occupational attainment, civil and caregiver status were gathered. Stepwise logistic regression models were performed in order to study the interaction between gender and sociodemographic factors in the willingness to participate in clinical trials and to undergo clinical trial-related procedures. Results: 1,606 out of the 2,544 participants were women (63.1%). Women were significantly younger and had lower educational attainment compared with men. In addition, women were more likely to be caregivers, single and unemployed. Women showed a significantly lower willingness than men to participate in a clinical trial (p = 0.003) and to undergo a lumbar puncture (p < 0.001). Single women were less willing to participate in clinical trials than single men (p = 0.041). Regarding clinical trial-related procedures, women with higher years of education were significantly less willing to undergo a lumbar puncture (p = 0.031). Conclusion: We found gender differences regarding the sociodemographic factors that predict the willingness to participate in clinical trials and to undergo clinical trial-related procedures. Our results highlight the urgent need to design recruitment strategies accounting for gender-related factors, particularly those related to marital status and education., The project leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/10300004. JNM is supported by project nr. LX22NPO5107 (MEYS): Financed by EU – Next Generation EU. MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (Grant agreement No. 948677), the Instituto de Salud Carlos III through the projects PI19/00155 and PI22/00456 (Co-funded by European Regional Development Fund (FEDER) "A way to make Europe"), and receives the support of a fellowship from”la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (fellowship code LCF/BQ/PR21/11840004). EMAU receives funding from the Alzheimer’s Association (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID), and from the Ministry of Science and Innovation (MCIN)/Spanish Research Agency (AEI) MCIN/AEI/https://doi.org/10.13039/501100011033 (PID2019-111514RA-I00 and RYC2018-026053-I, co-funded by the European Social Fund (FSE)). GSB receives funding from the Ministry of Science and Innovation/Spanish Research Agency (PID2020-119556RA-I00 funded by MCIN/AEI/https://doi.org/10.13039/501100011033/FEDER, UE). ABS receives funding from the Global Brain Health Institute (GBHI), Alzheimer's Association, Alzheimer's Society (GBHI ALZ UK-21–737797).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Physical activity changes during midlife link to brain integrity and amyloid burden

  • Akinci, Muge
  • Aguilar Dominguez, Pablo
  • Palpatzis, Eleni
  • Shekari, Mahnaz
  • Garcia Prat, Marina
  • Deulofeu, Carme
  • Fauria, Karine
  • García Aymerich, Judith
  • Gispert López, Juan Domingo
  • Suárez-Calvet, Marc
  • Grau-Rivera, Oriol
  • Sánchez Benavides, Gonzalo
  • Arenaza Urquijo, Eider M.
  • ALFA Study
Introduction: Evidence suggests that midlife physical activity may reduce Alzheimer's disease (AD) risk. In at-risk individuals, we investigated midlife physical activity changes in relation to AD-related pathologies. Methods: We included 337 cognitively unimpaired adults with baseline and follow-up physical activity evaluations within 4.07 ± 0.84 years. We performed multiple regressions considering follow-up amyloid-PET burden and MRI-based medial temporal lobe cortical thickness as outcomes. Independent variables encompassed changes in adherence to World Health Organization (WHO)-recommended physical activity levels, activity amounts, and sedentary behavior (no activity reported). Results: Remaining sedentary was associated with lower cortical thickness compared to doing limited physical activity, maintaining adherence, or becoming adherent to WHO recommendations. Becoming adherent to recommendations was linked to lower amyloid burden compared to becoming non-adherent. Increased activity amounts showed a dose-dependent association with lower amyloid burden. Discussion: Increasing physical activity and new adherence to WHO recommendations could be key objectives for preventive strategies during midlife. Clinical trial registration information: Registered at Clinicaltrials.gov (identifier: NCT02485730). Highlights: Boosting physical activity in midlife may have beneficial effects in preclinical AD. Physical activity increases relate to lower Aβ burden in a dose-dependent manner. Remaining sedentary links to lower cortical thickness in AD-vulnerable structures. New adherence to WHO-recommended physical activity levels may enhance brain health., This work was supported by ‘la Caixa’ Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer's Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Support has also been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant no. 2021 SGR 00913. EMA-U has received funding by the Ministry of Science and Innovation (PID2019-111514RA-I00) and the Alzheimer's Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID). EMA-U is supported by the Spanish Ministry of Science and Innovation—State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF) and EU Joint Programme-Neurodegenerative Disease Research (JPND2022-138). EP is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). MSC receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Grant agreement No. 948677), Project “PI19/00155”, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). We acknowledge support from the grant CEX2018-000806-S funded by MCIN/AEI/10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Program.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Multimodal biomarker characterization of amnestic objective subtle cognitive decline in aging and preclinical Alzheimer's disease

  • López-Martos, David
  • Cacciaglia, Raffaele
  • Suárez-Calvet, Marc
  • Salvadó, Gemma
  • Shekari, Mahnaz
  • González Escalante, Armand
  • Milà Alomà, Marta
  • Brugulat Serrat, Anna, 1986-
  • Minguillón, Carolina
  • Tonietto, Matteo
  • Borroni, Edilio
  • Klein, Gregory
  • Quijano-Rubio, Clara
  • Kollmorgen, Gwendlyn
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Gispert, Juan Domingo
  • Grau, Oriol (Grau Rivera)
  • Sánchez Benavides, Gonzalo
  • ALFA Study
Background The objective of this study was to provide a multimodal biomarker characterization of amnestic objective subtle cognitive decline (obj-SCD) in aging and preclinical Alzheimer's disease (AD). Methods Prospective observational study; data from the Alzheimer's and Families+ (ALFAs+) cohort, including cognitively unimpaired (CU) individuals with available baseline CSF biomarkers (normal or AD continuum profiles) and longitudinal neuropsychological assessment (2 time points, 3-year follow-up). Amnestic obj-SCD was defined using robust longitudinal neuropsychological references with multivariate base rate thresholds of significant decline (Free and Cued Selective Reminding Test, Memory Binding Test, Wechsler Memory Scale IV: Logical Memory). Study outcomes included plasma p-tau217, NfL, and GFAP; CSF p-tau181/Aß42, NfL, and GFAP; Aß and tau PET; and MRI Grey Matter volume (GMv). The associations of amnestic obj-SCD with fluid (plasma and CSF) and neuroimaging biomarkers (PET and GMv) were evaluated using mixed-effects and voxel-wise linear regression models, respectively. Results 350 CU individuals were included (mean age 61 years; 60% female; mean education 14 years; 35% CSF Aß-positive). Amnestic obj-SCD was identified in 10% of the sample, associated with greater AD pathology (higher plasma p-tau217, CSF p-tau181/Aß42, global Aß PET, medial temporal tau PET), neurodegeneration (higher plasma and CSF NfL, reduced GMv in cingulate cortex, longitudinal GMv reductions in hippocampus) and inflammation (higher plasma and CSF GFAP, longitudinal GMv increases in neocortical brain regions). Discussion These findings highlight the need for standardized clinical staging criteria to enhance early detection and risk stratification in aging and preclinical AD., The research leading to these results has received funding from “la Caixa” Foundation under agreement LCF/PR/SC22/68000001, the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). R.C. received funding from the MCIN/AEI/10.13039/501100011033/FEDER, EU,through the project PID2021-125433OA-100 and from the grant RYC2021-031128-I, funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR; M.S.-C. received funding from the ERC under the EU’s Horizon 2020 research and innovation program (grant no. 948677), ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through project no. SLD077/21/000001, projects PI19/00155 and PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the EU (FEDER), and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and the EU’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie (grant no. 847648 (LCF/BQ/PR21/11840004)); A.B.-S. received funding from the Alzheimer's Association Clinician Scientist Fellowship (AACSF) Program, through the grant AACSF-23-1145154; H.Z. is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356, #2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Familjen Beiglers Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, the UK Dementia Research Institute at UCL (UKDRI-1003), and an anonymous donor; K.B. is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270, and #AF-994551), Hjärnfonden, Sweden (#ALZ2022-0006, #FO2024-0048-TK-130 and FO2024-0048-HK-24), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-965240 and #ALFGBG-1006418), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022-2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, Familjen Rönströms Stiftelse, Stockholm, Sweden, and an anonymous filantropist and donor; J.D.G. was supported by the Spanish Ministry of Science and Innovation (RYC‑2013‑13054), received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018‑102261); O.G.-R. was supported by the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva program IJC2020-043417-I), funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR, Instituto de Salud Carlos III (ISCIII) through the projects "PI19/00117" and "PI24/00116" and co-funded by the European Union/FEDER. OG-R also receives funding from F. Hoffmann-La Roche Ltd, and has given lectures in symposia sponsored by Roche Diagnostics, S.L.U; G.S.-B. was supported by the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union/FSE+, supported by MCIN/AEI/10.13039/501100011033, through the project PID2020-119556RA-I00 and grant CP23/00039.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Effect of parity and ß-amyloid on cognition and hippocampal volume in postmenopausal women

  • Gallay, Clara
  • Soldevila-Domenech, Natalia
  • López-Martos, David
  • Sánchez Benavides, Gonzalo
  • Huguet, Jordi
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • Salvadó, Gemma
  • Sundermann, Erin E.
  • Grau, Oriol (Grau Rivera)
  • Brugulat Serrat, Anna, 1986-
  • ALFA Study
Background and objectives: Epidemiologic studies exploring the effect of parity on Alzheimer disease (AD) yield mixed results, and little is known about how parity may modify the impact of AD pathology on brain and cognitive aging. We examined the effect of parity and AD pathology on hippocampal volume (HV) and cognitive changes in cognitively unimpaired (CU) postmenopausal women. Methods: Analysis was performed on CU postmenopausal women from the ALFA+ observational cohort based in the BarcelonaBeta Brain research center, who completed 1 or 2 visits spaced by ∼3 years (mean = 3.38, SD = 0.55) with reproductive data, cognitive testing (modified Preclinical Alzheimer's Cognitive Composite), CSF biomarkers (Aβ42 and Aβ40), and structural MRI. We used linear mixed-effects models to investigate the interactive effects of parity, time, and Aβ status (based on CSF Aβ42/Aβ40) on cognition and HV. APOE-ε4 status, age, and total intracranial volume were included as covariates. Results: A total of 254 women were included in our analyses ranging from 49.2 to 73.4 years (mean age = 61.2) at visit 1. A significant interaction between parity and Aβ status was observed for cognitive decline and HV. In women with positive amyloid status, higher parity was associated with steeper cognitive decline (β = -0.035, 95% CI -0.068 to -0.003, p = 0.033) and lower HV across time points (β = -0.134, 95% CI -0.263 to -0.005, p = 0.036). Discussion: In CU postmenopausal women, higher parity interacts with AD pathology to influence cognitive decline and HV reductions. These findings suggest that parity may affect resilience to AD pathology in preclinical AD stages., The research leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer's Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant 2021 SGR 00913. C. Gallay is supported by the Alzheimer Association Clinician Scientist Fellowship grant (AACSF-23-1145154). G. Sanchez-Benavides receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency, PID2020-119556RA-I00. M. Suárez-Calvet receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 Research and Innovation Programme (grant agreement 948677), Project “PI19/00155,” funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, from a fellowship from “la Caixa” Foundation (ID 100010434), and from the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant agreement 847648. J. Domingo-Jispert has received research support from the EU/EFPIA Innovative Medicines Initiative JointUndertaking AMYPAD (grant agreement 115952), EIT Digital (Grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018-102261). G. Salvado received funding from the European Union's Horizon 2020 Research and Innovation Program under 503 Marie Sklodowska-Curie action grant agreement number 101061836, an Alzheimer's Association Research 504 Fellowship (AARF-22-972612), the Brightfocus Foundation (A2024007F), the Alzheimerfonden (AF-980942, 505 AF-994514, AF-1012218), Greta och Johan Kocks research grants and travel grants from the Strategic Research 506 Area MultiPark (Multidisciplinary Research in Parkinson's Disease) at Lund University. E. Sundermann receives funding from the NIH (5R01AG074221). O. Grau-Rivera receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117) and from the Spanish Ministry of Science Innovation and Universities (Juan de la Cierva programme IJC2020-043417-I). A. Brugulat-Serrat receives funding from the Alzheimer Association Clinician Scientist Fellowship (AACSF-23-1145154).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

APOE-ε4 modulates the association between regional amyloid deposition and cognitive performance in cognitively unimpaired middle-aged individuals

  • Brugulat Serrat, Anna, 1986-
  • Sánchez Benavides, Gonzalo
  • Cacciaglia, Raffaele
  • Shekari, Mahnaz
  • Milà Alomà, Marta
  • Vilor Tejedor, Natàlia, 1988-
  • Operto, Grégory
  • Falcón, Carles
  • Grau, Oriol (Grau Rivera)
  • Arenaza Urquijo, Eider M.
  • Minguillón, Carolina
  • Fauria, Karine
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • ALFA Study
Purpose: To determine whether the APOE-ε4 allele modulates the relationship between regional β-amyloid (Aβ) accumulation and cognitive change in middle-aged cognitively unimpaired (CU) participants. Methods: The 352 CU participants (mean aged 61.1 [4.7] years) included completed two cognitive assessments (average interval 3.34 years), underwent [18F]flutemetamol Aβ positron emission tomography (PET), T1w magnetic resonance imaging (MRI), as well as APOE genotyping. Global and regional Aβ PET positivity was assessed across five regions-of-interest by visual reading (VR) and regional Centiloids. Linear regression models were developed to examine the interaction between regional and global Aβ PET positivity and APOE-ε4 status on longitudinal cognitive change assessed with the Preclinical Alzheimer's Cognitive Composite (PACC), episodic memory, and executive function, after controlling for age, sex, education, cognitive baseline scores, and hippocampal volume. Results: In total, 57 participants (16.2%) were VR+ of whom 41 (71.9%) were APOE-ε4 carriers. No significant APOE-ε4*global Aβ PET interactions were associated with cognitive change for any cognitive test. However, APOE-ε4 carriers who were VR+ in temporal areas (n = 19 [9.81%], p = 0.04) and in the striatum (n = 8 [4.14%], p = 0.01) exhibited a higher decline in the PACC. The temporal areas findings were replicated when regional PET positivity was determined with Centiloid values. Regionally, VR+ in the striatum was associated with higher memory decline. As for executive function, interactions between APOE-ε4 and regional VR+ were found in temporal and parietal regions, and in the striatum. Conclusion: CU APOE-ε4 carriers with a positive Aβ PET VR in regions known to accumulate amyloid at later stages of the Alzheimer's disease (AD) continuum exhibited a steeper cognitive decline. This work supports the contention that regional VR of Aβ PET might convey prognostic information about future cognitive decline in individuals at higher risk of developing AD. Clinicaltrials: gov Identifier: NCT02485730. Registered 20 June 2015 https://clinicaltrials.gov/ct2/show/NCT02485730 and ClinicalTrials.gov Identifier:NCT02685969. Registered 19 February 2016 https://clinicaltrials.gov/ct2/show/NCT02685969 ., The research leading to these results has received funding from “la Caixa” Foundation (LCF/PR/GN17/10300004) and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant 2021 SGR 00913. NV-T is funded by a postdoctoral grant, Juan de la Cierva Programme (FJC2018-038085-I), Ministry of Science and Innovation-Spanish State Research Agency. Her research has received additional support of “la Caixa” Foundation (LCF/PR/GN17/10300004) and the Health Department of the Catalan Government (Health Research and Innovation Strategic Plan 2016–2020 Grant SLT002/16/00201). OG-R is supported by the Spanish Ministry of Science, Innovation and Universities (IJC2020-043417-I) and receives funding from the Alzheimer’s Association Research Fellowship Program (2019-AARF-644568). EA-U is supported by Alzheimer’s Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID), a “Ramón y Cajal” fellowship (RYC2018-026053-I) and by a grant of the Ministry of Science and Innovation (PID2019-111514RA-I00). MS-C receives funding from the European Research Council under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677), the Instituto de Salud Carlos III (PI19/00155), and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). JD-G holds a “Ramón y Cajal” fellowship (RYC-2013-13054).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A blood-based multi-pathway biomarker assay for early detection and staging of Alzheimer's disease across ethnic groups

  • Jiang, Yuanbing
  • Ortiz Romero, Paula, 1994-
  • Puig-Pijoan, Albert
  • Fernández-Lebrero, Aida
  • Contador, José
  • Suárez-Calvet, Marc
  • Ip, Nancy Y.
Introduction: Existing blood-based biomarkers for Alzheimer's disease (AD) mainly focus on its pathological features. However, studies on blood-based biomarkers associated with other biological processes for a comprehensive evaluation of AD status are limited. Methods: We developed a blood-based, multiplex biomarker assay for AD that measures the levels of 21 proteins involved in multiple biological pathways. We evaluated the assay's performance for classifying AD and indicating AD-related endophenotypes in three independent cohorts from Chinese or European-descent populations. Results: The 21-protein assay accurately classified AD (area under the receiver operating characteristic curve [AUC] = 0.9407 to 0.9867) and mild cognitive impairment (MCI; AUC = 0.8434 to 0.8945) while also indicating brain amyloid pathology. Moreover, the assay simultaneously evaluated the changes of five biological processes in individuals and revealed the ethnic-specific dysregulations of biological processes upon AD progression. Discussion: This study demonstrated the utility of a blood-based, multi-pathway biomarker assay for early screening and staging of AD, providing insights for patient stratification and precision medicine. Highlights: The authors developed a blood-based biomarker assay for Alzheimer's disease. The 21-protein assay classifies AD/MCI and indicates brain amyloid pathology. The 21-protein assay can simultaneously assess activities of five biological processes. Ethnic-specific dysregulations of biological processes in AD were revealed., This study was supported in part by the National Key R&D Program of China (2021YFE0203000); the Areas of Excellence Scheme of the University Grants Committee (AoE/M-604/16); the Research Grants Council of Hong Kong (the Collaborative Research Fund [C6027-19GF] and the Theme-Based Research Scheme [T13-605/18 W]); the Innovation and Technology Commission (InnoHK; ITCPD/17-9, INNOHK18SC01, ITS/207/18FP, MRP/042/18X, and MRP/097/20X); Chow Tai Fook Charity Foundation (CTFCF18SC01); the Guangdong Provincial Key S&T Program Grant (2018B030336001); the Guangdong Provincial Fund for Basic and Applied Basic Research (2019B1515130004); and the Fundamental Research Program of Shenzhen Virtual University Park (2021Szvup137). Yuanbing Jiang is a recipient of the Hong Kong Postdoctoral Fellowship Award from the Research Grants Council of the Hong Kong Special Administrative Region, China (Project No. HKUST PDFS2324-6S04). Marc Suárez-Calvet received funding from the European Research Council (ERC) under the European Union's Horizon 2020 Research and Innovation Programme (Grant Agreement No. 948677); Project “PI19/00155,” co-funded by Instituto de Salud Carlos III (ISCIII) and the European Union; and a fellowship from “La Caixa” Foundation (ID 100010434); and a fellowship from the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie Grant Agreement (No. 847648; LCF/BQ/PR21/11840004). Henrik Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018 and #2019-02397), the European Union's Horizon Europe Research and Innovation Programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Sex/gender effects of glial reactivity on preclinical Alzheimer's disease pathology

  • Vila-Castelar, Clara
  • Akinci, Muge
  • Palpatzis, Eleni
  • Aguilar Dominguez, Pablo
  • Operto, Grégory
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Blennow, Kaj
  • Zetterberg, Henrik
  • Falcón, Carles
  • Fauria, Karine
  • Gispert, Juan Domingo
  • Grau, Oriol (Grau Rivera)
  • Suárez-Calvet, Marc
  • Arenaza Urquijo, Eider M.
  • ALFA Study
Glial reactivity may contribute to sex/gender differences in Alzheimer's disease (AD) pathophysiology. Here, we investigated the differential effect of cerebrospinal fluid (CSF) glial markers on AD pathology and neurodegeneration by sex/gender among cognitively unimpaired older adults at increased risk of developing AD. We included 397 participants from the ALFA+ cohort with CSF Aβ42/40, p-tau181, sTREM2, YKL40, and GFAP, magnetic resonance imaging-based hippocampal volume (n = 299), and amyloid burden (centiloids) measured with [18F] flutemetamol positron emission tomography (n = 341). We ran multiple linear regression models to assess the association between glial markers, AD pathology and hippocampal volumes and their interaction with sex/gender, using False Discovery Rate to correct for multiple comparisons. Glial markers significantly contributed to explain amyloid burden, tau pathology, and hippocampal volumes, beyond age and/or primary AD pathology in a sex/gender-specific manner. Compared to men, women showed increased amyloid burden (centiloids) and CSF p-tau181 with increasing levels of sTREM2 and YKL40, and YKL40 and GFAP, respectively. Compared to women, men with greater tau burden showed lower hippocampal volumes as CSF YKL40 levels increased. Overall, our findings suggest that glial reactivity may contribute to sex/gender differences in AD progression, mostly, downstream amyloid. Further research identifying sex/gender-specific temporal dynamics in AD development is warranted to inform clinical trials., This publication is part of the ALFA study (ALzheimer and FAmilies). The authors would like to express their sincerest gratitude to the ALFA project participants, without whom this research would have not been possible. Collaborators of the ALFA study are: Federica Anastasi, Annabella Beteta, Anna Brugulat-Serrat, Raffaele Cacciaglia, Irene Cumplido-Mayoral, Alba Cañas, Marta del Campo, Carme Deulofeu, Ruth Dominguez, Maria Emilio, Ana Fernández-Arcos, Sherezade Fuentes, Patricia Genius, Armand González-Escalante, Laura Hernández, Felipe Hernández-Villamizar, Jordi Huguet, David López-Martos, Ferran Lugo, Paula Marne, Tania Menchón, Carolina Minguillon, Paula Ortiz, Wiesje Pelkmans, Albina Polo, Sandra Pradas, Blanca Rodríguez-Fernandez, Gonzalo Sánchez-Benavides, Mahnaz Shekari, Anna Soteras, Laura Stankeviciute, Marc Vilanova and Natalia Vilor-Tejedor. The authors would like to thank Jordi Huguet (Barcelonaβeta Brain Research Center, Barcelona) and Robin de Flores (INSERM, Caen, France) for their contributions to hippocampal subfield segmentation with Automated Segmentation of Hippocampal Subfields (ASHS). The Roche NeuroToolKit is a panel of exploratory prototype assays designed to robustly evaluate biomarkers associated with key pathologic events characteristic of AD and other neurological disorders, used for research purposes only and not approved for clinical use. Elecsys β-amyloid (1–42) CSF, Elecsys Phospho-Tau (181P) CSF and Elecsys Total-Tau CSF assays are approved for clinical use. COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. The research leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. The research leading to these results has received funding by the Ministry of Science and Innovation (PID2019-111514RA-I00) and the Alzheimer’s Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID) to EMA-U. EMA-U is supported by the Spanish Ministry of Science and Innovation - State Research Agency (RYC2018-026053-I), co-funded by the European Social Fund (ESF). EMA-U receives support from EU Joint Programme-Neurodegenerative Disease Research J(PND2022-138). EP is funded by the Spanish Ministry of Science and Innovation (PRE2020-095827). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). OG-R is supported by the Spanish Ministry of Science and Innovation –State Research Agency (IJC2020-043417-I/MCIN/AEI/10.13039/501100011033) and the European Union laquoNextGenerationEUraquo/PRTR. MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (Grant agreement No. 948677), the Instituto de Salud Carlos III through the projects PI19/00155 and PI22/00456 (Co-funded by European Regional Development Fund (FEDER) “A way to make Europe”), and receives the support of a fellowship from ”la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (fellowship code LCF/BQ/PR21/11840004). CV-C is supported by a grant from the National Institute on Aging (K99AG073452).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Associations between objective sleep metrics and brain structure in cognitively unimpaired adults: interactions with sex and Alzheimer's biomarkers

  • Stankeviciute, Laura
  • Tort-Colet, Núria
  • Fernández-Arcos, Ana
  • Sánchez Benavides, Gonzalo
  • Minguillón, Carolina
  • Fauria, Karine
  • Holst, Sebastian Camillo
  • Garcés, Pilar
  • Mueggler, Thomas
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Iranzo, Álex
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • Molinuevo, José Luis
  • Grau, Oriol (Grau Rivera)
  • ALFA Study
INTRODUCTION: Sleep disturbances are prevalent in Alzheimer's disease (AD), probably emerging during its preclinical stage. Poor subjective sleep quality is linked to reduced brain volume and cortical thickness (CTh), but associations with objective sleep measures, particularly regarding sex and AD pathology, remain unclear. METHODS: We characterized 171 cognitively unimpaired adults from the ALzheimer and FAmilies (ALFA) Sleep study using actigraphy, MRI, amyloid beta 42/40, and phosphorylated tau at threonine 181 in cerebrospinal fluid. RESULTS: Lower sleep efficiency, higher wake after sleep onset (WASO), and sleep fragmentation were associated with lower CTh in the medial temporal lobe and other regions linked with AD and sleep disruption, even after adjusting for AD biomarkers. Sex and AD biomarkers modified these associations, with longer WASO showing a stronger correlation with lower CTh in females. DISCUSSION: Disrupted sleep may reduce cortical integrity independently of AD biomarkers, suggesting alternative pathways. Females appear more vulnerable to impaired sleep, and AD pathology may exacerbate AD-related changes in CTh. Highlights: Poor sleep efficiency, increased WASO, and sleep fragmentation are associated with reduced CTh in regions vulnerable to early AD, independently of amyloid and tau pathology. In the presence of AD pathology, this relationship is altered, with A+T+ individuals exhibiting increased CTh associated with sleep disruption. Sex-specific effects suggest females are more vulnerable to sleep-related cortical thinning. These findings highlight the potential of targeting sleep as a secondary prevention strategy to preserve brain integrity and mitigate neurodegenerative processes in AD-vulnerable regions., The ALFA+ study receives funding from ‘la Caixa’ Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer's Association, and an anonymous international charity foundation through the TriBEKa Imaging Platform project (TriBEKa‑17‑519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under Grant 2017-SGR-892. H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (2022-01018 and 2019-02397), the European Union's Horizon Europe Research and Innovation Programme under Grant Agreement 101053962, Swedish State Support for Clinical Research (ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (201809-2016862), the AD Strategic Fund and the Alzheimer's Association (ADSF-21-831376-C, ADSF-21-831381-C, and ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (FO2022-0270), the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie Grant Agreement 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003). K.B. is supported by the Swedish Research Council (2017‑00915); the Alzheimer Drug Discovery Foundation (ADDF), USA (RDAPB‑201809‑2016615); the Swedish Alzheimer Foundation (AF‑742881); Hjärnfonden, Sweden (FO2017‑0243); the Swedish state under the agreement between the Swedish government and the County Councils, the ALF‑agreement (ALFGBG‑715986); the European Union Joint Program for Neurodegenerative Disorders (JPND2019‑466‑236); the National Institutes of Health (NIH), USA (Grant 1R01AG068398‑01); and the Alzheimer's Association 2021 Zenith Award (ZEN‑21‑848495). M.S.C. receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 Research and Innovation Programme (Grant Agreement 948677), the Instituto de Salud Carlos III (PI19/00155, PI22/00456), and from the ERC under the EU's ‘la Caixa’ Foundation (ID 100010434) and from the EU's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant (847648, LCF/BQ/PR21/11840004). J.D.G. is supported by the Spanish Ministry of Science and Innovation (RYC‑2013‑13054). J.D.G. has also received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (Grant Agreement 115952), EIT Digital (Grant 2021), and from Ministerio de Ciencia y Universidades (Grant Agreement RTI2018‑102261). G.S-B. receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency, PID2020-119556RA-I00. O.G.R. receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117), and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva Programme IJC2020-043417-I).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the alzheimer disease continuum

  • Benedet, Andrea L.
  • Milà Alomà, Marta
  • Salvadó, Gemma
  • Shekari, Mahnaz
  • Operto, Grégory
  • Gispert, Juan Domingo
  • Minguillón, Carolina
  • Molinuevo, José Luis
  • Suárez-Calvet, Marc
  • Translational Biomarkers in Aging and Dementia (TRIAD) study
  • ALFA Study
  • BioCogBank Paris Lariboisière cohort
Importance: Glial fibrillary acidic protein (GFAP) is a marker of reactive astrogliosis that increases in the cerebrospinal fluid (CSF) and blood of individuals with Alzheimer disease (AD). However, it is not known whether there are differences in blood GFAP levels across the entire AD continuum and whether its performance is similar to that of CSF GFAP. Objective: To evaluate plasma GFAP levels throughout the entire AD continuum, from preclinical AD to AD dementia, compared with CSF GFAP. Design, setting, and participants: This observational, cross-sectional study collected data from July 29, 2014, to January 31, 2020, from 3 centers. The Translational Biomarkers in Aging and Dementia (TRIAD) cohort (Montreal, Canada) included individuals in the entire AD continuum. Results were confirmed in the Alzheimer's and Families (ALFA+) study (Barcelona, Spain), which included individuals with preclinical AD, and the BioCogBank Paris Lariboisière cohort (Paris, France), which included individuals with symptomatic AD. Main outcomes and measures: Plasma and CSF GFAP levels measured with a Simoa assay were the main outcome. Other measurements included levels of CSF amyloid-β 42/40 (Aβ42/40), phosphorylated tau181 (p-tau181), neurofilament light (NfL), Chitinase-3-like protein 1 (YKL40), and soluble triggering receptor expressed on myeloid cells 2 (sTREM2) and levels of plasma p-tau181 and NfL. Results of amyloid positron emission tomography (PET) were available in TRIAD and ALFA+, and results of tau PET were available in TRIAD. Results: A total of 300 TRIAD participants (177 women [59.0%]; mean [SD] age, 64.6 [17.6] years), 384 ALFA+ participants (234 women [60.9%]; mean [SD] age, 61.1 [4.7] years), and 187 BioCogBank Paris Lariboisière participants (116 women [62.0%]; mean [SD] age, 69.9 [9.2] years) were included. Plasma GFAP levels were significantly higher in individuals with preclinical AD in comparison with cognitively unimpaired (CU) Aβ-negative individuals (TRIAD: Aβ-negative mean [SD], 185.1 [93.5] pg/mL, Aβ-positive mean [SD], 285.0 [142.6] pg/mL; ALFA+: Aβ-negative mean [SD], 121.9 [42.4] pg/mL, Aβ-positive mean [SD], 169.9 [78.5] pg/mL). Plasma GFAP levels were also higher among individuals in symptomatic stages of the AD continuum (TRIAD: CU Aβ-positive mean [SD], 285.0 [142.6] pg/mL, mild cognitive impairment [MCI] Aβ-positive mean [SD], 332.5 [153.6] pg/mL; AD mean [SD], 388.1 [152.8] pg/mL vs CU Aβ-negative mean [SD], 185.1 [93.5] pg/mL; Paris: MCI Aβ-positive, mean [SD], 368.6 [158.5] pg/mL; AD dementia, mean [SD], 376.4 [179.6] pg/mL vs CU Aβ-negative mean [SD], 161.2 [67.1] pg/mL). Plasma GFAP magnitude changes were consistently higher than those of CSF GFAP. Plasma GFAP more accurately discriminated Aβ-positive from Aβ-negative individuals than CSF GFAP (area under the curve for plasma GFAP, 0.69-0.86; area under the curve for CSF GFAP, 0.59-0.76). Moreover, plasma GFAP levels were positively associated with tau pathology only among individuals with concomitant Aβ pathology. Conclusions and relevance: This study suggests that plasma GFAP is a sensitive biomarker for detecting and tracking reactive astrogliosis and Aβ pathology even among individuals in the early stages of AD., The Translational Biomarkers in Aging and Dementia (TRIAD) is supported by the Canadian Institutes of Health Research (MOP-11-51-31; RFN 152985, 159815, 162303); Canadian Consortium of Neurodegeneration and Aging (MOP-11-51-31 -team 1); Weston Brain Institute, Brain Canada Foundation (Canadian Foundation for Innovation Project 34874; 33397), and the Fonds de Recherche du Québec–Santé (Chercheur Boursier, 2020-VICO-279314). The Alzheimer’s and Families (ALFA) study receives funding from “La Caixa” Foundation (LCF/PR/GN17/10300004) and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Dr Benedet is supported by the Swedish Alzheimer Foundation, Stiftelsen för Gamla Tjänarinnor, and Stohne Stiftelsen. Dr Vrillon is supported by Fondation Adolphe de Rotschild, Fondation Philippe Chatrier, Association des Anciens Internes des Hôpitaux de Paris, Fondation Vaincre Alzheimer, Stiftelsen för Gamla Tjänarinnor, Demensfundet, and Stohne Stiftelsen. Dr Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (grant 2018-02532), the European Research Council (grant 681712), Swedish State Support for Clinical Research (grant ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF) (grant 201809-2016862), the Alzheimer Disease (AD) Strategic Fund and the Alzheimer’s Association (grants ADSF-21-831376-C, ADSF-21-831381-C, and ADSF-21-831377-C), the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (grant FO2019-0228), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), and the UK Dementia Research Institute at University College London. Dr Blennow is supported by the Swedish Research Council (grant 2017-00915), the ADDF (grant RDAPB-201809-2016615), the Swedish Alzheimer Foundation (grant AF-742881), Hjärnfonden, Sweden (grant FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the Avtal om Läkarutbildning och Forskining agreement (grant ALFGBG-715986), the European Union Joint Program for Neurodegenerative Disorders (grant JPND2019-466-236), and the National Institutes of Health (grant 1R01AG068398-01). Dr Suárez-Calvet receives funding from the European Research Council under the European Union’s Horizon 2020 research and innovation programme (grant 948677), the Instituto de Salud Carlos III (grant PI19/00155), and the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva Programme grant IJC2018-037478-I).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Genotypic effects of APOE-ε4 on resting-state connectivity in cognitively intact individuals support functional brain compensation

  • Cacciaglia, Raffaele
  • Operto, Grégory
  • Falcón, Carles
  • González de Echávarri, José Maria
  • Sánchez Benavides, Gonzalo
  • Brugulat Serrat, Anna, 1986-
  • Milà Alomà, Marta
  • Blennow, Kaj
  • Zetterberg, Henrik
  • Molinuevo, José Luis
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • ALFA Study
The investigation of resting-state functional connectivity (rsFC) in asymptomatic individuals at genetic risk for Alzheimer's disease (AD) enables discovering the earliest brain alterations in preclinical stages of the disease. The APOE-ε4 variant is the major genetic risk factor for AD, and previous studies have reported rsFC abnormalities in carriers of the ε4 allele. Yet, no study has assessed APOE-ε4 gene-dose effects on rsFC measures, and only a few studies included measures of cognitive performance to aid a clinical interpretation. We assessed the impact of APOE-ε4 on rsFC in a sample of 429 cognitively unimpaired individuals hosting a high number of ε4 homozygotes (n = 58), which enabled testing different models of genetic penetrance. We used independent component analysis and found a reduced rsFC as a function of the APOE-ε4 allelic load in the temporal default-mode and the medial temporal networks, while recessive effects were found in the extrastriate and limbic networks. Some of these results were replicated in a subsample with negative amyloid markers. Interaction with cognitive data suggests that such a network reorganization may support cognitive performance in the ε4-homozygotes. Our data indicate that APOE-ε4 shapes the functional architecture of the resting brain and favor the idea of a network-based functional compensation., The project leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2017-SGR-892. JDG is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054). MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677) and the Instituto de Salud Carlos III (PI19/00155). KB is supported by the Swedish Research Council (#2017-00915), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-742881), Hjärnfonden, Sweden (#FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the National Institute of Health (NIH), USA, (grant #1R01AG068398-01), and the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 860197 (MIRIADE), and the UK Dementia Research Institute at UCL.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platform

  • Palmqvist, Sebastian
  • Anastasi, Federica
  • Puig-Pijoan, Albert
  • Fernández-Lebrero, Aida
  • Contador, Jose
  • Suárez-Calvet, Marc
  • Hansson, Oskar
Global implementation of blood tests for Alzheimer's disease (AD) would be facilitated by easily scalable, cost-effective and accurate tests. In the present study, we evaluated plasma phospho-tau217 (p-tau217) using predefined biomarker cutoffs. The study included 1,767 participants with cognitive symptoms from 4 independent secondary care cohorts in Malmö (Sweden, n = 337), Gothenburg (Sweden, n = 165), Barcelona (Spain, n = 487) and Brescia (Italy, n = 230), and a primary care cohort in Sweden (n = 548). Plasma p-tau217 was primarily measured using the fully automated, commercially available, Lumipulse immunoassay. The primary outcome was AD pathology defined as abnormal cerebrospinal fluid Aβ42:p-tau181. Plasma p-tau217 detected AD pathology with areas under the receiver operating characteristic curves of 0.93-0.96. In secondary care, the accuracies were 89-91%, the positive predictive values 89-95% and the negative predictive values 77-90%. In primary care, the accuracy was 85%, the positive predictive values 82% and the negative predictive values 88%. Accuracy was lower in participants aged ≥80 years (83%), but was unaffected by chronic kidney disease, diabetes, sex, APOE genotype or cognitive stage. Using a two-cutoff approach, accuracies increased to 92-94% in secondary and primary care, excluding 12-17% with intermediate results. Using the plasma p-tau217:Aβ42 ratio did not improve accuracy but reduced intermediate test results (≤10%). Compared with a high-performing mass-spectrometry-based assay for percentage p-tau217, accuracies were comparable in secondary care. However, percentage p-tau217 had higher accuracy in primary care and was unaffected by age. In conclusion, this fully automated p-tau217 test demonstrates high accuracy for identifying AD pathology. A two-cutoff approach might be necessary to optimize performance across diverse settings and subpopulations., We would like to express our gratitude to the participants, and relatives, in all studies, without whom this research would have not been possible. In addition, we thank B. Arslan for analyzing plasma Aβ in the Gothenburg cohort. The BioFINDER group was supported by the National Institute of Aging (grant no. R01AG083740 to O.H., S.P., R.O. and S.J.), Alzheimer’s Association (grant nos. SG-23-1061717 and ZEN24-1069572 to O.H.), GHR Foundation (O.H. and S.P.), European Research Council (ERC, grant no. ADG-101096455 to O.H.), Swedish Research Council (grant nos. 2023-00356 to O.H., 2021-02219 to N.M.-C. and 2018-02052 to S.P.), ERA PerMed (grant no. ERAPERMED2021-184 to O.H.), the Knut and Alice Wallenberg Foundation (grant no. 2022-0231 to O.H.), the European Union’s (EU’s) Horizon Europe research and innovation program under grant agreement no. 101053962 (to O.H.), the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson’s disease) at Lund University (to O.H.), the Swedish Alzheimer Foundation (grant nos. AF-1011949 and AF-994075 to S.P., AF-994229 to N.M.-C. and AF-981132 to S.P.), the Swedish Brain Foundation (grant nos. FO2023-0163 to N.M.-C., FO2024-0284 and FO2022-0204 to S.P. and FO2021-0293 to O.H.), the family Rönström’s Foundation (grant nos. FRS-0003 to N.M.-C. and FRS-0004 and FRS-0011 to S.P.), the Berg Family Foundation (O.H.), the Parkinson Foundation of Sweden (grant no. 1412/22 to O.H.), the Cure Alzheimer’s fund (O.H.), the Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse (O.H.), the Skåne University Hospital Foundation (grant no. 2020-O000028 to S.P.), EU Joint Programme Neurodegenerative Diseases (grant no. 2019-03401 to N.M.-C.), WASP and DDLS Joint call for research projects (grant no. WASP/DDLS22-066 to N.M.-C.), Regionalt Forskningsstöd (grant no. 2022-1346 to S.P.) and the Swedish Federal Government under the ALF-agreement (grant nos. 2022-Projekt0107 to N.M.-C., 2022-Projekt0080 to O.H. and 2018-Projekt0226 to S.P.). The precursor of [18F]flutemetamol was sponsored by GE Healthcare. For the Gothenburg group, S.K. was financed by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (nos. ALFGBG-1005471, ALFGBG-965923, ALFGBG-81392 and ALFGBG-771071), the Alzheimerfonden (grant nos. AF-842471, AF-737641, AF-929959 and AF-939825), the Swedish Research Council (grant nos. 2019-02075 and 2019-02075_15), Stiftelsen Psykiatriska Forskningsfonden and the Swedish Brain Foundation (grant no. FO2024-0097). A.D. was financed by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (grant no. ALFGBG-984092). H.Z. is a Wallenberg Scholar and a distinguished professor at the Swedish Research Council. K.B. is supported by the Swedish Research Council (grant nos. 2017-00915 and 2022-00732), the Swedish Alzheimer Foundation (grant nos. AF-930351, AF-939721, AF-968270 and AF-994551), Hjärnfonden, Sweden (grant nos. ALZ2022-0006, FO2024-0048-TK-130 and FO2024-0048-HK-24), the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (grant nos. ALFGBG-965240 and ALFGBG-1006418), the Alzheimer’s Association 2022–2025 (grant no. SG-23-1038904 QC), the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, Familjen Rönströms Stiftelse, Stockholm, Sweden and an anonymous philanthropist and donor. The Barcelona group thanks P. Ortiz-Romero, M. de Diego, E. Jiménez, J. Torres and M. del Campo for technical support. F.A. received funding from grant no. JDC2022-049347-I, funded by the MCIU/AEI/10.13039/501100011033 and the EU NextGeneration EU/PRTR. M.S.-C. received funding from the ERC under the EU’s Horizon 2020 research and innovation program (grant no. 948677); ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through project no. SLD077/21/000001; project PI19/00155 and PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the EU; and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and the EU’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie (grant no. 847648 (LCF/BQ/PR21/11840004)). For the Brescia group, A. Pilotto has beensupported by grants of Airalzh Foundation AGYR2021) Life-BIO grant, the LIMPE-DISMOV Foundation Segala Grant 2021, the Italian Ministry of University and Research PRIN COCOON (2017MYJ5TH) and PRIN 2021 RePlast (20202THZAW), the H2020 IMI IDEA-FAST (ID853981) and the Italian Ministry of Health, grant/award nos. RF-2018-12366209 and PNRR-Health PNRR-MAD-2022-12376110. V.Q. was supported by the H2020 IMI IDEA-FAST (grant no. ID853981). C.T. was supported by the PRIN 2021 RePlast (grant no. 20202THZAW). A. Padovani has been supported by grants of the Italian Ministry of University and Research PRIN COCOON (2017MYJ5TH) and PRIN 2021 RePlast (20202THZAW), the H2020 IMI IDEA-FAST (ID853981) and the Italian Ministry of Health, grant/award nos. RF-2018-12366209, RF-2019 RF-2019-12369272 and PNRR-Health PNRR-MAD-2022-12376110. The funders had no role in the design and conduct of the study, collection, management, analysis and interpretation of the data, preparation, review or approval of the paper and decision to submit the paper for publication.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Biological brain age prediction using machine learning on structural neuroimaging data: Multi-cohort validation against biomarkers of Alzheimer's disease and neurodegeneration stratified by sex

  • Cumplido-Mayoral, Irene
  • Operto, Grégory
  • Falcón, Carles
  • Shekari, Mahnaz
  • Cacciaglia, Raffaele
  • Milà Alomà, Marta
  • Minguillón, Carolina
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • OASIS study
Brain-age can be inferred from structural neuroimaging and compared to chronological age (brain-age delta) as a marker of biological brain aging. Accelerated aging has been found in neurodegenerative disorders like Alzheimer's disease (AD), but its validation against markers of neurodegeneration and AD is lacking. Here, imaging-derived measures from the UK Biobank dataset (N=22,661) were used to predict brain-age in 2,314 cognitively unimpaired (CU) individuals at higher risk of AD and mild cognitive impaired (MCI) patients from four independent cohorts with available biomarker data: ALFA+, ADNI, EPAD, and OASIS. Brain-age delta was associated with abnormal amyloid-β, more advanced stages (AT) of AD pathology and APOE-ε4 status. Brain-age delta was positively associated with plasma neurofilament light, a marker of neurodegeneration, and sex differences in the brain effects of this marker were found. These results validate brain-age delta as a non-invasive marker of biological brain aging in non-demented individuals with abnormal levels of biomarkers of AD and axonal injury., The project leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17–519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2017-SGR-892 and the Spanish Research Agency (AEI) under project PID2020-116907RB-I00 of the call MCIN/ AEI /10.13039/501100011033. FB is supported by the NIHR biomedical research center at UCLH. MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677), the Instituto de Salud Carlos III (PI19/00155), and from a fellowship from ”la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Neuroimaging-derived biological brain age and its associations with glial reactivity and synaptic dysfunction cerebrospinal fluid biomarkers

  • Cumplido-Mayoral, Irene
  • Sánchez Benavides, Gonzalo
  • Vilor Tejedor, Natàlia, 1988-
  • López-Martos, David
  • Brugulat Serrat, Anna, 1986-
  • Milà Alomà, Marta
  • Falcón, Carles
  • Cacciaglia, Raffaele
  • Minguillón, Carolina
  • Fauria, Karine
  • Kollmorgen, Gwendlyn
  • Quijano-Rubio, Clara
  • Molinuevo, José Luis
  • Grau, Oriol (Grau Rivera)
  • Suárez-Calvet, Marc
  • Vilaplana, Verónica
  • Gispert, Juan Domingo
  • ALFA Study
  • ADNI
Magnetic resonance Imaging (MRI)-derived brain-age prediction is a promising biomarker of biological brain aging. Accelerated brain aging has been found in Alzheimer's disease (AD) and other neurodegenerative diseases. However, no previous studies have investigated the relationship between specific pathophysiological pathways in AD and biological brain aging. Here, we studied whether glial reactivity and synaptic dysfunction are associated with biological brain aging in the earliest stages of the Alzheimer's continuum, and if these mechanisms are differently associated with AD-related cortical atrophy. We further evaluated their effects on cognitive decline. We included 380 cognitively unimpaired individuals from the ALFA+ study, for which we computed their brain-age deltas by subtracting chronological age from their brain age predicted by machine learning algorithms. We studied the cross-sectional linear associations between brain-age delta and cerebrospinal fluid (CSF) biomarkers of synaptic dysfunction (neurogranin, GAP43, synaptotagmin-1, SNAP25, and α-synuclein), glial reactivity (sTREM2, YKL-40, GFAP, and S100b) and inflammation (interleukin-6). We also studied the cross-sectional linear associations between AD signature and these CSF biomarkers, We further evaluated the mechanisms linking baseline brain-age delta and longitudinal cognitive decline by performing mediation analyses. To reproduce our findings on an independent cohort, we included 152 cognitively unimpaired and 310 mild cognitive impaired (MCI) individuals from the ADNI study. We found that higher CSF sTREM2 was associated with a younger brain-age after adjusting for AD pathology, both in ALFA+ cognitively unimpaired and in ADNI MCI individuals. Furthermore, we found that CSF sTREM2 fully mediated the link between older brain-age and cognitive decline in ALFA+. In summary, we showed that the protective microglial state reflected by higher CSF sTREM2 has a beneficial impact on biological brain aging that may partly explains the variability in cognitive decline in early AD stages, independently of AD pathology., The study was approved by the Independent Ethics Committee “Parc de Salut Mar,” Barcelona, and all participants gave written informed consent. The ALFA+ study receives funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa 17 519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 009132017-SGR-892. MS-C receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed (ERAPERMED2021-184); Project “PI19/00155” and “PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (FEDER); and from a fellowship from ”la Caixa” Foundation (ID 100010434) and the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). DLM is supported by the project PI19/00117, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (FEDER). VV has been supported by the project PID2020-116907RB-I00, funded by the Ministry of Science and Innovation - State Research Agency, MCIN/ AEI /10.13039/501100011033. GSB is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project PID2020-119556RA-I00 and by the Instituto de Salud Carlos III (ISCIII) through the project CP23/00039 (Miguel Servet contract), co-funded by the European Union (FSE+). OGR receives funding from the Alzheimer’s Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III co-funded by the European Union (FEDER) (PI19/00117) and from Ministry of Science and Innovation - State Research Agency MCIN/ AEI /10.13039/501100011033 co-funded by the the European Union «NextGenerationEU»/PRTR (IJC2020-043417-I). NV-T is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033, co-funded by the the European Union «NextGenerationEU»/PRTR (IJC2020-043216-I). In addition, NV-T receives funding from the Alzheimer’s Disease Data Initiative (ADDI) through the William H. Gates Sr. Fellowship program, and the PID2022-143106OA-I00 project, funded by MCIN/AEI /10.13039/501100011033 and co-funded by the European Union (FEDER). RC is supported by the Spanish Ministry of Science and Innovation - State Research Agency MCIN/AEI/10.13039/501100011033 through the project PID2021-125433OA-100 (co-funded by the European Union (FEDER)) and a Ramón y Cajal contract (RYC2021-031128-I, co-funded by the European Union «NextGenerationEU»/PRTR).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A novel ultrasensitive assay for plasma p-tau217: Performance in individuals with subjective cognitive decline and early Alzheimer's disease

  • González Ortiz, Fernando
  • González Escalante, Armand
  • Ortiz Romero, Paula, 1994-
  • Minguillón, Carolina
  • Contador, José
  • Suárez-Calvet, Marc
  • Blennow, Kaj
Introduction: Detection of Alzheimer's disease (AD) pathophysiology among individuals with mild cognitive changes and those experiencing subjective cognitive decline (SCD) remains challenging. Plasma phosphorylated tau 217 (p-tau217) is one of the most promising of the emerging biomarkers for AD. However, accessible methods are limited. Methods: We employed a novel p-tau217 immunoassay (University of Gothenburg [UGOT] p-tau217) in four independent cohorts (n = 308) including a cerebrospinal fluid (CSF) biomarker-classified cohort (Discovery), two cohorts consisting mostly of cognitively unimpaired (CU) and mild cognitively impaired (MCI) participants (MYHAT and Pittsburgh), and a population-based cohort of individuals with SCD (Barcelonaβeta Brain Research Center's Alzheimer's At-Risk Cohort [β-AARC]). Results: UGOT p-tau217 showed high accuracy (area under the curve [AUC] = 0.80-0.91) identifying amyloid beta (Aβ) pathology, determined either by Aβ positron emission tomography or CSF Aβ42/40 ratio. In individuals experiencing SCD, UGOT p-tau217 showed high accuracy identifying those with a positive CSF Aβ42/40 ratio (AUC = 0.91). Discussion: UGOT p-tau217 can be an easily accessible and efficient way to screen and monitor patients with suspected AD pathophysiology, even in the early stages of the continuum., This publication is part of the BBRC's β-AARC study, the MYHAT study, and the Pittsburgh study. The authors would like to express their most sincere gratitude to the project participants, without whom this research would have not been possible. The authors would like to thank Altoida for kindly supporting the CSF AD core biomarker characterisation of β-AARC study participants. F.G.-O. was funded by the Anna Lisa and Brother Björnsson's Foundation and Emil och Maria Palms Foundation. H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation ə under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation ə under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). K.B. is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721 and #AF-968270), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the Alzheimer's Association 2021 Zenith Award (ZEN-21-848495), and the Alzheimer's Association 2022-2025 Grant (SG-23-1038904 QC). M.S.C. receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Grant agreement No. 948677), Project “PI19/00155”, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). T.K.K. was supported by grants 1 R01 AG083874-01 and 1U24AG082930 from the National Institutes of Health (NIH), the Swedish Research Council (Vetenskåpradet; 2021-03244), the Alzheimer's Association (AARF-21-850325), the Swedish Alzheimer Foundation (Alzheimerfonden), the Aina (Ann) Wallströms and Mary-Ann Sjöbloms Stiftelsen, and the Emil och Wera Cornells stiftelsen. M.G. and the MYHAT study were funded by the NIH (grants AG052521 and R37 AG023651). The other Pittsburgh cohorts were financed by the NIH (grants P30 AG066468, P01AG025204, RF1AG025516, RF1AG052525, R01AG052446, and R01AG052446).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

sTREM2 is associated with amyloid-related p-tau increases and glucose hypermetabolism in Alzheimer's disease

  • Biel, Davina
  • Suárez-Calvet, Marc
  • Hager, Paul
  • Rubinski, Anna
  • Dewenter, Anna
  • Steward, Anna
  • Roemer, Sebastian
  • Ewers, Michael
  • Haass, Christian
  • Brendel, Matthias
  • Franzmeier, Nicolai
  • Alzheimer’s Disease Neuroimaging Initiative
Microglial activation occurs early in Alzheimer's disease (AD) and previous studies reported both detrimental and protective effects of microglia on AD progression. Here, we used CSF sTREM2 to investigate disease stage‐dependent drivers of microglial activation and to determine downstream consequences on AD progression. We included 402 patients with measures of earliest beta‐amyloid (CSF Aβ1‐42) and late‐stage fibrillary Aβ pathology (amyloid‐PET centiloid), as well as sTREM2, p‐tau181, and FDG‐PET. To determine disease stage, we stratified participants into early Aβ‐accumulators (Aβ CSF+/PET−; n = 70) or late Aβ‐accumulators (Aβ CSF+/PET+; n = 201) plus 131 controls. In early Aβ‐accumulators, higher centiloid was associated with cross‐sectional/longitudinal sTREM2 and p‐tau181 increases. Further, higher sTREM2 mediated the association between centiloid and cross‐sectional/longitudinal p‐tau181 increases and higher sTREM2 was associated with FDG‐PET hypermetabolism. In late Aβ‐accumulators, we found no association between centiloid and sTREM2 but a cross‐sectional association between higher sTREM2, higher p‐tau181 and glucose hypometabolism. Our findings suggest that a TREM2‐related microglial response follows earliest Aβ fibrillization, manifests in inflammatory glucose hypermetabolism and may facilitate subsequent p‐tau181 increases in earliest AD., The study was funded by grants from the LMU (FöFoLe,1032, awarded to NF;FöFoLe,1119, awarded to DB), the Hertie foundation for clinical neurosciences(awarded to NF), and the SyNergy excellence cluster (EXC2145/ID390857198).MSC receives funding from the European Research Council (ERC) under theEuropean Union’s Horizon2020research and innovation programme (Grantagreement No.948677), the Instituto de Salud Carlos III (PI19/00155), and froma fellowship from“la Caixa”Foundation (ID100010434) and from theEuropean Union’s Horizon2020research and innovation programme underthe Marie Skłodowska-Curie grant agreement No.847648(LCF/BQ/PR21/11840004). We thank the ADNI participants and their families who made thisstudy possible. Open Access funding enabled and organized by Projekt DEAL.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A head-to-head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic

  • Anastasi, Federica
  • Fernández-Lebrero, Aida
  • Ortiz Romero, Paula, 1994-
  • Torres-Torronteras, Javier
  • González Escalante, Armand
  • Contador, Jose
  • García Escobar, Greta
  • Manero, Rosa María
  • Navalpotro-Gómez, Irene
  • Jiménez-Moyano, Esther
  • Grau-Rivera, Oriol
  • Campo, Marta del
  • Puig-Pijoan, Albert
  • Suárez-Calvet, Marc
Introduction: Blood-based biomarkers for Alzheimer's disease (AD) have been widely studied, but direct comparisons of several biomarkers in clinical settings remain limited. Methods: In this cross-sectional study, plasma biomarkers from 197 participants in the BIODEGMAR cohort (Hospital del Mar, Barcelona) were analyzed. Participants were classified based on AD cerebrospinal fluid (CSF) core biomarkers. We assessed the ability of plasma p-tau181, p-tau217, p-tau231, t-tau, and Aβ42/40 to classify Aβ pathology status. Results: Plasma p-tau biomarkers had a greater diagnostic performance and larger effect sizes compared to t-tau and Aβ42/40 assays in detecting Aβ pathology. Among them, plasma p-tau217 consistently outperformed the others, demonstrating superior area under the curves. Furthermore, p-tau217 showed the strongest correlation between plasma and CSF levels, underscoring its potential as a reliable surrogate for CSF biomarkers. Discussion: Several plasma biomarkers, targeting different epitopes and using different platforms, demonstrated high performance in detecting AD in a memory clinic setting. Highlights: Plasma p-tau biomarkers demonstrated higher diagnostic performance and larger effect sizes than t-tau and Aβ42/40 assays in detecting Alzheimer's disease. Among the p-tau biomarkers, p-tau217 assays consistently outperformed the others, providing superior classification of Aβ pathology status across different phosphorylation sites. p-tau217 assays showed the strongest correlation between plasma and CSF levels, indicating its potential as a reliable surrogate for CSF biomarkers. Several plasma p-tau biomarkers can be used in a specialized memory clinic to accurately detect Alzheimer's disease., Federica Anastasi receives funding from the JDC2022-049347-I grant, funded by the MCIU/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR. Henrik Zetterberg is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union's Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer's Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). Marc Suárez-Calvet receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through the project SLD077/21/000001; Project “PI19/00155″ and “PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from ”la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Awareness of episodic memory and meta-cognitive profiles: associations with cerebrospinal fluid biomarkers at the preclinical stage of the Alzheimer's continuum

  • López-Martos, David
  • Suárez-Calvet, Marc
  • Milà Alomà, Marta
  • Gispert, Juan Domingo
  • Minguillón, Carolina
  • Quijano-Rubio, Clara
  • Kollmorgen, Gwendlyn
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Grau, Oriol (Grau Rivera)
  • Sánchez Benavides, Gonzalo
Introduction: The lack of cognitive awareness, anosognosia, is a clinical deficit in Alzheimer's disease (AD) dementia. However, an increased awareness of cognitive function, hypernosognosia, may serve as a marker in the preclinical stage. Subjective cognitive decline (SCD) might correspond to the initial symptom in the dynamic trajectory of awareness, but SCD might be absent along with low awareness of actual cognitive performance in the preclinical stage. We hypothesized that distinct meta-cognitive profiles, both hypernosognosia and anosognosia, might be identified in preclinical-AD. This research evaluated the association between cerebrospinal fluid (CSF) AD biomarkers and the awareness of episodic memory, further exploring dyadic (participant-partner) SCD reports, in the preclinical Alzheimer's continuum. Methods: We analyzed 314 cognitively unimpaired (CU) middle-aged individuals (mean age: 60, SD: 4) from the ALFA+ cohort study. Episodic memory was evaluated with the delayed recall from the Memory Binding Test (MBT). Awareness of episodic memory, meta-memory, was defined as the normalized discrepancy between objective and subjective performance. SCD was defined using self-report, and dyadic SCD profiles incorporated the study partner's report using parallel SCD-Questionnaires. The relationship between CSF Aβ42/40 and CSF p-tau181 with meta-memory was evaluated with multivariable regression models. The role of SCD and the dyadic contingency was explored with the corresponding stratified analysis. Results: CSF Aβ42/40 was non-linearly associated with meta-memory, showing an increased awareness up to Aβ-positivity and a decreased awareness beyond this threshold. In the non-SCD subset, the non-linear association between CSF Aβ42/40 and meta-memory persisted. In the SCD subset, higher Aβ-pathology was linearly associated with increased awareness. Individuals presenting only study partner's SCD, defined as unaware decliners, exhibited higher levels of CSF p-tau181 correlated with lower meta-memory performance. Discussion: These results suggested that distinct meta-cognitive profiles can be identified in preclinical-AD. While most individuals might experience an increased awareness associated with the entrance in the AD continuum, hypernosognosia, some might be already losing insight and stepping into the anosognosic trajectory. This research reinforced that an early anosognosic profile, although at increased risk of AD-related decline, might be currently overlooked considering actual diagnostic criteria, and therefore its medical attention delayed., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The design and execution of the study were independent of any influence from funding sources. This includes data collection, analysis, interpretation, manuscript preparation, review, and approval. The research leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. DL-M was supported by Instituto de Salud Carlos III through the project PI19/00117 (Co-funded by European Regional Development Fund/European Social Fund “A way to make Europe”/”Investing in your future”). MS-C receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed (ERAPERMED2021-184); Project “PI19/00155” and “PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). JG receives funding from the European Comission Innovative Health Initiative (Grant Agreement: 101112145), the BrightFocus Foundation (Grant Reference ID: A2022034S), and La Marató de TV3 (Project: 202318 30-31-32). HZ was a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). KB was supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721 and #AF-968270), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), and the Alzheimer’s Association 2022-2025 Grant (SG-23-1038904 QC). OG-R was supported by the Spanish Ministry of Science and Innovation –State Research Agency (IJC2020-043417-I/MCIN/AEI/10.13039/501100011033) and the European Union laquoNextGenerationEUraquo/PRTR. GS-B was supported by the Agencia Estatal de Investigación AEI/10.13039/501100011033 through the project PID2020-119556RA-I00 and Instituto de Salud Carlos III (ISCIII) through the project CP23/00039 (Miguel Servet contract), co-funded by the European Union (FSE+).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Omega-3 blood biomarkers relate to brain glucose uptake in individuals at risk of Alzheimer's disease dementia

  • Lázaro, Iolanda
  • Grau, Oriol (Grau Rivera)
  • Suárez-Calvet, Marc
  • Fauria, Karine
  • Minguillón, Carolina
  • Shekari, Mahnaz
  • Falcón, Carles
  • Garcia Prat, Marina
  • Huguet, Jordi
  • Molinuevo, José Luis
  • Gispert, Juan Domingo
  • Sala Vila, Aleix
  • ALFA Study
Introduction: Brain glucose hypometabolism is a preclinical feature of Alzheimer's disease (AD). Dietary omega-3 fatty acids promote brain glucose metabolism, but clinical research is incipient. Circulating omega-3s objectively reflect their dietary intake. Methods: This was a cross-sectional study in 320 cognitively unimpaired participants at increased risk of AD dementia. Using lipidomics, we determined blood docosahexaenoic (DHA) and alpha-linolenic (ALA) acid levels (omega-3s from marine and plant origin, respectively). We assessed brain glucose metabolism using [18-F]-fluorodeoxyglucose (FDG) positron emission tomography (PET). Results: Blood ALA directly related to FDG uptake in brain areas known to be affected in AD. Stronger associations were observed in apolipoprotein E ε4 carriers and homozygotes. For DHA, significant direct associations were restricted to amyloid beta-positive tau-positive participants. Discussion: Blood omega-3 directly relate to preserved glucose metabolism in AD-vulnerable brain regions in individuals at increased risk of AD dementia. This adds to the benefits of omega-3 supplementation in the preclinical stage of AD dementia. Highlights: Blood omega-3s were related to brain glucose uptake in participants at risk of Alzheimer's disease (AD) dementia.Complementary associations were observed for omega-3 from marine and plant sources.Foods rich in omega-3 might be useful in early features of AD., The research leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer's Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2021 SGR 00913. OG-R is supported by the Spanish Ministry of Science and Innovation –State Research Agency (IJC2020-043417-I/MCIN/AEI/10.13039/501100011033) and the European Union laquoNextGenerationEUraquo/PRTR. MSC receives funding from the European Research Council (ERC) under the European Unionʼs Horizon 2020 research and innovation programme (Grant agreement No. 948677), Project “PI19/00155,” funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and from a fellowship from “la Caixa” Foundation (ID 100010434) and from the European Unionʼs Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648(LCF/BQ/PR21/11840004). This work was supported by funding from Instituto de Salud Carlos III (PI22/00071) and by a grant from the California Walnut Commission, Folsom, CA, US (to AS-V). The funding agencies had no input in the study design, data collection, analyses, or writing and submission of the manuscript.